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Abstract 
The widespread use of highly active antiretroviral therapy (HAART) has resulted in 
longer lifespans for HIV seropositive women in the United States, during which 
preventive health care is recommended. Failing to complete recommended cancer 
screening tests can result in cancer being diagnosed at a later stage with a poorer 
prognosis. The purpose of the study, based on the ecosocial theory, was to describe the 
sociodemographic and clinical variables of HIV seropositive women who failed to 
complete recommended screening tests for breast, cervical, and colorectal cancers and 
determine if the presence of hypertension, obesity, diabetes, depression, or tobacco use 
impacted the completion of these screening tests. The electronic medical records of 142 
HIV seropositive women were reviewed. Univariate and bivariate analyses and logistic 
regression were conducted to create a model associated with the completion of preventive 
health care screening tests. For breast cancer, cervical cancer, and colorectal cancer, 69%, 
71.8%, and 69.7% failed to complete screening, respectively. Number of years living 
with HIV infection and HIV stage were associated with breast cancer screening; distance 
between residence and health care facility and HIV stage were associated with cervical 
cancer screening; and age and marital status were associated with colorectal cancer 
screening. Addressing issues related to the completion of cancer screening tests over the 
lifespans of HIV seropositive women can result in positive social change by preventing 
disease and disability, which can negatively impact these women, their families, and their 
communities. 
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Chapter 1: Introduction to the Study 
Background of the Study 
Approximately 1 in every 4 of the more than 1.1 million individuals living with 
human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) 
in the United States are women (Centers for Disease Prevention and Control [CDC], 
2013a), and women accounted for about one fourth of new HIV/AIDS cases diagnosed 
each year in the United States (CDC, 2014a). Once considered an acute disease 
associated with premature death, since the advent of highly active antiretroviral therapy 
(HAART), HIV is now viewed as a chronic illness, similar to diabetes, which requires 
medical management throughout an individual’s lifespan (Clarke, 1994). A chronic 
disease is a disease with a prolonged course, without a spontaneous resolution, and for 
which a complete cure is rarely achieved (McKenna, Taylor, Marks, & Koplan, 1998). 
In the presence of a chronic illness or disease, the overall focus of health care often 
changes from the primary prevention of a health threat to the prevention of further 
disability, or secondary prevention (Clarke, 1994).  
Approximately half, or 117 million, adults in the United States have one or more 
chronic illnesses resulting from a complex interplay of genetic, environmental, and 
social factors, and these illnesses are impacted further by gender, age, race or ethnicity, 
and socioeconomic disparities (CDC, 2014b; Morewitz, 2006), all of which should be 
considered when discussing the completion of preventive health care actions for women 
with HIV infection. Not only should preventive health care actions be considered when 
developing programs and policies related to women with HIV infection but also the 
effect a woman’s health has on the entire family unit. Sixty percent of women with HIV 
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infection reported having at least one child, compared to 18% of men (Schuster et al., 
2000), and the number of HIV seropositive women who gave birth increased about 30% 
between 2000 and 2006 (CDC, 2014c), so keeping HIV seropositive women as healthy 
as possible throughout their lifespan by developing programs to improve the completion 
of preventive health care actions can result in positive social change through 
maintenance of a healthy family unit. 
Individuals with chronic illnesses, like those without a chronic illness or 
condition, need to maintain an optimal level of health to reduce or prevent future 
disability (Institute of Medicine [IOM], 2012; McKenna et al., 1998). Evidence-based 
preventive health care recommendations have been developed to aid health care 
providers in the provision of screening procedures and tests during lifespan periods 
when certain preventable diseases are most likely to occur (Ockene et al., 2007). 
However, the likelihood of receiving the preventive health care services related to these 
recommendations differs significantly by gender (Ferrante, Chen, Crabtree, & 
Wartenberg, 2007), age (Shenson, Bolen, Adams, Seeff, & Blackman, 2005), 
socioeconomic factors (O’Malley, Forrest, & Mandelblatt, 2002), insurance status 
(Ackerson & Gretebeck, 2007), and the presence of a disability (Yankashas et al., 2010), 
a comorbid condition (Fallon, Wilcox, & Laken, 2006), or more than one comorbid 
conditions (Wong, Howard, Tong, & Craig, 2011). Considering the differences between 
groups, preventive health care recommendations, which are aimed at the general 
population, may not address issues specifically related to individuals with comorbid 
conditions. Gonzalez, Ferrante, Van Durme, Pal, and Roetzhein (2001) found higher 
rates of late stage cancer diagnoses and higher mortality rates due to comorbid 
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conditions among 32,074 Florida residents with colorectal cancer, breast cancer, prostate 
cancer, or melanoma when the authors analyzed cancer registry data, indicating a 
possible need to adjust screening recommendations for individuals with comorbid 
illnesses. 
Specific to HIV infection, a cancer registry-based study followed 85,268 women 
with HIV infection to determine the incidence of invasive cancers from 60 before to 120 
months after an AIDS-defining event, including a period of time prior to the use of 
HAART, and found the incidence of invasive breast cancer was less than expected, but 
eventually equaled the incidence rate in the general population (Goedert et al., 2006). 
Another cancer registry-based study conducted over 12 years, 3 of which were before 
the use of HAART, found cervical cancer incidence was elevated (SIR = 2.9, 95% CI = 
1.9, 4.2), breast cancer was the third most prevalent non-AIDS-defining cancer prior to 
the 5 year follow-up period, and cervical cancer incidence increased slightly pre- and 
post-AIDS diagnosis (RR = 2.2, 95% CI = 0.9–5.5; Engels et al., 2008). However, both 
studies were limited to invasive breast cancers, and breast cancer prognosis was 
improved when the cancer was diagnosed in a noninvasive stage. 
In this study, I examined independent variables categorized according to the 
constructs of the ecosocial theory, described by Krieger (1994, 2002), to determine 
which independent variables, individually or in combination, positively or negatively 
impacted the dependent variables, which were the completion of preventive health care 
actions for breast cancer, cervical cancer, or colorectal cancer in HIV seropositive 
women who received health care services from an infectious disease specialist in an 
urban, ambulatory care center.  
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Chapter 1 continues with the problem statement, purpose, research questions, 
theoretical foundation, rationale, design, variable definitions, scope, assumptions, and 
limitations. In Chapter 2, I will discuss the literature review of the identified problem, 
the theoretical foundation, and the study variables. In Chapter 3, I will discuss the 
research design and rationale, sampling, development of the data abstraction instrument, 
data access and collection, the data analysis plan, validity and reliability issues, and the 
protection of data from the medical records of a protected population. Data collection 
will be discussed, and results presented in Chapter 4. Chapter 5 will include an 
interpretation of the study results, as well as limitations, and recommendations for future 
research. 
Problem Statement 
The majority of women participating in the HIV Cost and Services Utilization 
Study (HCSUS) reported receiving annual gynecological examinations, while other 
preventive health care was often lacking (RAND, 2006). Determining whether HIV 
seropositive women in the United States receive appropriate preventive health care is 
difficult due to multiple factors including: (a) frequent changes in the recommendations 
published by the United States Preventive Services Task Force (USPSTF); (b) a lack of 
standardization in the recommendations published by various agencies; (c) lack of 
standardized documentation, tracking, and reporting related to ordering and completion 
of preventive health care actions within, as well as across, different health care providers 
and healthcare delivery systems, such as primary care sites and medical centers; (d) the 
wide variety of endpoints found in published studies on the delivery of preventive health 
care services including whether the screening test was ordered by a health care provider 
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versus the client actually completed the testing; (e) a lack of studies on whether follow-
up testing was ordered and/or completed if the results of the initial screening test were 
abnormal or inconclusive (Agency for Healthcare Research and Quality [AHRQ], U.S. 
Department of Health and Human Services [USDHHS], 2007); (f) the various sources of 
the data, such as billing, insurance claim data, or patient medical records used to track 
completion of preventive health care actions (Armstrong, Long, & Shea, 2004); and (g) 
reliability and validity of instruments, as well as the methodology, used to abstract 
preventive health action completion data from sources. 
The identification of variables significantly related to preventive health care 
actions in HIV seropositive women would allow health care providers and program 
planners to prioritize preventive health care services and focus resources on groups who 
may be at risk for lower completion rates, while maintaining higher completion rates in 
low risk groups. Preventive health care recommendations, developed for the general 
population, may not be applicable to subgroups of the population with life- or health-
threatening conditions, such as HIV infection. The presence of certain variables, 
identified during the review of the literature for this study, particularly in HIV 
seropositive women, indicated a possible need for agencies and professional 
organizations to revise preventive health care recommendations, so health care providers 
could recommend screening tests to these individuals at a time interval when the 
majority of health threats could be diagnosed earlier and outcomes associated with 
maintained or improved health could be realized.  
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Purpose of the Study 
The purpose of the quantitative study was to describe, compare, and determine 
which independent variables differed significantly between HIV seropositive women 
who completed recommended preventive health care actions for breast cancer, cervical 
cancer, or colorectal cancer and HIV seropositive women who failed to complete those 
same preventive health care actions, with or without a diagnosis of one or more 
comorbid conditions, when seen by an infectious disease specialist at an ambulatory care 
center in Newark, New Jersey, three or more times during the 12 months prior to data 
collection.   
Electronic medical records (EMRs), or the electronic versions of clinical records 
used for diagnosis and treatment within one health care setting, are part of, and contain 
less information, than electronic health records (EHRs), which often include information 
from more than one health care setting in more than one state (Garrett & Seidman, 
2011). The study abstracted data from 142 EMRs, originally recorded in hard copy 
medical records then transcribed into an electronic format, as well as information 
originally recorded directly into the EMR, over a period of years, as related to the 
independent and dependent variables. Since 2004, when the federal government 
indicated almost every U.S. citizen should have an EHR by 2014, there was an increase 
in the adoption of EHRs in office-based practices and ambulatory care settings (Hing, 
Hall, & Ashman, 2010). In 2009, The American Recovery and Reinvestment Act 
became law, and a section of the law, titled the Health Information Technology for 
Economic and Clinical Health (HITECH) Act, allowed for incentive payments to 
Medicare and Medicaid providers who used certified EHRs as a method to improve the 
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delivery of health care services (Hing et al., 2010; Hsiao, Hing, Socey, & Cai, 2010, 
2011). 
The National Center for Health Statistics (NCHS) conducted the annual National 
Ambulatory Medical Care Survey (NAMCS) over several years. In 2001, 18.2% of 
responding physicians reported having an EMR/EHR system, but this percentage 
decreased to 17.3% in both 2002 and 2003, then increased from 20.8% in 2004 to 42.0% 
in 2008 (Hsiao et al., 2011). In 2006, the NAMCS queried respondents about the use of 
a basic EMR/EHR system. Where a minimal EMR/EHR system contained physician 
clinical notes, laboratory or imaging reports, and computerized orders for prescriptions 
or tests, a basic EMR/EHR system included patient demographics, patient health history, 
problem list, a comprehensive list of medications and allergies, along with the ability to 
view both laboratory and imaging reports, in addition to the elements of a minimal 
EMR/EHR system (Hsiao et al., 2011). In 2006, 10.5% of survey respondents indicated 
the use of a basic EMR/EHR system, with the percentage increasing steadily in 2007 
(11.8%), 2008 (16.9%), 2009 (21.8%), and 2010 (24.9%; Hing et al., 2010; Hsiao et al., 
2011). In 2011, 28 states equaled or exceeded the overall percentage of U.S. respondents 
(57%) reporting the use of any type of EMR/EHR system, and 21 states equaled or 
exceeded the overall U.S. percentage (33.9%) of respondents reporting the use of a basic 
EMR/EHR system (Hsiao et al., 2011). 
Beginning in 2008, NCHS added a supplemental questionnaire to assess the use 
of any EMR/EHR by physicians who participated, or intended to participate, in the 
incentive program (Hsiao et al., 2010). In 2009, 48.3% of physicians responding to the 
survey indicated they used any type of EMR/EHR system in their office-based practices, 
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and estimated percentages for the 2010 and 2011 surveys were 50.7% and 57.0%, 
respectively (Hsiao et al., 2010, 2011). As EMRs become more widespread, the use of 
the data contained in EMRs for research studies and the evaluation of clinical care 
standards also becomes more widespread, which indicates yet another need to 
incorporate standardized terminology, definitions, scales and measurements into 
EMR/EHR systems (Ryge & DeVincenzi, 1983). 
Defined in a later section, the constructs of the ecosocial theory includes: (a) 
embodiment; (b) pathways of embodiment; (c) cumulative interplay; (d) accountability 
and agency; and (e) analytic implications and predictions (Krieger, 1994, 2002). 
Independent variables associated with the construct of embodiment, and used to 
determine eligibility for this study, include: (a) female gender; (b) date of birth; (c) age, 
calculated from date of birth; (d) HIV status, categorized as HIV seropositive or HIV 
seronegative; and (e) seen by an infectious disease specialist at least three times during 
the 12 months prior to data collection. Age cohort, or group, in 10-year intervals, was 
used in the analyses, while census age groups were determined for comparison to 
statistics from national databases and the results of other studies.  
Independent variables associated with the pathways of embodiment construct 
included: (a) race; (b) ethnicity; (c) marital status; (d) education level; (e) employment 
status; and (f) type of insurance. The independent variables associated with the construct 
of cumulative interplay included: (a) time, in years, infected with HIV, which was 
calculated by subtracting the year of earliest HIV diagnosis from the year of data 
collection; (b) the lowest CD4 cell count in the EMR; (c) history of AIDS-defining 
conditions, including opportunistic infections (Appendix A); (d) HIV stage determined 
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using the lowest CD4 count in the EMR combined with the history of opportunistic 
infections; (e) distance between the residence and the ambulatory care center calculated 
from residential and facility zip codes; (f) hypertension; (g) obesity; (h) diabetes 
mellitus; (i) depression; and (j) tobacco use. The independent variables associated with 
the construct of accountability and agency included: (a) health care provider; (b) health 
care facility; and (c) health care delivery model. The three accountability and agency 
variables were controlled by limiting EMRs on the sampling frame to those of HIV 
seropositive women seen by a board-certified infectious disease specialist in the same 
ambulatory care center in New Jersey, three times or more within the 12 months prior to 
data collection. In the ecosocial theory, analytic implications and predictions contribute 
to contingent hypotheses (Krieger, 2002), and, while prediction was beyond the scope of 
the study, the dependent variables associated with this construct were the completion of, 
or failure to complete, preventive health care screening recommendations for breast 
cancer, cervical cancer, or colorectal cancer.    
Research Questions and Hypotheses 
The research questions, alternative hypotheses, and null hypotheses were derived 
directly from the study purpose, and are listed below by the dependent variables. 
Dependent variables in the study were related to the completion of, or failure to 
complete, preventive health care actions, specifically breast cancer screening 
mammography, cervical cancer screening Pap smear, with or without HPV testing, or 
colorectal cancer screening by fecal occult blood testing (FOBT), sigmoidoscopy, or 
colonoscopy. Analyses related to each research question, which are discussed in more 
detail in a later section, were conducted separately on each of the dependent variables. 
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The research questions and hypotheses are listed in a manner to reflect the primarily 
univariate analyses of the data resulting from a smaller sample drawn from a single 
clinical practice site. 
Breast Cancer Screening Research Questions 
Research Question 1. Does the completion of breast cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women seen 
by an infectious disease specialist at the same ambulatory care center, three or more 
times, during the 12 months prior to data collection? 
Hypothesis H1a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will complete significantly more breast 
cancer screenings compared to HIV seropositive women in older age cohorts. 
Hypothesis H0a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will not complete significantly more breast 
cancer screenings compared to HIV seropositive women in older age cohorts. 
Research Question 2. Does the completion of breast cancer screening differ 
significantly by the race of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H2a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
11 
 
prior to data collection, will complete significantly more breast cancer screening tests 
compared to Black or non-White HIV seropositive women. 
Hypothesis H0a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection, will not complete significantly more breast cancer screening 
tests compared to Black or non-White HIV seropositive women. 
Research Question 3. Does the completion of breast cancer screening differ 
significantly by the ethnicity of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H3a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more breast cancer screening 
tests compared to Hispanic HIV seropositive women. 
Hypothesis H0a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more breast cancer 
screening tests compared to Hispanic HIV seropositive women. 
Research Question 4. Does the completion of breast cancer screening differ 
significantly by the marital status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
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Hypothesis H4a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more breast cancer screening 
tests compared to single, partnered, divorced or widowed HIV seropositive women. 
Hypothesis H0a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more breast cancer 
screening tests compared to single, partnered, divorced or widowed HIV seropositive 
women. 
Research Question 5. Does the completion of breast cancer screening differ 
significantly by the education level of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H5a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more breast 
cancer screening tests compared to HIV seropositive women in all other education 
levels. 
Hypothesis H0a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more breast 
cancer screening tests compared to HIV seropositive women in all other education 
levels. 
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Research Question 6. Does the completion of breast cancer screening differ 
significantly by the employment status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H6a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more breast cancer screening 
tests compared to HIV seropositive women in all other employment status categories. 
Hypothesis H0a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more breast cancer 
screening tests compared to HIV seropositive women in all other employment status 
categories. 
Research Question 7. Does the completion of breast cancer screening differ 
significantly by the type of insurance in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H1a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
breast cancer screening tests compared to HIV seropositive women with all other types 
of insurance, including no insurance, self-pay and charity care. 
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Hypothesis H0a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
breast cancer screening tests compared to HIV seropositive women with all other types 
of insurance, including no insurance, self-pay and charity care. 
Research Question 8. Does the completion of breast cancer screening differ 
significantly by the length of time, in quartiles, in infected with HIV in women seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection? 
Hypothesis H8b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
breast cancer screening tests compared to HIV seropositive women infected for longer 
periods of time. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
breast cancer screening tests compared to HIV seropositive women infected for longer 
periods of time. 
Research Question 9. Does the completion of breast cancer screening differ 
significantly by HIV stage in HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
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Hypothesis H9b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more breast 
cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
Hypothesis H0b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more breast 
cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
Research Question 10. Does the completion of breast cancer screening differ 
significantly by CD4 cell count in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H10b. HIV seropositive women with CD4 counts of 500 cells/mm3 
or more, seen by an infectious disease specialist at the same ambulatory care center three 
or more times, during the 12 months prior to data collection, will complete significantly 
more breast cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Hypothesis H0b. HIV seropositive women with CD4 counts of 500 cells/mm3 or 
more, seen by an infectious disease specialist at the same ambulatory care center three or 
more times, during the 12 months prior to data collection, will not complete significantly 
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more breast cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Research Question 11. Does the completion of breast cancer screening differ 
significantly by distance, in quartiles, in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H11b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will complete 
significantly more breast cancer screening tests compared to HIV seropositive women 
who live farther from the health care facility. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will not 
complete significantly more breast cancer screening tests compared to HIV seropositive 
women who live farther from the health care facility. 
Research Question 12. Does completion for breast cancer screening differ 
significantly between HIV seropositive women diagnosed with hypertension, and seen 
by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of hypertension? 
Hypothesis H12. There will be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with hypertension, 
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compared to HIV seropositive women without hypertension, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with hypertension, 
compared to HIV seropositive women without hypertension, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Research Question 13. Does the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with obesity, and seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women 
without a diagnosis of obesity?  
Hypothesis H13a. There will be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
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Research Question 14. Does the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with diabetes mellitus, and 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of diabetes mellitus?  
Hypothesis H14. There will be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without diabetes mellitus, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without mellitus, and seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Research Question 15. Does the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with depression, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women 
without a diagnosis of depression?  
Hypothesis H15. There will be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
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disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Research Question 16. Does completion of breast cancer screening differ 
significantly between HIV seropositive women who use tobacco, and have been seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women who 
do not use tobacco? 
Hypothesis H16. There will be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women who use tobacco, and 
have been seen by an infectious disease specialist at the same ambulatory care center 
three or more times, during the 12 months prior to data collection, compared to HIV 
seropositive women who do not use tobacco.  
Hypothesis H0. There will not be a statistically significant difference in the 
completion of breast cancer screening in HIV seropositive women who use tobacco, and 
have been seen by an infectious disease specialist at the same ambulatory care center 
three or more times, during the 12 months prior to data collection, compared to HIV 
seropositive women who do not use tobacco.  
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Cervical Cancer Screening Research Questions 
Research Question 1. Does the completion of cervical cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women seen 
by an infectious disease specialist at the same ambulatory care center, three or more 
times, during the 12 months prior to data collection? 
Hypothesis H1a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will complete significantly more cervical 
cancer screenings compared to HIV seropositive women in older age cohorts. 
Hypothesis H0a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
cervical cancer screenings compared to HIV seropositive women in older age cohorts. 
Research Question 2. Does the completion of cervical cancer screening differ 
significantly by the race of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H2a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection, will complete significantly more cervical cancer screening tests 
compared to Black or non-White HIV seropositive women. 
Hypothesis H0a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
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prior to data collection, will not complete significantly more cervical cancer screening 
tests compared to Black or non-White HIV seropositive women. 
Research Question 3. Does the completion of cervical cancer screening differ 
significantly by the ethnicity of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H3a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more cervical cancer 
screening tests compared to Hispanic HIV seropositive women. 
Hypothesis H0a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more cervical cancer 
screening tests compared to Hispanic HIV seropositive women. 
Research Question 4. Does the completion of cervical cancer screening differ 
significantly by the marital status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H4a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more cervical cancer 
screening tests compared to single, partnered, divorced or widowed HIV seropositive 
women. 
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Hypothesis H0a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more cervical cancer 
screening tests compared to single, partnered, divorced or widowed HIV seropositive 
women. 
Research Question 5. Does the completion of cervical cancer screening differ 
significantly by the education level of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H5a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more cervical 
cancer screening tests compared to HIV seropositive women in all other education 
levels. 
Hypothesis H0a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
cervical cancer screening tests compared to HIV seropositive women in all other 
education levels. 
Research Question 6. Does the completion of cervical cancer screening differ 
significantly by the employment status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
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Hypothesis H6a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more cervical cancer 
screening tests compared to HIV seropositive women in all other employment status 
categories. 
Hypothesis H0a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more cervical cancer 
screening tests compared to HIV seropositive women in all other employment status 
categories. 
Research Question 7. Does the completion of cervical cancer screening differ 
significantly by the type of insurance in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H1a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
cervical cancer screening tests compared to HIV seropositive women with all other types 
of insurance, including no insurance, self-pay and charity care. 
Hypothesis H0a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
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cervical cancer screening tests compared to HIV seropositive women with all other types 
of insurance, including no insurance, self-pay and charity care. 
Research Question 8. Does the completion of cervical cancer screening differ 
significantly by the length of time, in quartiles, in infected with HIV in women seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection? 
Hypothesis H8b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
cervical cancer screening tests compared to HIV seropositive women infected for longer 
periods of time. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
cervical cancer screening tests compared to HIV seropositive women infected for longer 
periods of time. 
Research Question 9. Does the completion of cervical cancer screening differ 
significantly by HIV stage in HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H9b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more cervical 
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cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
Hypothesis H0b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
cervical cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
Research Question 10. Does the completion of cervical cancer screening differ 
significantly by CD4 cell count in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H10b. HIV seropositive women with CD4 counts of 500 cells/mm3 
or more, seen by an infectious disease specialist at the same ambulatory care center three 
or more times, during the 12 months prior to data collection, will complete significantly 
more cervical cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Hypothesis H0b. HIV seropositive women with CD4 counts of 500 cells/mm3 or 
more, seen by an infectious disease specialist at the same ambulatory care center three or 
more times, during the 12 months prior to data collection, will not complete significantly 
more cervical cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Research Question 11. Does the completion of cervical cancer screening differ 
significantly by distance, in quartiles, in HIV seropositive women seen by an infectious 
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disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H11b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will complete 
significantly more cervical cancer screening tests compared to HIV seropositive women 
who live farther from the health care facility. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will not 
complete significantly more cervical cancer screening tests compared to HIV 
seropositive women who live farther from the health care facility. 
Research Question 12. Does the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with hypertension, and seen 
by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of hypertension?  
Hypothesis H12. There will be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with hypertension, 
compared to HIV seropositive women without hypertension, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
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Hypothesis H0. There will not be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with hypertension, 
compared to HIV seropositive women without hypertension, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Research Question 13. Does the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with obesity, and seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women 
without a diagnosis of obesity?  
Hypothesis H13a. There will be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
Research Question 14. Does the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with diabetes mellitus, and 
seen by an infectious disease specialist at the same ambulatory care center three or more 
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times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of diabetes mellitus?  
Hypothesis H14. There will be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without diabetes mellitus, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without mellitus, and seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Research Question 15. Does the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with depression, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women 
without a diagnosis of depression?  
Hypothesis H15. There will be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
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Hypothesis H0. There will not be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Research Question 16. Does the completion for cervical cancer screening differ 
significantly between HIV seropositive women who use tobacco, and have been seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, compared to HIV seropositive women who 
do not use tobacco?  
Hypothesis H16. There will be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women who use tobacco, 
and have been seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, compared to 
HIV seropositive women who do not use tobacco.  
Hypothesis H0. There will not be a statistically significant difference in the 
completion of cervical cancer screening in HIV seropositive women who use tobacco, 
and have been seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, compared to 
HIV seropositive women who do not use tobacco.  
Colorectal Cancer Screening Research Questions 
Research Question 1. Does the completion of colorectal cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women seen 
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by an infectious disease specialist at the same ambulatory care center, three or more 
times, during the 12 months prior to data collection? 
Hypothesis H1a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will complete significantly more colorectal 
cancer screenings compared to HIV seropositive women in older age cohorts. 
Hypothesis H0a. HIV seropositive women in the youngest age cohort, seen by 
an infectious disease specialist at the same ambulatory care center, three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
colorectal cancer screenings compared to HIV seropositive women in older age cohorts. 
Research Question 2. Does the completion of colorectal cancer screening differ 
significantly by the race of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H2a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection, will complete significantly more colorectal cancer screening 
tests compared to Black or non-White HIV seropositive women. 
Hypothesis H0a. White HIV seropositive women, seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection, will not complete significantly more colorectal cancer screening 
tests compared to Black or non-White HIV seropositive women. 
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Research Question 3. Does the completion of colorectal cancer screening differ 
significantly by the ethnicity of HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H3a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more colorectal cancer 
screening tests compared to Hispanic HIV seropositive women. 
Hypothesis H0a. Non-Hispanic HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more colorectal cancer 
screening tests compared to Hispanic HIV seropositive women. 
Research Question 4. Does the completion of colorectal cancer screening differ 
significantly by the marital status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H4a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will complete significantly more colorectal cancer 
screening tests compared to single, partnered, divorced or widowed HIV seropositive 
women. 
Hypothesis H0a. Married HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
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months prior to data collection, will not complete significantly more colorectal cancer 
screening tests compared to single, partnered, divorced or widowed HIV seropositive 
women. 
Research Question 5. Does the completion of colorectal cancer screening differ 
significantly by the education level of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H5a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more colorectal 
cancer screening tests compared to HIV seropositive women in all other education 
levels. 
Hypothesis H0a. HIV seropositive women who are college graduates, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women in all other 
education levels. 
Research Question 6. Does the completion of colorectal cancer screening differ 
significantly by the employment status of HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H6a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
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months prior to data collection, will complete significantly more colorectal cancer 
screening tests compared to HIV seropositive women in all other employment status 
categories. 
Hypothesis H0a. Employed HIV seropositive women, seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection, will not complete significantly more colorectal cancer 
screening tests compared to HIV seropositive women in all other employment status 
categories. 
Research Question 7. Does the completion of colorectal cancer screening differ 
significantly by the type of insurance in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H1a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women with all other 
types of insurance, including no insurance, self-pay and charity care. 
Hypothesis H0a. HIV seropositive women with private or military insurance, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women with all other 
types of insurance, including no insurance, self-pay and charity care. 
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Research Question 8. Does the completion of colorectal cancer screening differ 
significantly by the length of time, in quartiles, in infected with HIV in women seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection? 
Hypothesis H8b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women infected for 
longer periods of time. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of time, 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, will not complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women infected for 
longer periods of time. 
Research Question 9. Does the completion of colorectal cancer screening differ 
significantly by HIV stage in HIV seropositive women seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection? 
Hypothesis H9b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will complete significantly more colorectal 
cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
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Hypothesis H0b. HIV seropositive women in the lowest stage of HIV, seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection, will not complete significantly more 
colorectal cancer screening tests compared to HIV seropositive women at higher or more 
progressed HIV stages. 
Research Question 10. Does the completion of colorectal cancer screening 
differ significantly by CD4 cell count in HIV seropositive women seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection? 
Hypothesis H10b. HIV seropositive women with CD4 counts of 500 cells/mm3 
or more, seen by an infectious disease specialist at the same ambulatory care center three 
or more times, during the 12 months prior to data collection, will complete significantly 
more colorectal cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Hypothesis H0b. HIV seropositive women with CD4 counts of 500 cells/mm3 or 
more, seen by an infectious disease specialist at the same ambulatory care center three or 
more times, during the 12 months prior to data collection, will not complete significantly 
more colorectal cancer screening tests compared to HIV seropositive women with CD4 
counts less than 500 cells/mm3. 
Research Question 11. Does the completion of colorectal cancer screening 
differ significantly by distance, in quartiles, in HIV seropositive women seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection? 
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Hypothesis H11b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will complete 
significantly more colorectal cancer screening tests compared to HIV seropositive 
women who live farther from the health care facility. 
Hypothesis H0b. HIV seropositive women in the lowest or first quartile of 
distance in miles, seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, will not 
complete significantly more colorectal cancer screening tests compared to HIV 
seropositive women who live farther from the health care facility. 
Research Question 12. Does the completion of colorectal cancer screening 
differ significantly between HIV seropositive women diagnosed with hypertension, and 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of hypertension?  
Hypothesis H12. There will be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with 
hypertension, compared to HIV seropositive women without hypertension, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with 
hypertension, compared to HIV seropositive women without hypertension, and seen by 
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an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Research Question 13. Does the completion of colorectal cancer screening 
differ significantly between HIV seropositive women diagnosed with obesity, and seen 
by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of obesity?  
Hypothesis H13a. There will be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with obesity, 
compared to HIV seropositive women without obesity, and seen by an infectious disease 
specialist at the same ambulatory care center three or more times, during the 12 months 
prior to data collection. 
Research Question 14. Does the completion of colorectal cancer screening 
differ significantly between HIV seropositive women diagnosed with diabetes mellitus, 
and seen by an infectious disease specialist at the same ambulatory care center three or 
more times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of diabetes mellitus?  
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Hypothesis H14. There will be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without diabetes mellitus, and seen by 
an infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with diabetes 
mellitus, compared to HIV seropositive women without mellitus, and seen by an 
infectious disease specialist at the same ambulatory care center three or more times, 
during the 12 months prior to data collection. 
Research Question 15. Does the completion of colorectal cancer screening 
differ significantly between HIV seropositive women diagnosed with depression, and 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women without a diagnosis of depression?  
Hypothesis H15. There will be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Hypothesis H0. There will not be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women with depression, 
compared to HIV seropositive women without depression, and seen by an infectious 
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disease specialist at the same ambulatory care center three or more times, during the 12 
months prior to data collection. 
Research Question 16. Does the completion of colorectal cancer screening 
differ significantly between HIV seropositive women who use tobacco, and have been 
seen by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection, compared to HIV seropositive 
women who do not use tobacco? 
Hypothesis H16. There will be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women who use tobacco, 
and have been seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, compared to 
HIV seropositive women who do not use tobacco.  
Hypothesis H0. There will not be a statistically significant difference in the 
completion of colorectal cancer screening in HIV seropositive women who use tobacco, 
and have been seen by an infectious disease specialist at the same ambulatory care 
center three or more times, during the 12 months prior to data collection, compared to 
HIV seropositive women who do not use tobacco.  
Ecosocial Theory 
The ecosocial theory (Krieger, 1994, 2008) is an epidemiological theory 
designed for the examination of societal patterns of health, as well as disease 
distributions associated with exposure, susceptibility, and resistance over the lifespan in 
populations (Figure 1).   
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Figure 1  
Simplified depiction of the ecosocial theory 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Adapted from Krieger (2008) 
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The core constructs of the ecosocial theory are: (a) embodiment; (b) pathways of 
embodiment; (c) cumulative interplay; (d) accountability and agency; and (e) analytic 
implications and predictions (Krieger, 2002, 2008). The variables associated with each 
core concept of the ecosocial theory are discussed in the following paragraphs. 
Embodiment  
A concept referring to how individuals biologically incorporate the material and 
social world, from in utero to death, where no aspect of biology can be understood 
without knowledge of the historical context as well as individual and societal ways of 
living. From an epidemiological perspective, embodiment is: (a) a construct, a process, 
and a reality contingent upon bodily existence; (b) a multilevel phenomenon integrating 
soma, psyche, and society within a historical and ecological context; (c) a clue to hidden 
and revealed life histories; and (d) a reminder of entangled consequences associated with 
diverse forms of social inequality (Krieger, 2008). To reduce biological, historical, 
material, and social variability, the study limited the eligibility of participants, as 
represented by their EMRs, to HIV seropositive women aged 40 years and older seen 
three or more times during the 12 months prior to data collection.  
Pathways of Embodiment 
Pathways of embodied are “causal pathways that involve exposure, 
susceptibility, and resistance” (Krieger, 2008). The expression of population health 
comes from the knowledge of embodiment, and the causal pathways resulting from the 
multiple levels of embodiment across time and space must be considered in a historical 
context; these pathways are shaped by societal power, material conditions, and 
biological processes and are part of the political economy, all of which are used to 
42 
 
analyze population ecology (Krieger, 2008). In the study, the pathways construct was 
represented by the independent variables of race, ethnicity, marital status, education 
level, employment status, and type of insurance. In her example of hypertension in 
African Americans, Krieger (2001) discussed how perceived, recalled, or anticipatory 
racial discrimination can initiate a physical stress response resulting in hypertension and 
how occupational segregation is connected to economic deprivation and the 
consumption of foods with high fat and salt contents, all of which can contribute to 
hypertension, while individual and social resources, such as relations resulting from 
birth into a family, attending school, and getting married, are related to resistance to 
racial oppression and can reduce the risk of hypertension in African Americans (Krieger, 
2001). Data related to each of the variables mentioned above were abstracted directly 
from the EMR and limited to the categories specified by the EMR software. 
Cumulative Interplay  
Cumulative interplay is expressed in the embodiment pathways as the presence 
and distribution of factors associated with exposure, susceptibility, and resistance at 
multiple causal levels in multiple domains on a spatiotemporal scale (Krieger, 2008). 
The literature review for the study compared the prevalence of HIV infection, breast 
cancer, cervical cancer, and colorectal cancer at the community, state, and national 
levels to support the choice of Newark as the location for the study. According to the 
New Jersey Department of Health (NJDOH, 2013), 33% of individuals living with HIV 
in New Jersey were females aged 13 years and older, and 4 out of 5 of those women 
were racial or ethnic minorities. The study was conducted at a health care facility located 
in Newark, New Jersey, in Essex County, where almost one-third of the state’s cases of 
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HIV, as well as AIDS, are located (NJDOH, 2013). The literature review discusses how 
the area in which a HIV seropositive woman resides can affect the type of health care 
she receives, and location can impact the completion of preventive health care actions. 
Distance from a regular source of health care can impact completion of preventive health 
care actions; the issues associated with distance are discussed in the literature review, 
and in this study, distance was calculated, to the tenth of a mile, between the residence 
and the health care facility. Referring back to Krieger’s example, African Americans 
may be more susceptible to hypertension because they are residentially segregated into 
older housing with lead-based paint in neighborhoods with stores featuring high-alcohol-
containing beverages instead of fresh vegetables (Krieger, 2001).  
Levels of Cumulative Interplay  
Study variables were presented in relation to the three sublevels of the 
cumulative interplay construct: (a) exposure, (b) susceptibility, and (c) resistance.  
Cumulative interplay–exposure. Variables were the year of HIV diagnosis and 
the number of years with HIV infection.  
Cumulative interplay–susceptibility. Variables included a diagnosis of an 
AIDS-defining condition or opportunistic infection and the lowest CD4 cell count, 
which are both used to determine HIV stage, the CD4 cell count associated with each 
screening interval, or the CD4 cell count at the time the preventive health care action 
was completed or due, according to USPSTF recommendations, the HIV stage for the 
screening interval, distance between the residence and the health care facility, and the 
diagnosis of one or more comorbid conditions limited to hypertension, obesity, diabetes 
mellitus, and depression, and tobacco use.  
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AIDS-defining conditions. A complete list of AIDS-defining conditions 
(ADCs), including opportunistic infections (OIs), is provided in Appendix A. The more 
common ADCs and OIs included in the data abstraction manual, are discussed later, and 
were listed in bold font for easy identification. 
CD4 cell count. In the pre-HAART time period, lower CD4 cell count, higher 
plasma HIV-1 RNA, and an AIDS-defining condition were associated with shorter 
survival, but not clinical outcomes in women with HIV infection (Anastos et al., 1999), 
while low CD4 cell counts and higher HIV-1 RNA levels were predictive of clinical 
outcomes, including AIDS-defining illness and death, in women with HIV infection 
during the post-HAART period (Anastos et al., 2004). The site of the study used a 
laboratory certified by the College of American Pathologists so all results for CD4 cell 
counts, regardless of manufacturer, were acceptable for study purposes. 
HIV stage. According to the revised CDC HIV case definitions, confirmed HIV 
cases are classified in one of four possible HIV stages (Schneider et al., 2008). Stage 1 
HIV cases had a CD4+ T-lymphocyte count of equal to, or greater than, 500 cells/µL or 
a CD4+ T-lymphocyte percentage to total lymphocytes equal to, or greater than, 29% in 
the absence of an AIDS-defining condition, as described in Appendix A. Stage 2 HIV 
cases had a CD4+ T-lymphocyte count of 200 to 499 cells/µL or a CD4+ T-lymphocyte 
percentage to total lymphocytes of 14% to 28% in the absence of an AIDS-defining 
condition, as described in Appendix A. Stage 3 HIV cases, or AIDS cases, had a CD4+ 
T-lymphocyte count of less than  200 cells/µL or a total CD4+ T-lymphocyte percentage 
of total lymphocytes of less than 14%, or a documented adult AIDS-defining condition, 
as described in Appendix A. Stage 4 HIV cases, or the unknown stage, were designated 
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as such because there is a lack of information for classification assignment (CDC, 
2008a; Schneider et al., 2008; Sax et al., 2008).   
Distance. Discussed in more detail later, as distance between residence and 
health care facility increased, fewer health care visits were observed in several studies.   
Comorbid Conditions. Some studies discussed in the review of the literature found the 
increased number of health care provider visits required by a diagnosis of hypertension 
or diabetes mellitus increased the opportunities for preventive health care referrals, 
while the comorbid conditions of obesity, depression, and tobacco use were associated 
with resistance to the completion of preventive health care actions, as women with these 
conditions were more likely to avoid health care visits thereby reducing the number of 
contacts with referring providers. Comorbid conditions are listed in the EMR by 
common name, as well as by diagnostic code from the Classification of Diseases, 
Functioning, and Disability: International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM; CDC, 2010a). 
Hypertension. At the time of the study, approximately 67 million U.S. adults, or 
31%, had hypertension, yet less than half had their hypertension controlled (CDC, 
2013b). White men and women were similarly at risk for the development of 
hypertension, and White women had a higher risk as age increased. However, African 
American and Hispanic women were more likely to develop hypertension than their 
male counterparts (CDC, 2013b). In a study examining comorbidity and cancer 
screening, hypertension was the only comorbid condition associated with an increased 
likelihood of completing cervical cancer screening (Kiefe, Funkhouser, Fouad, & May 
1998).  
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Obesity. Almost 36% of U.S. adults were obese at the time of the study, and the 
highest prevalence was observed in women aged 60 years and older (42.3%) with a 
significant aged-related trend (p < 0.001) noted when compared to women aged 20 to 30 
years (Ogden, Carroll, Kit, & Flegal, 2012). Overweight and obesity were associated 
with a lower likelihood of cancer screening completion. Body mass index (BMI) from 
18.1 to 24.9 and 25 to 29.9 was inversely related to increased age among women aged 
40 to 49 years, 50 to 64 years, and 65 to 74 years, and severely obese women with a 
BMI greater than 40 kg/m2 were less likely to complete breast cancer screening (OR = 
0.50, 95% CI = 0.37, 0.68) and cervical cancer screening (OR = 0.43, 95% CI = 0.27, 
0.70) (Ferrante et al., 2007). Data collected via chart abstraction (N = 1,297) between 
April 2003 and December 2004 from 22 family medicine practices in New Jersey and 
Pennsylvania indicated obese patients had a 25% decreased likelihood of being screened 
for colorectal cancer compared to non-obese patients (OR = 0.75, 95% CI = 0.62, 0.91, p 
= 0.004) and the study acknowledged a relationship between higher body mass and 
higher prevalence of diabetes in the general population (Ferrante et al., 2006). Data from 
the 2006, 2007, and 2008 BRFSS and the US Census was used to model the prevalence 
of obesity and diabetes in 3,141 counties in the U.S., the results of which indicated 
county-level obesity and diabetes prevalence were highly correlated (r = 0.72; CDC, 
2009a). Higher body mass index was positively associated with greater likelihood of 
insulin resistance in women with HIV infection (El-Sadr et al., 2005; Howard et al., 
2005) so data on the diagnosis of diabetes mellitus in HIV seropositive women was 
collected.  
47 
 
Diabetes mellitus. Data from the National Health Interview Survey (NHIS) 
indicated a steady increase in the number of U.S. females diagnosed with diabetes from 
1980 to 2009 with only a slight decrease occurring in 1986, 1987, and 1995 from just 
over three million women to almost ten million women, respectively (CDC, 2011a). The 
greatest number of cases in 2008 was observed in the 45 to 64 year old age group 
(4,734,000) and this age group had the highest number of cases for White females 
(3,323,000), Black females (867,000), and Hispanic females (658,000; CDC, 2011a). 
The prevalence of diabetes was significantly greater in non-Hispanic Black women 
compared to non-Hispanic White women; the prevalence of diabetes significantly 
increased with age; and individuals with a diabetic parent or sibling were about four 
times more likely to develop diabetes compared to an individual without a family history 
of diabetes (adjusted O R =3.95, 95% CI = 3.25, 4.79, p < 0.001) (Annis, Caulder, Cook, 
& Duquette, 2005). This information indicated some subgroups of the population might 
benefit from diabetes screening including HIV seropositive individuals. 
In HIV infection insulin clearance rates and insulin sensitivity are increased in 
peripheral tissues, while the medications used to treat OIs, such as pentamidine to 
prevent and treat Pneumocystis carnii pneumonia (PCP), can cause β-cell toxicity, 
hypoglycemia and later onset diabetes (Spollett, 2006). Protease inhibitor use can result 
in impaired glucose tolerance due to insulin resistance in up to 40% of the patients on 
HAART and can accelerate pre-existing glucose tolerance abnormalities prompting the 
International AIDS Society–U.S. Panel to develop recommendations for the screening 
and treatment of metabolic complications (Schambelan et al., 2002). Protease inhibitors 
were also found to significantly increase fasting glucose levels and double insulin levels 
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independently of changes in body mass index in a study pairing protease inhibitor-naïve 
participants with participants taking protease inhibitors (Mulligan et al., 2000). 
However, women with HIV infection who have not been taking protease inhibitors were 
found to have a greater risk for undiagnosed diabetes if they were currently taking 
methadone, had a body mass index of >25, a family history of diabetes, or were 
physically inactive (Howard et al., 2005).  
Depression. A diagnosis of depression is usually made according to the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR; American Psychiatric Association [APA], 2000) and a definition of 
depression based on the criteria presented in the DSM-IV-TR was too lengthy for study 
purposes. The USPSTF did not recommend screening for depression in adults at the time 
of the study (USPSTF, 2009a) but the literature review noted a relationship between a 
diagnosis of depression and a decreased likelihood to complete preventive health 
screening tests. Revised statistics from the BRFSS were used to estimate depression in 
U.S. adults in 2006 and 2008 (CDC, 2011b). Depressive symptoms for the past two 
weeks were most often reported in age groups 18 to 24 years (11.1%) and 45-64 years 
(9.6%), females (10.2%), non-Hispanic Blacks (12.9%), individuals with less than a 
high school education (17.4%), previously married (14.6%), unemployed (21.5%) or 
those unable to work (39.3%), and the uninsured (15.2%) (CDC, 2011b). Cox 
proportional hazards regression models were used in a previous study to calculate 
adjusted hazard ratios for 4,154 health maintenance organization patients with type 2 
diabetes and after adjusting for age, gender, race/ethnicity, and education level minor 
depression was associated with a 1.67-fold increase in mortality (p = 0.003) while major 
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depression was associated with a 2.30-fold increase in mortality (p < 0.0001; Katon et 
al., 2005). In a prospective cohort study of 4,184 patients of the Group Health 
Cooperative with type 2 diabetes after adjusting for demographic characteristics, clinical 
characteristics, and health habits major depression was associated with non-
cardiovascular, non-cancer-related mortality (HR = 2.15, 95% CI = 1.43, 3.24) and all-
cause mortality (HR = 1.52, 95% CI = 1.19, 1.95; Lin et al., 2009).  
A qualitative study using a modified version of the Objects Content Test (OCT) 
adapted from the Twenty Statement Test to measure self-attitudes was conducted with 
48 women with HIV infection aged 18 to 55 years and, of the 369 needs identified by 
the study participants, the greatest number of needs were psychologically related 
including support by family and friends, love and understanding, and counseling 
(Bunting, Bevier, & Baker, 1999). Patel et al. (2008) examined the responses of 628 
individuals with HIV infection and found 55% of the sample reported being concerned 
about psychological symptoms during the past three months and 49% of these 
respondents reported being bothered by sadness or depression.  
Tobacco use. Results of the 2005 and 2010 National Health Interview Surveys 
indicated a decrease in the overall prevalence of tobacco use among U.S. adults but 
decreases were not observed across all groups (King, Dube, Kaufman, Shaw, & 
Pechacek, 2011). Females aged 25 years to 44 years were more likely to smoke in both 
2005 (21.4%, 95% CI = 20.2, 22.6) and 2010 (19.8%, 95% CI = 18.4, 21.2), were more 
likely to be American Indian/Alaskan Native (26.8%, 95% CI = 15.5, 38.1, and 36.0%, 
95% CI = 24.1, 47.9, respectively), were less educated (44.1%, 95% CI = 37.6, 50.6 had 
earned a GED), and lived below the poverty level (25.7%, 95% CI = 23.6, 27.8; King et 
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al., 2011). I recorded self-reported tobacco use as a behavioral comorbid condition from 
the EMR intake record, medication log, or progress note screens. 
Cumulative interplay–resistance. Associated with a lack of or decrease in the 
completion of preventive health care actions, resistance variables in my study were the 
eligibility variables of a minimum three visits during the 12 months prior to data 
collection with the same type of health care provider at the same health care facility.  
Accountability and Agency 
Krieger (2008) described this construct as the entities and individuals responsible 
for and able to change the current patterns of population health as expressed in terms of 
embodiment pathways. As a result, epidemiological studies examining similar factors 
and causal explanations for a phenomenon but at different causal levels and/or different 
spatiotemporal scales should be able to identify the benefits and limitations associated 
with the chosen causal level and/or spatiotemporal scale (Krieger, 2008). Referring back 
to Krieger’s (2001) example of hypertension in African Americans, many African 
Americans reside in communities with a lack of health care providers or health care 
facilities causing a later diagnosis of hypertension and poorer medical management of 
the condition.  
Health care provider and health care agency. In my study health care provider and 
health care facility were considered cumulative interplay–resistance variables because 
the literature review indicated seeing the same provider at the same facility improved 
preventive health care screening completion. However, these variables were also 
associated with individuals and institutions possibly responsible for health inequities. 
For study purposes, the primary health care provider was board-certified in both internal 
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medicine and infectious diseases, had practiced in the infectious disease clinic of the 
ambulatory care center, and maintained a private practice for over 20 years. While the 
organizational structure of the university-based hospital associated with the ambulatory 
care center changed in 2009 the health care delivery model remained unchanged. 
Through eligibility criteria restrictions for health care provider and health care facility I 
attempted to control for health care delivery model variations. A thorough examination 
of the accountability and agencies contributing to a decrease in the completion of 
preventive health care actions in HIV seropositive women is beyond the scope of the 
study but the study attempted to control variability in standards of practice and the type 
of information entered into the medical record over time by limiting EMR eligibility to 
board-certified infectious disease specialists and a single infectious disease clinic in an 
ambulatory care center in Newark, New Jersey. 
U.S. Preventive Services Task Force recommendations. The recommendations 
published by the USPSTF may have created social inequities in health because the 
majority of evidentiary studies discussed in Chapter 2 upon which the recommendations 
are based were conducted using dominant groups, specifically White, non-Hispanic 
females for breast and cervical cancer and White males and females for colorectal 
cancer, though later studies used for evidentiary purposes have included more racial and 
ethnic groups. To control for variations among preventive health care recommendations 
published by different agencies and organizations only the USPSTF recommendations 
were considered in my study.  
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Analytic Implications and Predictions  
Stated as a contingent hypothesis by Krieger (2008) analytic implications and 
predictions refer to the determinants of disease distributions at the population level and 
were not reducible to mechanisms of disease causation at the individual level (Krieger, 
2002). Population patterns of health and disease are the embodied biological expressions 
of different lifestyles afforded by a society’s political economy and ecology and the 
policies and practices of a society benefit and preserve the economic and social 
privileges of the dominant group or groups while simultaneously constraining the 
conditions imposed on the non-dominant group or groups (Krieger, 2008).  
No variables were directly associated with the constructs of analytic implications 
and predictions. However, Krieger (2008) discussed contingent hypotheses resulting 
from different biological expressions which contributed to the various population 
patterns of health and illness, and the constraints on lifestyle imposed on non-dominant 
groups by policies and practices that preserve the economic and social privileges of the 
dominant group. While causation and prediction were beyond the scope of my study the 
results provided information on the proportion of HIV seropositive women 40 years and 
older who completed preventive health care actions for breast cancer, cervical cancer, 
and colorectal cancer and identified statistically significant independent variables 
associated with the completion of these preventive health care actions which can be 
compared to state and national statistics. Though generalizability may be limited the 
results may be useful to clinicians, program planners, and policymakers for the 
identification of HIV seropositive women at greater risk for failure to complete cancer 
screening in populations similar to the study sample so interventions aimed at improving 
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screening completion can be planned and instituted. The next section discusses the 
operational definitions for independent and dependent variables including the labels and 
coding schema used for data entry into the data analysis software. The constructs of the 
ecosocial theory are presented in Table 1 with the study variables and research 
questions. Variables for eligibility and the calculation or determination of other variables 
are listed by construct to aid understanding.  
Table 1 
Summary of Constructs and Relationships of Study Variables to Research Questions  
Construct Study Variable Research Question 
Embodiment Gender limited to female only Eligibility 
Date of birth Eligibility 
Age (continuous) Eligibility 
Age group  
40-53, 54-79 
RQ1 
Age cohort 
40-49, 50-79 
Comparison to state and national 
documents 
HIV status limited to 
seropositive by ELISA with 
WB confirmation 
Eligibility 
Three visits during the 12 
months prior to data collection 
Eligibility 
Pathways of Embodiment Race RQ2 
Ethnicity RQ3 
Marital status RQ4 
Education level RQ5 
Employment status RQ6 
Insurance RQ7 
(table continues) 
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(table continues) 
 
Construct Study Variable Research Question 
Cumulative Interplay Year of HIV diagnosis; 
subtracted from year of data 
collection 
Calculation of HIV time variable 
Time living with HIV RQ8 
Diagnosis of AIDS-defining 
condition 
Determination of HIV stage variable 
Lowest CD4 cell count Determination of HIV stage variable 
HIV stage RQ9 
CD4 cell count RQ10 
Distance between residence 
and ambulatory care center 
RQ11 
Diagnosis of hypertension RQ12 
Diagnosis of obesity RQ13 
Diagnosis of diabetes RQ14 
Diagnosis of depression RQ15 
Tobacco use RQ16 
Accountability and agency Health care provider; limited 
to infectious disease specialist 
Eligibility; study design 
Health care facility; limited to 
infectious disease clinic in 
ambulatory care center 
Eligibility; study design 
Model of health care delivery; 
limited by health care provider 
and facility 
Eligibility; study design 
Analytic implications and 
predictions 
Limited to USPSTF 
recommendations 
Study design 
Incidence and prevalence of 
HIV/AIDS in women in 
Newark, New Jersey 
Study design 
Note: adapted from various published articles on the ecosocial theory authored by 
Nancy Krieger. 
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Nature of the Study 
Based on the ecosocial theory (Krieger, 2008) my cross sectional study used 
observational methodology to collect and examine information extracted from the EMRs 
of 142 patients who received health care services from an infectious disease specialist an 
ambulatory care center to identify variables including comorbid conditions associated 
with the completion of, or failure to complete, preventive health care actions in a sample 
of HIV seropositive women in an urban area of the northeastern United States.  
Many HIV seropositive women were not receiving preventive health care 
services and,when the services are actually ordered by a health care provider these 
women were not completing the preventive health care actions associated with the 
screening recommendations. In HIV seropositive women failure to complete preventive 
health care actions can result in higher rates of cancer or other preventable diseases, 
more serious types or degrees of disease, and poorer prognoses. Women with HIV 
infection participating in two early studies, the New York Cervical Disease Study and 
the HIV Epidemiology Research Study (HERS), were at least 4 times more likely to be 
diagnosed with cervical squamous intraepithelial lesions (SILs) when compared to HIV 
seronegative women (Ellerbrock et al., 2000; Schuman et al., 2003). The results the 
Women’s Interagency HIV Study (WIHS) supported the findings of the earlier study but 
also identified a possible link among human papillomavirus (HPV) infection, higher 
plasma HIV ribonucleic acid (RNA) levels, and an increased likelihood of developing 
SIL over time which suggested a need for different cervical cancer screening 
recommendations for women with HIV infection (Ahdieh-Grant et al., 2004). The 
review of the literature related to preventive health care services in women with HIV 
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infection discussed in Chapter 2 supported the findings of HERS and WIHS , study 
results for HIV seronegative women, or studies where HIV infection was not a variable.  
 Seeing the same health care provider whether the provider is a generalist or a 
specialist, having a regular site where care is sought (Allen, Wieland, Griffin, & Gozalo, 
2009), and the health care delivery model of the provider and/or the site such as an acute 
care  model (Wagner et al., 2001) impacted the completion of preventive health care 
screening. Allen and coauthors (2009) stated their study results indicated the need for 
health care models focused on the continuity of both health care provider and health care 
site to improve the completion of preventive health services not just screenings. A 
simulation study examined the risks, benefits, and life expectancy of 1,000 women if 
each woman had one additional screening mammogram suggested the number of 
comorbidities should be the primary factor when determining whether to screen older 
women (Lansdorp-Vogelaar et al., 2014). Similarly the site in which health care was 
received influenced the completion of preventive health care services. The Research 
And Development (RAND) Corporation estimated up to 60% of individuals with HIV 
infection did not receive regular medical care yet women in the HCSUS had a greater 
likelihood of receiving gynecological care if they received gynecological care at the 
same place they received care for HIV infection (RAND, 2006). However, few studies 
found during the literature review determined whether the gynecological care received 
through HIV clinics was symptom-related or was care received as the result of 
preventive health care recommendations. Furthermore, few studies examined whether 
other preventive health care services such as mammography were available through the 
HIV care setting or offered to women with HIV infection.  
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Independent Variables Definitions 
The information in the EMRs was originally collected for medical care purposes 
and not for research purposes or for this study so the variables and related categories 
were defined operationally according to the design of the EMR software used in the 
infectious disease clinic.  
Embodiment Variables 
The embodiment variables included female gender, age, age cohort, census age 
group, three visits during the 12 months prior to data collection, and diagnosis of an 
AIDS-defining condition or opportunistic infection. 
Gender. The variable of female gender was abstracted from the EMR and used 
for the development of the sampling frame and eligibility purposes where female = 1, 
not female = 0, and all eligible EMRs had to have a gender code of 1.  
Date of birth. Abstracted directly from the EMR in MM/DD/YYYY format and 
immediately subtracted from the year of the study to calculate the variable of age, the 
use of date of birth in the study was limited to sampling frame development and 
eligibility purposes and was not coded for analysis. 
Age, age cohort, and census age group. Calculated from DOB, the continuous 
variable of age was recorded in whole years and eligible EMRs had to have a value of 
40 or more. Age was divided by the mean to form a two-category variable (Age 2) and 
was also transformed into the categorical variables of age cohort, in 10-year intervals 
(40–49 = 1, 50–59 = 2, 60–69 = 3, 70–79 = 4, 80–89 = 5, 90 years and older = 6) for 
analysis, and census age group (35–44 = 1, 45–54 = 2, 55–64 = 3, 65 years and older = 
4) for comparison to national databases and other studies.  
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Three visits in twelve months prior to data collection. The discrete, nominal 
variable limiting eligibility to three visits during the twelve months prior to data 
collection was shortened to 3VisitYr and coded as yes = 1 and no = 0 where a value of 
zero rendered the EMR ineligible. 
HIV status. A positive ELISA and a positive Western Blot (WB) for 
confirmation coded as 1 must have been recorded in the EMR for abstraction into the 
variable of HIV status for inclusion in the study. A missing result for either the ELISA 
or WB was coded as 0 and the EMR was ineligible. 
Pathway of Embodiment Variables 
The pathway of embodiment variables included race, ethnicity, marital status, 
education level, employment status, and type of insurance.  
Race. The discrete, nominal variable of race was limited to the categories in the 
proprietary EMR software. The categories and codes for race consisted of Black = 1, 
White = 2, Asian/Pacific Islander = 3, American Indian/Alaskan Native = 4, other = 5, 
and only one choice was allowed. 
Ethnicity. The discrete, nominal variable of ethnicity was limited to Hispanic = 
1 and non-Hispanic = 0.  
Marital status. The discrete, nominal categories and codes for marital status 
were single or never married = 1, married, = 2, partnered = 3, separated = 4, divorced = 
5, and widowed = 6.  
Education level. The discrete, ordinal categories and codes for education level 
included less than high school = 1, high school graduate = 2, some college = 3, and 
college graduate = 4.  
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Employment status. The discrete, nominal categories and codes for 
employment status were unemployed = 0, employed part time = 1, employed full time = 
2, self-employed = 3, disabled = 4, retired = 5, active military = 6, and other = 7.   
Insurance. Insurance categories and codes included Medicare = 1, Social 
Security Disability = 2, Medicaid = 3, private insurance = 4, state health maintenance 
organization (HMO) = 5, charity care = 6, self-pay = 7, not insured = 8, and other = 9.  
Cumulative Interplay Variables 
The independent variables associated with the construct of cumulative interplay–
exposure were HIV year and HIV Time. The independent variables associated with 
cumulative interplay–susceptibility were the diagnosis of an AIDS-defining condition, 
the lowest CD4 cell count recorded in the EMR, HIV stage, the CD4 cell count 
associated with each screening interval, the HIV stage associated with each screening 
interval, distance between residence and facility, comorbid diagnoses of hypertension, 
obesity, diabetes mellitus, and depression, and tobacco use. Height and weight measures 
were abstracted to calculate BMI and a data check variable was incorporated into the 
study to compare agreement between the obesity diagnosis in the EMR and the obesity 
diagnosis based on the BMI. The cumulative interplay–resistance variable of health care 
delivery model was controlled and not abstracted for analysis.  
HIV year and HIV time. The year on the laboratory reports for the variable of 
HIV status was abstracted as a four-digit value and subtracted from the year the study 
was conducted to create the continuous variable of HIV time. Only HIV time was 
included in the analyses and HIV time was divided by the mean into two categories to 
form the new variable labeled Time2. 
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AIDS-defining conditions (ADC).  ADCs include opportunistic infections 
(OIs), are associated with Stage3 HIV infection or AIDS, and have been identified by 
the CDC for the National Notifiable Diseases Surveillance System (Schneider et al., 
2008). Some of the AIDS-defining conditions such as recurrent bacterial infections are 
limited to children under the age of 13 years and were omitted from the list used in my 
study.  The EMRs were reviewed for diagnostic codes related to ACDs and OIs 
(Appendix A) and a diagnosis of any ADC was coded as Yes = 1 while the absence of 
an ADC was coded as No = 0.  
Lowest CD4 cell count. The continuous variable of lowest CD4 cell count in the 
EMR was abstracted to determine the variable of initial HIV stage and was not analyzed.  
Interval CD4 cell count. The continuous variable of CD4 cell count associated 
with each screening interval was abstracted to determine the variable of interval HIV 
stage. 
HIV stage. The categorical variables for initial HIV stage  and interval HIV 
stage were coded according to the 1993 Revised Classification System for HIV Infection 
and Expanded Surveillance Case Definitions for AIDS Among Adolescents and Adults 
(CDC, 1992), where A1 = 1, A2 = 2, A3 = 3, B1 = 4, B2 = 5, B3 = 6, C1 = 7, C2 = 8, 
and C3 = 9. The stages associated with AIDS were A3, B3, C1, C2 and C3 while A1, A2 
and A3 were considered asymptomatic, and B1, B2 and B3 were symptomatic without 
the diagnosis of an AIDS-defining condition.  
Distance. The continuous variable of distance was abstracted as three whole 
numbers with a single decimal place and was divided by the mean of the variable to 
form a new categorical variable labeled Distance 2 for analysis.  
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Hypertension. Defined as a systolic blood pressure of 140 mmHg or higher and 
a diastolic blood pressure of 90 mmHg or higher for three or more times,  a diagnosis of 
hypertension = 1 while no diagnosis of hypertension = 0. 
Obesity. Though obesity is associated with multiple physiological, behavioral, 
and psychological causes obesity was classified as a physiological comorbid condition 
for study purposes, Height and weight measurements were collected from the EMR and 
converted into a body mass index (BMI) coefficient (USDHHS, 2015). For study 
purposes, obesity was defined as a BMI of 30.0 or greater or the diagnosis of obesity 
written in the EMR. The variable obese BMI corresponded to obese by BMI = 1 and not 
obese by BMI = 0. Another variable was obese by diagnosis in the EMR where a 
diagnosis of obesity listed in the EMR = 1 and no diagnosis of obesity in the EMR = 0. 
To assess agreement between the two variables a third variable was created and labeled 
obese by both where a diagnosis of obesity in both the EMR and by BMI calculation = 1 
and a lack of agreement = 0. 
Diabetes mellitus (DM). The USPSTF did not recommend screening for Type 2 
diabetes mellitus in asymptomatic adults at the time of the study (USPSTF, 2008a). In 
the study, a diagnosis of DM was coded as 1 and no diagnosis of DM was coded as 0. 
Since mortality rates in individuals with diabetes were significantly increased in the 
presence of comorbid major depression (Katon et al., 2005; Lin et al., 2009), a diagnosis 
of depression was abstracted from the EMRs.  
Depression (DEP). For study purposes depression was defined as a diagnosis of 
any type of depression, minor or major, for any length of time with or without treatment 
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documented in the EMR. A diagnosis of depression was coded as 1 and no diagnosis of 
depression was coded as 0. 
Tobacco use (TOBUSE). Tobacco use in the study was defined as current or 
past use of any tobacco-containing product not limited to cigarettes. The USPSTF 
recommends smoking cessation for all individuals so the study collected data related to 
the use of tobacco products including ICD-9-CM codes, tobacco use documented in the 
list of diagnoses from the health care provider progress notes, or from the History and 
Physical form to determine if the HIV seropositive woman was using tobacco, which 
might act as a mediating variable, at the time a preventive health care action was 
completed or was supposed to be completed. No tobacco use was coded as 0 and a 
history of or current tobacco use was coded as 1.  
Dependent Variable Definitions 
Assessment of the dependent variables in the study included the frequency and 
type of preventive health care actions completed or not completed as appropriate to age, 
medical history, and current USPSTF recommendations (Appendix B). Completion of a 
preventive health screening test for breast, cervical, or colorectal cancer in the study was 
recorded as not completed = 0, completed on time = 1, completed early = 2, and 
completed late = 3. When cell counts were less than 5 the four categories were collapsed 
into two categories; not completed = 0 and completed = 1 without consideration for 
timing. The method of screening test was not evaluated in the study because this data 
was not routinely or uniformly recorded in the EMR. However, the following sections 
provide information on acceptable screening tests for each type of cancer according to 
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USPSTF recommendations  and additional information on the preventive health care 
actions for breast cancer, cervical cancer, and colorectal cancer. 
Breast cancer screening. Mammography sensitivity ranged from 77% to 95%, 
specificity ranged from 94% to 97%, and positive predictive value (PPV) increased with 
age (USPSTF, 2009b). Acceptable screening tests for breast cancer include screening 
mammography, breast ultrasound, or breast magnetic resonance imaging while clinical 
breast examination (CBE) and breast self-examination (BSE) are not recommended. For 
study purposes, the completion of a screening test for breast cancer was determined 
through the result of any acceptable screening test in the EMR and was coded according 
to completion and timeliness described above.  
Cervical cancer screening. A Papanicolaou (Pap) test using either liquid-based 
or conventional cytology was acceptable for screening purposes. An absence of 
endocervical component was still acceptable for screening test completion because the 
lack of a testable sample was due to test methodology and not because the individual did 
not take the action to complete the screening test. Cervical cancer screening did not have 
to include human papillomavirus (HPV) screening but the result of HPV testing was 
recorded on the data abstraction form. HIV seropositive women with a history of 
cervical cancer were expected to complete cervical cancer screening tests at the interval 
recommended by the USPSTF until removal of the cervix was documented in the EMR 
(Moyer, 2012). The completion of a cervical cancer screening test was determined 
through the results of any acceptable screening test and was coded according to 
completion and timeliness described above. 
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Colorectal cancer screening. The USPSTF does not publish sensitivity or 
specificity data related to the screening tests for colorectal cancer in the agency’s 
recommendations but sensitivity and specificity are ranked for each test from least to 
most. From least to most sensitive were (a) Hemoccult II;  (b) fecal immunochemical 
tests; (c) Hemoccult SENSA and flexible sigmoidoscopy; and (d) colonoscopy 
(USPSTF, 2009a). From least to most specific were (a) Hemoccult SENSA; (b) fecal 
immunochemical tests and Hemoccult II; (c) flexible sigmoidoscopy; and (d) 
colonoscopy (USPSTF, 2009c). Results from any of these screening test methods were 
acceptable for completion of colorectal screening in my study and the completion of a 
colorectal cancer screening test was determined through the results of any acceptable 
screening test in the EMR and coded as described above. 
Assumptions 
A major assumption of the study was the EMR contained a complete record of 
every hard copy medical record and no information had been omitted; complete 
information in the EMR was likely untrue but verification through comparison of the 
hardcopy medical record to the EMR was beyond the scope of the study. The study 
collected data only from the EMRs of patients seen in an ambulatory care department 
where 29.4% of 2006 NHAMCS respondents reported using any type of EMR/EHR 
system and the projected use of any EMR/EHR system was estimated between 62.6% 
and 71.2% by 2009 (Hing, et al, 2010).  No other electronic or hard copy record such as 
a billing database was used in the study since clinicians and researchers were not 
allowed to access to the billing records; the study focused on the main source of data 
accessible to clinicians and researchers which was the EMR for the site of the study. The 
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ambulatory care center where the study was conducted was in the process of converting 
hardcopy medical records to EMRs beginning with active patients. At the time a patient 
completed a visit the most recent information was captured electronically and the 
hardcopy medical record was flagged for transcription into electronic format. Eligibility 
criteria for the study limited the inclusion of EMRs to those of patients who had 
completed a minimum of 3 visits within the twelve months prior to data collection to 
reduce the likelihood of including a medical record not completely converted into the 
electronic format.  
The data abstraction forms related to the study were designed to capture 
information from reports of results for (a) Pap smear; (b) vaginal culture; (c) 
mammogram; (d) colonoscopy; or (e) sigmoidoscopy which were reported in an 
electronic format for several years at the facility and were downloaded or scanned into 
the EMR for patients seen in the ambulatory care center. Since laboratory, procedure, 
and imaging reports required less labor to transfer into the EMR than handwritten 
progress notes requiring transcription I assumed these originally electronic documents 
would be in the EMR and the documents would be free of transcription errors. 
Limitations 
Mann (2003) described retrospective studies as lacking bias as the information 
on the exposure variables and outcomes of interest was collected for a purpose other 
than research. Inaccurate recollection of events or recall bias was a major source of bias 
in retrospective studies but was eliminated in the study through the use of laboratory, 
procedure, and imaging reports in the EMRs instead of collecting data directly from 
clients. The study controlled for confounding between or among independent variables 
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by collecting data on those variables associated with the outcome of interest identified 
from previous studies (Mann, 2003) and discussed in the review of the literature. 
The ecosocial theory reduced some bias in study design by highlighting the 
importance measurement level and time (Krieger, 1999). The use of individual 
socioeconomic indicators instead of household-level indicators would not accurately 
represent the socioeconomic position of women and socioeconomic indicators related to 
health should be measured across the lifespan of a woman as exposures or economic 
disadvantage at an early age influence adult health.  
A major limitation of the study could have been missing data. As noted earlier 
the transfer of patient information from hardcopy charts to the EMR system at the 
facility where the study was conducted was not complete and began with current 
patients as they completed recently scheduled appointments with health care providers 
throughout the facility. While many departments such as laboratories and surgical 
pathology at the facility converted to electronic reports several years prior to the 
conversion to EMR patients not seen in the ambulatory care center on a regular basis 
only had laboratory results, surgical records, procedure documents, inpatient charts, 
emergency room charts, information releases, and consents scanned into the EMR 
system. Documents not scanned routinely into the EMR included progress notes, flow 
charts, and health care provider order sheets for inpatient, outpatient, and physician 
practice offices located on the teaching hospital campus. The scanned documents or 
electronically reported information most commonly found in the EMR for all patients 
regardless of whether they had been seen recently or not were those necessary to 
measure the completion of preventive health care actions.  I assumed any individual 
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documents missed in the mandatory record scanning such as a single laboratory report 
were randomly distributed across the study population and would not systematically bias 
the study findings.  
There was no documentation to assist me in determining if the EMR under 
review was the entire patient record or only a portion of the hardcopy medical record 
scanned into the EMR. Study eligibility criteria stated the patient must have been seen in 
the ambulatory care center 3 or more times during the 12 months prior to data collection. 
During the development of the sampling frame information on gender, date of birth, 
HIV status, and number of visits was used as eligibility criteria. Some eligible records 
may have been omitted from the study because the patient was younger than 40 years of 
age or had less than three visits recorded in the EMR at the time the sampling frame was 
compiled. Some patients may have attained 40 years of age or the required number of 
visits by the time data collection was actually conducted but the time constraints of the 
study did not allow an investigation of the number of records that became eligible in the 
time interval between the sampling frame development and data collection. The 
maturing of the client associated with the EMR and the increased number of visits were 
occurrences expected to happen randomly across all EMRs in all client populations. 
Scope and Delimitations 
As mentioned previously, comparing the hard copy medical record to the EMR 
was beyond the scope of the study since I was the only data abstractor and there was no 
funding to cover the increased manpower needed to locate and re-file each of the hard 
copy medical records at the study facility. As with the occurrence of EMRs omitted 
between sampling frame development and data collection time, the number and type of 
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documents needed to determine the completion of preventive health care actions missing 
from the EMR but present in the hardcopy record was expected to occur randomly 
across all EMRs in all client populations. Due to the specialized structure of EMRs 
across various facilities and the specialized nature of the data abstraction instruments 
designed from those EMRs the findings of the study may have limited generalizability.  
Significance of the Study 
Determining if the preventive health care actions for breast, cervical, or 
colorectal cancer screening were completed by HIV seropositive women would allow 
clinicians to identify if a significant proportion of their client population was failing to 
complete recommended preventive health care actions and would allow clinicians and 
program planners to work with HIV seropositive women to identify barriers and 
facilitating factors aimed at the improvement of completion for preventive health care 
actions. Establishing the prevalence or proportion of women who were referred for 
screening compared to women not referred would be desirable for identifying facility- or 
provider-related factors but this information would most likely be found in the progress 
notes or on a document used to record health care provider orders. At the time the study 
was conducted these hard copy documents were not uniformly transferred into electronic 
format across all client medical records and for all time periods so the information was 
not collected. Future studies at this and other facilities may want to examine these 
factors once EMR systems are standardized and complete. Improvements at the agency 
or institutional level associated with the provision of preventive health care services and 
changes to facilitate the completion of preventive health care actions might include 
programs aimed at improving cancer screening completion in specific groups such as 
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older adults and racial/ethnic minorities (Shenson et al., 2005), improving continuity of 
care or coordination of services between different departments (O’Malley et al., 2002), 
or using non-physician health care providers such as nurse practitioners (Ackerson & 
Gretebeck, 2007).   
From a public health perspective determining which groups of HIV seropositive 
women had a greater likelihood of failing to complete age appropriate preventive health 
care actions could assist program planners with the development of new programs and 
the revision of existing programs. Determining which variables such as comorbid 
conditions impact the completion of preventive health care actions in HIV seropositive 
women would allow surveillance personnel to incorporate these factors into routinely 
collected data associated with existing HIV surveillance databases so adverse trends 
could be identified and addressed in a timely manner. Preventive health care 
recommendations must be incorporated into the provision of services to individuals and 
groups with chronic illnesses but the cost effective delivery of those services may need 
to be established at the institutional and societal levels to ensure the preventive health 
care screening procedures and tests are available to all individuals and groups in various 
geographic areas. Identifying factors that facilitate, inhibit, or prevent optimal health 
across the lifespan could assist policy makers in the development of social policy with a 
positive effect on population health outcomes. If an individual is to attain optimal health 
the factors facilitating the attainment of optimal health must be incorporated into every 
level of society across the individual’s lifespan.  Research identifying geographical areas 
and subpopulations where population health has been neglected or has remained at a 
sub-optimal level for one or more generations can provide the data necessary to support 
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the enactment of policies aimed at positive social change expressed as improved 
population, group, and individual health.  
Summary 
Examining embodiment-related variables such as age, pathway-related variables 
including race and ethnicity, cumulative interplay variables such as HIV stage, distance 
from health care facility, and comorbid conditions can provide a more comprehensive 
picture of the issues associated with the completion or failure to complete preventive 
health care actions and can assist clinicians in the identification of individuals at risk for 
failure to complete screening tests. The medical records review methodology has been 
used for the identification of important variables in research studies and for program 
evaluation purposes, and the methodology will be discussed further in Chapter 2. As 
EMRs become more prevalent, as more hard copy records are replaced by electronic 
medical records, and the conversion process progresses across facilities establishing a 
consistent and accurate manner for quickly and efficiently abstracting data, EMRs will 
be an important and cost-effective methodology for studies developed and conducted for 
research, evaluation, and planning processes designed to reduce disparities across 
groups.  
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Chapter 2: Literature Review 
The literature review begins with a restatement of the identified problem and 
purpose of the study, the search strategy used to identify the documents included in the 
literature review, a brief examination of the ecosocial theory, a review of HIV infection 
in women, preventive health recommendations associated with breast cancer, cervical 
cancer, and colorectal cancer including specifics relevant to HIV seropositive women, 
and concludes with a discussion of how comorbid conditions influence the completion 
of preventive health care actions measured in the study. During the literature review, 
several inequities associated with the completion of preventive health care actions were 
identified and are discussed in relation to the independent and dependent variables. 
Subsequent sections discuss the methodology including: (a) the data abstraction tool; (b) 
the abstraction process; (c) the protection of information abstracted from the medical 
records; and (d) a brief summary. 
Problem and Study Purpose 
The problem identified for research in my study was based on published research 
articles indicating the presence or absence of certain independent variables associated 
with differences in the completion of preventive health care actions. Although studies 
were found that compared the relevance of the USPSTF recommendations between men 
and women, cancer survivors, and individuals with comorbid conditions such as diabetes 
mellitus, a lack of research to determine if the USPSTF recommendations for breast 
cancer, cervical cancer, or colorectal cancer were relevant to HIV seropositive women 
was noted. The purpose of the quantitative study was to describe, compare, and 
determine which variables differed significantly between HIV seropositive women who 
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completed recommended preventive health care actions for breast cancer, cervical 
cancer, or colorectal cancer, and HIV seropositive women who failed to complete those 
same preventive health care actions, with or without a diagnosis of one or more 
comorbid conditions, when seen by an infectious disease specialist at an ambulatory care 
center in Newark, New Jersey, three or more times during the 12 months prior to data 
collection.   
Search Strategy 
The review of the literature was conducted using online university library 
resources. Research databases accessed for the study included Academic Search 
Premier, Cumulative Index to Nursing & Allied Health Literature (CINAHL) Plus, 
Educational Resource Information Center (ERIC), MEDLINE, OvidSP Health, 
ProQuest Central, ProQuest Health and Medical Complete, ProQuest Nursing and Allied 
Health Source, ProQuest Interdisciplinary Dissertations and Theses, PsycARTICLES 
and PsycINFO, PubMed Central, and Sage Journals Online. Several journal-specific 
web sites were also searched including the Journal of the American Medical Association 
(JAMA), Archives of Internal Medicine, Morbidity and Mortality Weekly Report, and 
Preventing Chronic Disease: Public Health Research, Practice, and Policy. 
An initial search of articles, editorials, and comments from journals, books, 
manuscripts, government and private organization publications, conference abstracts, 
papers and presentations, thesis and dissertation sources, bibliographies, and papers 
available on individual authors’ web sites was conducted for the key words HIV, women 
or female, adult and United States, and the search results were limited by publication 
year (after 2000) and by topic to breast cancer, cervical cancer, colon cancer, 
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hypertension, obesity, diabetes, depression, and/or tobacco use. Articles on preventive 
health care actions were limited to breast cancer, cervical cancer, and colorectal cancer 
and included both current and historical preventive health recommendations published 
by the USPSTF.  
Each document from the search results was examined for appropriateness, 
quality, and relevance to the study; links to related documents and cited documents were 
also examined. Changes to the study as required by the Walden University dissertation 
committee and reviewers were completed prior to the human subjects’ review that 
required no changes to the study. Had changes to the study been required after approval 
by the Walden University human subjects institutional review board (IRB; 04-13-15-
0050052), data abstraction would have been delayed until approval of the study 
revisions. 
Theoretical Foundation 
As previously discussed the core constructs of the ecosocial theory are: (a) 
embodiment; (b) pathways of embodiment; (c) cumulative interplay; (d) accountability 
and agency; and (e) analytic implications and predictions (Krieger, 2008). Krieger 
(2001) considered the ecosocial theory to be one of the three major theories used by 
social epidemiologists: (a) psychosocial theory; (b) social production of disease and/or 
political economy of health; and (c) ecosocial theory. According to Krieger (2001), all 
three theories presented constructs to explain social inequities in health and describe 
disease distribution and cannot be reduced to mechanism-oriented disease causation but 
their major differences are the emphasis each places on the social and biological 
condition related to population health, how social and biological explanations are 
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integrated, and how recommendations for actions to reduce health-related inequities are 
derived.  
According to Krieger (2001), the psychosocial theory focuses on endogenous 
biological responses to human interactions and less attention is paid to the sources of 
psychosocial threats and buffers, how these threats and buffers are distributed, and how 
the distribution of the threats and buffers is determined by social, political, and 
economic policies. Little attention is paid to the effects of time except when referring to 
periods of time associated with rapid social change and Krieger (2001) uses stress as an 
example of a concept associated with the literature published by epidemiologists using 
the psychosocial theory. 
Social production of disease or the political economy of health was associated 
with the upstream-downstream metaphor commonly used in social epidemiology and 
could be used to address economic and political determinants of health and illness such 
as structural barriers and to analyze group differences associated with who benefits from 
certain policies at whose cost (Krieger, 2001). An example was the negative health 
impacts associated with income inequality leading to the programs instituted by the 
International Monetary Fund and the World Bank aimed at reducing poverty and the 
free-trade agreements instituted by the World Trade Organization (Krieger, 2001).  
The ecosocial theory is described as a multi-level, multidimensional, and 
dynamic explanatory framework used to guide inquiry and action and generate testable 
principles to analyze dynamic patterns of population health and illness at each level of 
organization such as individual, family, and community and on multiple scales including 
space and time for the development of mathematic models to illustrate and understand 
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the complex and unique interaction of organisms and processes (Krieger, 2001).  The 
primary construct of the ecosocial theory is embodiment. Concepts of biologic 
embodiment include: (a) reproduction; (b) development; (c) growth; (d) interaction 
among organisms; (e) existence in time and space; and (f) evolution. The concepts of 
social embodiment are: (a) societal context as related to but not limited to historical 
period, economic trends, and political rights; (b) social position; (c) social production 
related to but not limited to the exchange and distribution of goods, services, and 
information; (d) social consumption; and (e) social reproduction or engagement in 
processes which sustain and modify social structures (Krieger & Smith, 2004). Low 
birth weight is cited as an example of an embodied expression of social inequality. 
Socially patterned exposures before and during the pregnancy include maternal 
malnutrition; exposure to toxic substances such as lead; smoking; infections; domestic 
violence; racial discrimination; economic adversity; inadequate medical and dental care; 
and inadequate prenatal care (Krieger & Smith, 2004). Actions to reduce the incidence 
of low birth weight and improve the outcomes of low birth weight babies need to 
address issues at multiple biological and social levels over time such as the provision of 
food programs to prevent malnutrition and improve growth and development beginning 
when the mother is an infant herself; the reduction of interactions with toxic substances; 
and increased interactions with those in social positions to provide the goods, services, 
ideas, and information to meet not only the basic needs for physical survival but the 
social needs to lead a meaningful life (Krieger & Smith, 2004). 
Disparities or inequalities among groups specifically differences among racial, 
ethnic, social, and economic groups are concepts identified for continued research using 
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the ecosocial theory. Zierler and Krieger (1998) utilize the ecosocial theory to 
investigate the social inequities of HIV infection in terms of increased risk associated 
with gender. Reductions in federal spending for social programs aimed at reducing 
poverty, increasing economic inequalities among racial and ethnic groups, and the 
racially biased effort to reduce drug use which all occurred in the early 1980s were cited 
by the authors as factors contributing to increased susceptibility to HIV infection by 
women and HIV infection was a biologic expression of the social experiences associated 
with these three factors (Zierler & Krieger, 1998). As social programs were reduced or 
eliminated, more households had incomes below the poverty level and these households 
tended to be headed by Black and Hispanic females with low education levels; women 
in these households were forced to look elsewhere for economic survival such as selling 
illicit drugs or having sex for money which increased their risk of exposure to: (a) HIV 
infection; (b) violence; (c) isolation from supportive social groups; (d)  racism (Zierler 
& Krieger, 1998). Male partners could be a source of income but could also be a source 
of illicit drug use; could negatively influence a woman’s participation in harm-reduction 
activities such as participation in needle exchange programs or drug treatment programs; 
and could be a source of domestic abuse; to escape domestic abuse a woman might find 
herself homeless which could increase her chances of being raped or having unprotected 
sex for money with multiple partners (Zierler & Krieger, 1998). 
A study in Massachusetts used 1990 census block group data, 1990 census data, 
and AIDS surveillance data from 1988 through 1994 to examine the association between 
economic deprivation and AIDS incidence. In the total population, the cumulative 
incidence of HIV infection was seven times higher among men and women in census 
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block groups where 40% of more of the population lived below the poverty line 
compared to census block groups where less than 2% of the population lived below the 
poverty line (Zierler et al., 2000). In HIV seropositive women racial inequities were 
pronounced. In census block groups where less than 2% of the population lived below 
the poverty line no White females with HIV infection were reported while 131 and 133 
cases per 100,000 were reported in Hispanic and Black females, respectively. In census 
block groups where more than 40% of the population lived below the poverty line 13 
cases per 100,000 were reported in White females while 352 and 442 cases per 100,000 
were reported in Hispanic and Black females, respectively (Zierler et al., 2000). The 
ecosocial theory has been used to examine disparities associated with the variables 
identified for examination in my study and the constructs of the ecosocial theory such as 
agency and accountability were useful for examining the relevance of the USPSTF 
recommendations for breast, cervical, and colorectal screening for HIV seropositive 
women. 
Women with HIV Infection 
HIV/AIDS Incidence and Prevalence  
According to the 2009 HIV Surveillance Report women accounted for 25% of all 
HIV cases in the United States (CDC, 2011c) and the rate of women aged 13 years and 
older infected with HIV increased from 163.0 per 100,000 population in 2006 to 171.9 
per 100,000 population in 2008 (CDC, 2011c). In 2009 over 11,000 women were 
estimated to have HIV infection in the United States and of those new HIV cases in 
women 57% were Black, 21% were White and 16% were Hispanic (CDC, 2011d). The 
rate of AIDS diagnosis in women aged 13 years and older in the United States increased 
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from 80.1 per 100,000 population in 2006 to 86.5 per 100,000 population in 2008 then 
decreased in 2009 (CDC, 2011c; CDC, 2011d). The site of my study was located in 
Newark, New Jersey and for HIV/AIDS reporting purposes Newark is a division of the 
New York-New Jersey-Pennsylvania metropolitan statistical area (MSA) which was 
ranked ninth highest in the United States for HIV infection and fourth highest for AIDS 
diagnosis at the time of study development (CDC, 2011d). According to the same 2009 
HIV Surveillance Report the estimated rate of HIV diagnosis for Newark in 2009 was 
35.4 per 100,000 population and the estimated rate of AIDS diagnosis in 2009 was 26.2 
per 100,000 population while the estimated rate for persons living with HIV infection at 
year-end 2008 was 686.1 per 100,000 population and the estimated rate for persons 
living with AIDS at year-end 2008 was 345.4 per 100,000 (CDC, 2011d). 
HIV Treatment and Side Effects  
The goals of HIV-related antiretroviral therapy (ART) are: a) prolonged 
suppression of HIV viral replication; b) restoration or preservation of immune function; 
and c) improved clinical outcome (Sax et al, 2008). A thorough discussion of ART 
regimes is beyond the scope of this dissertation but at the time of the study there were 31 
antiretroviral medications available for use in the United States (USDHHS, 2011) and 
these medications are more effective when given in combination according to the 
Guidelines for the Use of Antiretroviral Agent for HIV-1-infected Adults and 
Adolescents. A recent National Institutes of Health (NIH) study confirmed early 
treatment with ART especially when the person with HIV infection presents with an 
opportunistic infection (OI) significantly reduce the occurrence of new OIs, suppressed 
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HIV plasma levels, promoted higher CD4 cell counts, and prolonged the time to AIDS 
progression (USDHHS, 2011; Zolopa et al., 2010). 
An important consideration when discussing HIV treatments is the distinction 
between the highly active antiretroviral therapy (HAART) time periods: (a) pre-HAART 
which began with the first diagnosed case of HIV and extended to approximately 1996; 
and (b) post-HAART which began with the widespread use of HAART around 1996 and 
extended to the time of my study (Bartlett, Gallant, & Pham, 2009). The pre-HAART 
period is frequently divided into 3 time periods: (a) when no treatments were available; 
(b) when monotherapy with zidovudine (AZT) was the only treatment; and (c) when 
multidrug treatment regimes were available but not as effective as HAART.  
A thorough discussion of the adverse reactions or side effects associated with 
HIV treatments is also beyond the scope of this dissertation but adverse reactions range 
from headache, fatigue, and nausea to virologic failure or death (Nguyen, 2009). Some 
comorbid conditions such as obesity and diabetes mellitus occur more frequently in 
clients with HIV infection who are taking HAART due to metabolic abnormalities 
including dyslipidemia and insulin resistance (Data Collection on Adverse Events of 
Anti-HIV Drugs [DAD] Study Group, 2007; De Wit et al., 2008). Adverse events can be 
reduced or managed when health care providers follow the aforementioned antiretroviral 
therapy guidelines (USDHHS, 2011) and when patients with HIV infection especially 
those of advanced age adhere to their medication regimes (Silverberg et al., 2007), see 
the prescribing health care provider as required, and immediately reported any problems 
to their health care provider.   
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HIV-Related Outcomes and Prognosis  
HIV infection is a chronic condition involving progressive immunodeficiency 
characterized by reductions in CD4 cell count and decreased CD4 cell responsiveness, a 
long clinic latency period, and the appearance of opportunistic infections (Sax et al, 
2008). Without treatment for HIV infection and opportunistic infections the immune 
system can be compromised and death can be the outcome. While a goal of treatment is 
to increase the time period between infection with HIV and progression to AIDS several 
factors influence AIDS progression particularly in women. HIV-specific factors 
associated with progression to AIDS include: (a) the HIV subtype (Easterbrook et al., 
2010); (b) coinfection with HIV and human T lymphotropic virus type 1 (HTLV-1) or 
type 2 (HTLV-2; Beilke et al., 2004); and (c) HIV replication capacity (Goetz et al., 
2010).  
While fewer women progress to AIDS within 12 months of their HIV diagnosis 
(31% or 3,227) compared to men (34% or 10,541) the proportion of women who 
progress to AIDS 12 months or more after their HIV diagnosis (69%) was greater than 
the proportion of men who progressed (66%; CDC, 2011c, 2011d). One study used 
primates (rhesus macaques) infected with simian immunodeficiency virus (SIV) and 
humans infected with HIV to examine relationships between variations of the X 
chromosome and HIV disease progression (Siddiqui et al., 2009). Several factors 
influenced the progression from HIV to AIDS in women including: (a) ART during the 
pre-HAART era (Lemp et al., 1992; Poundstone, Chaisson, & Moore, 2001); (b) 
antiretroviral use during the post-HAART era (Jarrin et al., & the Concerted Action on 
SeroConversion to AIDS and Death in Europe [CASCADE] Collaboration, 2008; 
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Poundstone et al., 2001); (c)  HIV disease stage at time of HAART initiation (Anastos et 
al., 2002; Ganesan et al., & the Infectious Disease Clinical Research Program [IDCRP] 
HIV Working Group, 2010); (d) adherence to ART/HAART (Ford et al., 2010); (e) 
pregnancy (Tai et al., 2007); (f) body mass index (Jones et al., 2003); (g) alcohol use 
(Baum et al., 2010); (h) crack cocaine use (Baum et al, 2010; Cook et al., 2008); (i) 
stimulant and non-injection drug use (Kapadia et al., 2005) and (j) tobacco smoking 
(Feldman et al., 2006).  
Disparities in Health 
HIV-Related Disparities 
In 2009 the rate of new HIV cases among Black women was 15 times greater 
than the rate in White women and over three times the rate in Hispanic women (CDC, 
2011c). The CDC estimates 1 in every 32 Black women, 1 in every 106 Hispanic 
women, 1 in every 182 Native American/Pacific Islander women, and 1 in every 217 
American Indian/Alaska Native women in the United States will be diagnosed with HIV 
infection while only 1 in every 526 White or Asian women will be diagnosed with HIV 
infection (CDC, 2011c).  
Cancer-Related Disparities 
During the development of my study the percentage of deaths attributable to 
cancer in U.S. women remained relatively unchanged. In 2007 and 2010 cancer was the 
second leading cause of death in U.S. women and accounted for about 22% of all deaths 
(CDC, 2011e; CDC, 2014a). When race and ethnicity are considered for those same 
years, cancer remained the leading cause of death in Asian/Pacific Islander women 
(27.2% and 28.3%, respectively) and American Indian/Alaska Native women (18.8% 
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and 19.5%, respectively) (CDC, 2011e), and became the leading cause of death in 
Hispanic women in 2011 (22.6%; CDC, 2014a).  In 2009 New Jersey was ranked the 
eleventh most populous state with an estimated 8,707,739 people (U.S. Census Bureau, 
2009). By 2012 the estimated population of New Jersey had risen to 8,864,590, and 
approximately 277,000 people lived in Newark where the site of the study was located 
(U.S. Census Bureau, 2013). In 2014 New Jersey was ranked ninth in overall cancer 
incidence for females (450.0, 95% CI = 447.5, 452.6), ninth in female breast cancer 
(129.6,  CI = 128.2, 131.0), fourth for female in-situ breast cancer (40.6, CI = 39.8, 
41.4), fifteenth for cervical cancer (8.3, CI = 8.0, 8.7), and fourteenth in colorectal 
cancer in females (39.9, CI = 39.1, 40.7) while New Jersey was ranked twenty-third in 
overall cancer deaths for females (151.0, CI = 149.2, 153.7), third for deaths related to 
female breast cancer (24.6, CI = 24.0, 25.2), sixteenth in deaths related to cervical 
cancer (14.3, CI = 13.9, 14.7), and twenty-first for deaths related colorectal cancer in 
females (2.3, CI = 2.1, 2.5; U.S. Cancer Statistics Working Group [USCSWG], 2014). 
My study examined the completion of cancer screening for breast cancer and colorectal 
cancer because these are two of the most common cancers in U.S. adult women and 
cervical cancer screening is an AIDS-defining illness.  
Breast cancer. The Surveillance Epidemiology and End Results (SEER) Cancer 
Statistics Review for 2006 to 2008 estimated the lifetime risk of a U.S. women being 
diagnosed with breast cancer regardless of race or ethnicity at 12.29%, CI = 12.23, 12.36 
(USDHHS, 2011). Based on 2009 to 2011 SEER data, this lifetime risk is almost 
unchanged at 12.33% (CI = 12.27, 12.40; USDHHS, 2014). The lifetime risk in two 
recent time periods from 2006 to 2008 and 2009 to 2011 was greatest for adult White 
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women, 12.67%,  CI [12.59, 12.74] and 12.70%, CI [12.63, 12.77] respectively than for 
all other races and ethnicities (USDHHS, 2011; USDHHS, 2014). According to data 
from the National Program of Cancer Registries (NPCR) as reported by the U.S. Cancer 
Statistics Working Group (USCSWG) between 2003 and 2007 breast cancer was the 
most commonly reported invasive cancer in adult women of all races and ethnicities in 
the United States with an age-adjusted incidence rate of 120.5 per 100,000 population, 
CI = 120.3, 120.8 (USCSWG, 2010) and incidence rates were highest in the northeastern 
United States (126.8 per 100,000 population; CDC, 2010b). By 2011 breast cancer was 
still the most commonly reported invasive cancer in U.S. adult women and the age-
adjusted incidence rate had increased slightly to 122.0 per 100,000 population, CI = 
121.5, 122.5 (USCSWG, 2014).  
Cervical cancer. Based on SEER data collected from 2006 to 2008 the 
estimated lifetime risk of an adult woman in the United States developing cervical 
cancer was 0.68%, 95% CI [0.67, 0.70] and the risk was greater in adult Asian/Pacific 
Islander women, 0.71%, CI [0.65, 0.79], adult Black women, 0.84, CI [0.79, 0.89] and 
adult Hispanic women 1.10% (,CI = 1.04, 1.17; USDHHS, 2011). Based on SEER data 
collected from 2009 to 2011 the lifetime risk of a U.S. adult female developing cervical 
cancer was slightly lower at 0.65% (CI = 0.63, 0.66; USDHHS, 2014), between 1999 
and 2011 the age-adjusted incidence rate for cervical cancer in U.S. women was 7.5, CI 
[7.3, 7.6], and of the top ten invasive cancers cervical cancer was only the tenth most 
frequently reported invasive cancer in American Indian/Alaska Native women 
(USCSWG, 2010). When HPV-related cervical cancer rates were reported for the years 
2004-2008 cervical cancer was more common in Hispanic (11.3%; CI = 11.1, 11.6) and 
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Black women (9.9%; CI = 9.7, 10.2; CDC, 2014a) emphasizing the need to consider 
HPV infection when discussing cervical cancer disparities since cancer registries do not 
track the presence of HPV at the time of cervical cancer diagnosis (CDC, 2010c).  
Colorectal cancer. Based on data from 2006--2008 the lifetime risk of an adult 
woman in the United States being diagnosed with colorectal cancer was 4.91%, 95% CI 
[4.87, 4.96] regardless of race and this lifetime risk increased to 5.12%, CI [5.07, 5.16] 
if the cancer was invasive or if the woman was Black (5.15%; CI = 5.00, 5.30) or 
Asian/Pacific Islander (5.04%; CI = 4.83, 5.27; USDHHS, 2010). Data from 2009--2011 
showed a slight decrease in the lifetime risk of an adult woman in the United States 
developing colorectal cancer (4.49%; CI = 4.45, 4.53) compared to 2006--2008 data 
with the lifetime risk only slightly higher if the cancer was invasive (4.64; CI = 4.60, 
4.69; USDHHS, 2014). The age-adjusted incidence rate for colorectal cancer in women 
of all races and ethnicities between 2007 and 2011 was 34.9% per 100,000 population, 
CI [34.6, 35.1] which made colorectal cancer the second most common cancer in 
Asian/Pacific Islander and Hispanic women and the third most common cancer in 
White, Black, and American Indian/Alaska Native women (USCSWG, 2014) with 
incidence rates higher in the northeastern United States (42.4 per 100,000 population; 
CDC, 2010b). Between 2007 and 2011 colorectal cancer was the third most common 
cancer-related cause of death in women of all races (24.6 per 100,000, CI = 24.0, 25.2) 
and colorectal cancer death rates remained significantly higher in Black women (21.0 
per 100,000, CI = 20.6, 21.3) compared to all other races and ethnicities (USCSWG, 
2010, 2014).  
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Disparities Associated with Preventive Health Care Actions 
My study examined the completion of preventive health care actions specifically 
the completion of screening for breast, cervical, and colorectal cancers according to the 
USPSTF recommendations in U.S. women with HIV infection so the discussion on 
disparities related to preventive health care is limited to these three cancers. White 
women had a greater lifetime risk of developing breast cancer but Hispanic women had 
a greater risk of dying from breast cancer compared to other race or ethnic groups. Using 
pooled data from the seven-site Breast Cancer Surveillance Consortium (N = 1,010,515), 
17,558 women received an initial diagnosis of breast cancer, 83.5% were classified as 
invasive of which 43% were stage 2 or higher and 33% were grade 3 or 4 (Smith-
Bindman et al., 2006). While breast cancer rates were significantly higher, but similar in 
White and African American women compared to other racial and ethnic groups African 
American females tended to have larger tumors at a more advanced stage and a higher 
grade with more lymph node involvement compared to their White counterparts in the 
study (Smith-Bindman et al., 2006). While Hispanic and Black females had a greater 
lifetime risk of developing cervical cancer particularly when they were infected with 
HPV cervical cancer was only in the top ten cancer-related causes of death for American 
Indian/Alaska Native women. Black and Asian/Pacific Island women had a greater risk 
of being diagnosed with colorectal cancer during their lifetime and colorectal cancer was 
more common in Hispanic and Asian/Pacific Island women but Black women died from 
colorectal cancer at a much higher rate. One reason cited for the disparities associated 
with the risk, incidence, and mortality related to breast, cervical, and colorectal cancers 
among women of different racial and ethnic groups was attributed to differences in 
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access to, as well as the use of, preventive screening programs for these cancers. 
However race and ethnicity were not the only factors associated with disparities in 
preventive health care practices.  
Levy-Storms, Bastani and Reuben (2004) surveyed 499 women aged 60 to 84 
years recruited from 60 community-based meal sites, senior centers, and senior clubs in 
the Los Angeles area between October 1998 and September 2000. The average age of 
respondents was approximately 74 year, and respondents tended to have an annual 
income of less than $20,000 (68%), less than a high school education (18%), and only 
about one-fourth were married (Levy-Storms et al., 2004). Ten percent of the 
respondents reported they had never had a mammogram and the authors indicated their 
findings supported the findings of other studies. Coughlin, Uhler, Hall, and Briss (2004) 
examined 1999 BRFSS data to identify factors associated with nonadherence to breast 
and cervical cancer screening in 56,528 U.S. females aged 18 years or older. According 
to the study findings never having had either a mammogram or a Pap smear was 
associated with one or more of the following factors: (a) not being married; (b) lower 
education level; (c) lower household income; (d) a larger number of household 
members, including children; (e) being unemployed; (f) not having seen a physician in 
the past year; (g) a lack of health insurance; (h) a lack of other preventive health 
screening tests; (i) obesity; and (j) tobacco use. A usual source of care and being 
continuously insured for the previous 12 months were the two primary factors associated 
with having a mammogram in a study of 2,231 females aged 50 to 69 years conducted 
by Litaker and Tomolo (2007) using 1998 Ohio Family Health Survey (OFHS) data. 
Insurance status was also a significant factor in the study by Sabatino et al. (2008). 
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When the authors compared National Health Interview Survey (NHIS) data collected in 
1993 and 2005 the mammography screening rates had increased. However the greatest 
difference in screening rates for both years was between uninsured women and those 
with private insurance and this difference was consistent across racial and ethnic groups 
(Sabatino et al., 2008). Colorectal cancer screening rates were even lower than the rates 
for breast and cervical cancer screening in most groups. When Trivers, Shaw, Sabatino, 
Shapiro, and Coates (2008) compared colorectal cancer screening rates from the 2000 
and 2005 National Health Interview Survey (NHIS) they noted an increase in screening 
rates from 2000 (men, 38.1%; 95% CI = 36.1, 40.2; women, 37.1%; CI = 35.3, 38.9) to 
2005 (men, 44.0%;  CI = 41.9, 46.1; women, 44.8%; CI = 42.8, 46.8). However, 
colorectal cancer screening rates did not improve for Hispanic women (28.9; CI = 23.8, 
34.6 in 2000 and 27.1%; CI = 22.0, 32.8 in 2005) or in uninsured women (20.6; CI = 
16.5, 25.3 in 2000 and 19.3%; CI = 15.7, 23.4 in 2005). After adjusting for race, income, 
insurance, age, education, region of country, and years of US residence screening 
disparities between Hispanic and non-Hispanic men disappeared but the disparities 
between Hispanic and non-Hispanic women remained after statistical adjustment and 
insurance coverage was identified as a predictor of screening behavior independent of 
income particularly in women (Trivers et al., 2008). In a study of colorectal screening 
rates in 2000 and 2003 (Liang et al, 2006) that included women the only factor 
significantly associated with current screening was a dental visit in the last year (p < 
0.001) but a dental visit in the last year, age, gender, race, ethnicity, household income, 
and education was not significantly associated with ever having been screened. 
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Disparities Summary 
When statistics presented in the preceding sections were examined HIV 
incidence was higher in Black and Hispanic women compared to other race or ethnic 
groups. Breast cancer is the most common cancer in U.S. women regardless of race or 
ethnicity, the leading cause of cancer death in Hispanic women, and the second leading 
cause of cancer death in U.S. women of other racial or ethnic groups. Colorectal cancer 
is the second most common cancer in Asian/Pacific Islander and Hispanic women, the 
third most common cancer in White, Black and American Indian/Alaska Native women, 
and the third leading cause of cancer death regardless of race or ethnicity (CDC, 2011e). 
Cervical cancer is more common in Black and Hispanic women (USCSWG, 2010) but 
when HPV infection was present the incidence of cervical cancer increased 3 to 4 times 
in Black and Hispanic women, respectively (CDC, 2010c) and HPV infection is not 
tracked by most cancer registries. Cervical cancer is more common in some groups of 
women with HIV infection. The incidence of overall cancer including breast, cervical, 
and colorectal cancer in women is higher in New Jersey compared to almost all other 
states and the overall cancer-related mortality, and the mortality associated with breast 
and colorectal cancer in New Jersey women is higher when compared to other states 
(CDC, 2011e).  
A variety of factors associated with the failure to initiate and maintain the 
recommended schedule of preventive health care actions can lead to a delay in 
diagnosis, larger tumor size, invasive disease at the time of diagnosis, and higher 
mortality. Many of the factors associated with nonadherence to screening 
recommendations are discussed later in this chapter and associated data was collected in 
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the study since the presence of one or more of these factors can be related to the 
completion of preventive health care actions in women with HIV infection.  
U.S. Preventive Services Task Force Recommendations 
The U.S. Public Health Service convened the first USPSTF in 1984 and since 
1998 the USPSTF has been sponsored by the Agency for Healthcare Research and 
Quality (AHRQ). The USPSTF is an independent panel of private sector experts in 
prevention and primary care who conduct thorough assessments of scientific evidence 
upon which recommendations for screening, counseling, and the use of preventive 
medications are based. The recommendations of the USPSTF are considered the gold 
standard for clinical preventive services (USPSTF, 2010a). 
In my study the dependent variables included; the number and type of preventive 
health care actions completed or not completed as appropriate to age, medical history, 
and USPSTF recommendations current at the time of the preventive health care action. 
Appendix B contains USPSTF recommendations arranged by publication month and 
year. Gregory-Mercado et al. (2007) examined whether participation in more than one 
screening program for breast cancer improved rescreening rates in subsequent years. 
Almost 14,000 women participated in both the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP) and the Well-Integrated Screening and 
Evaluation for Women Across the Nation (WISEWOMAN) program between 2000 and 
2004. Women enrolled in both the NBCCEDP and the WISEWOMAN programs were 
2.8 times more likely to be rescreened in subsequent years than women who participated 
in only one of the programs 
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USPSTF Recommendations for Breast Cancer 
The initial Guide to Clinical Preventive Services recommended clinical breast 
self-examination (CBE) for all women over the age of 40 years, mammography every 
one to two years beginning at age 50 years and concluding around age 75 if no cancer or 
cancer-related changes had been noted (USPSTF, 1989).  The second edition of the 
Guide to Clinical Preventive Services recommended a mammography every one to two 
years with or without CBE for women aged 50 to 69 year, and screening for women 
aged 40 to 49 years was only recommended if the woman was at high risk for breast 
cancer (USPSTF, 1996). The recommendations changed again reducing the beginning 
age for screening mammography to 40 years with screening every one to two years 
(USPSTF, 2002). The Guide published in 2009 noted an update to the recommendations 
for breast cancer was in progress and when the update was published a few months later 
the USPSTF recommended biennial mammography for women aged 50 to 74 years 
(USPSTF, 2008b, 2009b, 2009d).  
USPSTF recommendations were split in the Guide published in August 2010 
when the Affordable Care Act retained the 2002 recommendations for breast cancer 
screening and the USPSTF supported the recommendations published in 2009 
(USPSTF, 2009d, 2010b). By October 2012 no mention was made of the Affordable 
Care Act in the USPSTF publication but mammography was divided into two 
categories; film mammography; other mammography methods including digital 
mammography and magnetic resonance imaging (MRI) mammography which were both 
viewed as having insufficient evidence to support their use for screening purposes 
(Moyer, 2012; USPSTF, 2012a).  
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At the time of the study the USPSTF recommended breast cancer screening for 
women aged 50 to 74 years of age via film or digital mammography (USPSTF, 2009b, 
2009d). Clinical breast self-examination was not recommended due to a lack of 
standardized approach and reporting procedures (USPSTF, 2009b). Due to changes in 
the recommendations over time I calculated breast cancer screening intervals for each 
EMR based on the date of birth to determine if a screening test was completed or not 
completed according to the USPSTF recommendations published over time. Breast 
cancer screening recommendations were limited to those released by the USPSTF even 
though I acknowledge the existence of recommendations by other agencies and 
organizations. 
USPSTF Recommendations for Cervical Cancer 
Initially Pap testing was recommended every one to three years for all women 
beginning with the onset of sexual activity and continuing until age 65 years if Pap tests 
were consistently normal (USPSTF, 1989). An addition to the 1996 recommendations 
stated a woman should have a cervix and specified at least every three years as the 
interval while removing the age limits due to insufficient evidence (USPSTF, 1996). The 
Guide published in 2009 noted an update to the recommendations for cervical cancer 
was in progress (USPSTF, 2009e) and this information was restated in the Guide 
published the following year (USPSTF, 2010b). While the publication of the update was 
delayed until March 2012 the publication contained some major changes including a 
recommendation for a Pap smear every three years for women aged 21 to 65 years and 
for women aged 30 to 65 years who wanted to lengthen the recommended screening 
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interval a combination of Pap smear with HPV testing was recommended every five 
years (Moyer, 2012).  
At the time of the study the USPSTF recommended cervical cancer screening for 
women aged 21 years or when first becoming sexually active whichever was earlier and 
an HPV test was recommended in combination with cervical cytology in women aged 
30 years to 65 years who preferred to extend the cervical cancer screening interval from 
3 years to 5 years (USPSTF, 2008c, 2012b). Due to changes in the recommendations 
over time the study developed cervical cancer screening intervals for each EMR based 
on the date of birth to determine if a screening test was completed or not completed 
according to the USPSTF recommendations published over time. Cervical cancer 
screening recommendations were limited to those released by the USPSTF even though 
I acknowledge the existence of recommendations by other agencies and organizations. 
USPSTF Recommendations for Colorectal Cancer 
Early evidence for colorectal screening was insufficient to support the use of 
FOBT or sigmoidoscopy for colorectal screening (USPSTF, 1989). By 1996 the 
evidence supported a change in the recommendations to annual screening using FOBT, 
sigmoidoscopy, or both for all persons aged 50 years and older (USPSTF, 1996). An 
update to existing published recommendations included colonoscopy as a screening 
method and limited the upper age of screening to 75 years (USPSTF, 2008d).  
USPSTF recommendations for colorectal cancer screening at the time of the 
study were the same for men and women; fecal occult blood testing (FOBT), 
sigmoidoscopy, or colonoscopy in adults beginning at age 50 years and continuing until 
age 75 years (USPSTF, 2009c). The intervals for each screening method differed: (a) 
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annual screening with FOBT; (b) flexible sigmoidoscopy every five years in 
combination with mid-interval FOBT; and (c) colonoscopy every ten years (USPSTF, 
2009c). The study developed colorectal cancer screening intervals for each EMR based 
on the date of birth to determine if a screening test was completed or not completed 
according to the USPSTF recommendations published over time. Colorectal cancer 
screening recommendations were limited to those released by the USPSTF even though 
I acknowledge the existence of recommendations by other agencies and organizations. 
Completion of Preventive Health Care Recommendations 
Using data from the SEER Program collected from 2000 to 2003 Brenner, 
Hoffmeister, Arndt, and Haug (2007) determined the risk for colorectal cancer in 
average risk females occurred four to eight years later than in average risk males; the 10 
year cumulative mortality for men at age 50 years is reached by women between ages 54 
and 56 years. Women are less likely to develop cancer in the distal colon and rectum 
compared to men and life expectancy after treatment for colorectal cancer was higher in 
women (Brenner et al., 2007). Friedemann-Sanchez, Griffin, and Partin (2007) 
conducted focus groups of men and women who were primary care patients at the 
Minneapolis Veterans Affairs Medical Center and found significant gender differences 
related to enabling factors and barriers associated with the completion of colorectal 
cancer screening with the preparation for a colonoscopy being foremost for women. 
Gender differences in colorectal cancer as well as USPSTF recommendations for breast 
and cervical cancer screening limited to females supported my decision to limit the 
study to females only. The review of the literature identified several demographic or 
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individual characteristics that had an influence on the completion of preventive health 
care actions in women.  
Age group.  Shenson et al. (2005) examined data stratified by 49 states from 
105,860 respondents aged 50 years and older to the 2002 BRFSS to determine 
compliance with breast cancer, cervical cancer, and colorectal cancer screening 
according to USPSTF recommendations. Women aged 50--64 years and 64 years or 
older were considered current for preventive health care screenings if they had: (a) a 
mammogram within the previous two years beginning at age 40 years; (b) a Pap test 
within the previous three years beginning at age 18 years and if they had an intact 
cervix; and (c) a FOBT within the past 12 months or endoscopy for colorectal cancer 
screening within the previous ten years beginning at age 50 years. Of the women aged 
50 to 64 years; between 69.7% and 90.7% were current with breast cancer screening; 
between 75.3% and 94.5% were current with cervical cancer screening; and between 
33.9% and 59.1% were current with colon cancer screening. Of the women aged 65 
years and older; between 68.4% and 85.8% were current with breast cancer screening; 
between 61.2% and 87.5% were current with cervical cancer screening; and between 
48.5% and 74.6% were current with colon cancer screening (Shenson et al., 2005) 
suggesting the completion of preventive health care recommendations declines with 
increased age. However in a qualitative study of 98 focus group participants held in the 
New York City metropolitan area and Newark, New Jersey conducted to identify 
barriers and supportive factors associated with cervical cancer screening women aged 50 
years to 64 years were more likely to be screened than women in younger or older age 
95 
 
categories suggesting the influence of other factors not just age (Guilfoyle, Franco, & 
Gorin, 2007).  
Race and ethnicity. African American, Asian, and non-Black Hispanic were 
significantly associated with a lower likelihood of completing preventive health 
screening tests (Shenson et al., 2005) though the effect of race or ethnicity may be 
negated in the presence of one or more comorbid conditions (Kiefe et al, 1998); 
comorbid conditions will be discussed in a later section. After examining 26,401 
appointments for 1,086 women with HIV infection Tello et al. (2008) observed African 
American women were less likely to keep HIV gynecological appointments (OR = 0.63, 
95% CI = 0.45, 0.90). Focus groups involving 55 African American men and women 
(56%) aged 40 years and older found a preference for colonoscopy and FOBT and 
identified a fear of positive test results and embarrassment as major barriers to colorectal 
cancer screening; colorectal cancer knowledge and awareness were viewed as actions to 
improve colorectal cancer screening rates in the African American community (Greiner, 
Born, Nollen, & Ahluwalia, 2005). 
An examination of predisposing and enabling factors associated with the use of 
preventive care services for cervical cancer screening by ethnic minority women living 
in three community housing developments in Los Angeles County was conducted 
utilizing a sampling frame of 1,394 households identified during the previously 
conducted cross sectional study the Services Access in Urban Public Housing (SAUPH) 
study (Bazargan, Bazargan, Farooq, & Baker, 2004). Of the 418 households randomly 
sampled from the frame 391 households were determined to be eligible for participation 
27 were ineligible because members did not speak either English or Spanish so only 287 
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households actually participated in the study. The secondary study was conducted 
between May 1998 and August 1999 using data from 230 African American and 
Hispanic women. Five predisposing characteristics were associated with an absence of 
cervical cancer screening: (a) older age; (b) being Hispanic compared to African 
American; (c) lower level of education; (d) able to speak English; and (e) a finding of 
powerful others external locus of control on the Multidimensional Health Locus of 
Control (MHLC) Scale while three enabling factors were associated with a lack of 
cervical cancer screening: (a) no medical coverage; (b) a lack of continuity of medical 
care; and (c) less use of public services and benefits (Bazargan et al., 2004). In a 
secondary analysis of data from the 2000 National Health Interview Survey Lees, 
Wortley, and Coughlin (2005) reported Spanish-speaking Hispanics were significantly 
less likely to report colorectal cancer screening compared to Whites, Blacks and 
English-speaking Hispanics even after adjusting for individual characteristics such as 
socioeconomic factors as well as access and utilization factors. Hispanic-speaking 
individuals can be excluded from studies in the absence of an interpreter, bilingual study 
staff, or Spanish language survey while non-English speaking individuals can be 
included in studies using EMRs.  In a study conducted by Guilfoyle et al. (2007) some 
women reported belief in a higher power as a coping mechanism when deciding whether 
screening was necessary; reported prayer as a way to survive cancer; and Hispanic 
women were more likely to hold fatalistic beliefs or the belief a higher power controlled 
the development and outcome of cancer associated with cervical cancer screening when 
compared to other groups. Ackerson, Pohl, & Low (2008) conducted a qualitative study 
to explore background and personal factors associated with the utilization of cervical 
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cancer screening resources and the perception of vulnerability to cervical cancer in 
seven low-income African American women in south central Michigan. The participants 
who did not have routine cervical cancer screenings were influenced by important 
individuals in their lives such as mothers or other relatives and peers to associate seeking 
health care with becoming ill or increasing their risk of illness (Ackerson et al., 2008). 
These findings suggest the categories of race and ethnicity may not capture the 
entire influence of minority group membership such as speaking a different language or 
dialect than the majority of individuals in an area. The influence of other individuals 
such as a spouse or children or the influence of a higher power with control over 
whether a person will develop cancer may be issues. Examining cultural and religious 
differences was beyond the scope of this study because information on preferred 
language, birthplace, citizenship status, religious preference, and number of household 
members is not routinely documented in the EMR; the study did collect data on marital 
status.  
Socioeconomic status and insurance. In a study targeting women living in 
census tracts where more than 30% of the households reported incomes less than 200% 
of the federal poverty threshold 75% of 1,205 survey respondents had regular Pap 
smears and 65% of respondents had mammograms while only 29% of respondents had 
FOBTs, according to National Cancer Institute, American Cancer Society, and USPSTF 
recommendations (O’Malley et al., 2002). In the focus group results reported by 
Greiner, Born, et al (2005) 26% of participants preferred FOBTs. However when 279 
study participants classified as low income or income less than $1,200 per month were 
surveyed in a related study fewer FOBT cards were returned if the participant was aged 
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40 to 49 years compared to age 50 years and older (OR = 1.05, 95% CI=1.01, 1.10, p < 
0.01) and the odds of the FOBT card being returned increased 5% with each additional 
year of age over 50 years suggesting income may not be significantly associated with the 
completion of colorectal cancer screening (Greiner, James et al., 2005).  
A cross sectional random subset (n = 106) of enrollment and baseline surveys 
from low income participants of the longitudinal Open Doors to Health (ODH) study 
was compared to medical records for colorectal cancer screening response validation 
purposes; type of health insurance and employment status were significantly related to 
the completion of colorectal cancer screening (Emmons et al., 2009). A systematic 
review of the literature on cervical cancer screening in African American and Hispanic 
women found a lack of health care insurance or insurance requiring a copay; the lack of 
a primary health care provider or usual source of health care; and socioeconomic factors 
including high school or lower education level and lower income levels were associated 
with lesser likelihood of having had a Pap smear (Ackerson & Gretebeck, 2007). My 
study planned to include an examination of socioeconomic factors including educational 
level, employment status, and the type of insurance. Income information was not 
routinely captured in the EMR at the time of my study and the protection of 
confidentiality related to the use of actual addresses for the determination of household 
income from census block data prohibited the collection of financial data for study 
purposes. 
Continuity of care and primary health care provider. Haas et al. (2007) 
linked National Health Interview Survey data collected in 2000 and 2003 by hospital 
referral region using data from the Survey of Colorectal Cancer Screening Practices 
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survey to determine if regional variations in beliefs and recommendations associated 
with colorectal cancer screening existed. After statistical adjustment for individual 
characteristics colorectal cancer screening was significantly greater in regions where the 
majority of physicians (50% to 80%) recommended initial colorectal cancer screening at 
age 50 years (OR = 1.09, 95% CI = 1.01, 1.18) and respondents with a usual source of 
health care, private insurance, Medicare plus supplemental coverage, or a previous 
diagnosis of cancer were more likely to complete screening (Haas et al., 2007).  
Continuity of care at the same facility,  with the same primary health care 
provider, and health care insurance were factors associated with a greater likelihood of 
having cancer screening according to published recommendations (O’Malley et al., 
2002). Having a primary or usual source of health care reduced or eliminated some of 
the inequities observed in health care access related to preventive health care screening. 
In an article written by Hills and Mullett (2005) describing different models of primary 
care for women the authors concluded: 
If or when health care is adjusted to follow a primary health care approach, 
women’s interests will be well served…women should be included in planning 
not only because they know what services they and their families need but also 
because women are often the major initiators of accessing health 
services…primary health care professionals must also be involved to ensure that 
a full range of services such as cardiac care, family violence prevention, breast 
health, mental health, bone health, reproductive health, menopause, health 
promotion, and chronic care management are integrated into all primary health 
care serving agencies (p. 336). 
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After examining variations in health care provider characteristics including 
education, experience, and HIV knowledge as well as primary care components and 
patient outcomes Hecht, Wilson, Wu, Cook, and Turner for the Society of General 
Internal Medicine AIDS Task Force (1999) noted the need for a multidisciplinary 
approach to HIV care and suggested the greater expertise of an HIV specialist was 
associated with better patient outcomes. 
 To reduce the variability observed in studies related to the presence or lack of a 
primary health care provider or usual source of health care my study limited the 
inclusion of EMRs to clients who had been seen predominately by a single health care 
provider who was board-certified in infectious disease care, board-certified in internal 
medicine, and had over twenty years experience in HIV/AIDS patient care. Due to the 
occurrence of primary care provider vacations and illness, unscheduled visits by 
patients, and the multidisciplinary nature of HIV care other health care providers who 
were board-certified in infectious disease care saw many of the patients during the 
provision of health care services over time. However the facility in which the health care 
services were received was limited to the infectious disease clinic of the ambulatory care 
center where only health care providers experienced in the care of women with HIV 
infection attended to patients. As discussed earlier zip code was used to determine 
distance in miles between residence and the health care facility in the study. 
Comorbid Conditions and the Completion of Preventive Health Care Actions 
In a study published in 2001 Gonzalez et al. examined incidence data from the 
Florida Cancer Data System (FCDS) which was linked to the State of Florida Agency 
for Health Care Administration (AHCA) discharge abstracts for 1994 and used 1990 
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U.S. Census data to estimate socioeconomic measures by zip code (13%) or census tract 
(87%) for prostate (N = 8,659), colorectal (N = 8.035), breast (female only; N = 9,832), 
and melanoma (N = 1,524; total N = 34,616). Nineteen categories of comorbid 
conditions were identified using the Charlson comorbidity index and higher scores on 
the index were associated with an increased burden of comorbidity though the number 
of comorbidities was collapsed to three levels: (a) 0; (b) 1; (c) 2 or more during data 
analysis. For all four cancers cases with any comorbid conditions were more likely to be 
diagnosed at a later stage. While the presence of any comorbid condition was associated 
with later stage of colorectal cancer diagnosis an increasing number of comorbid 
conditions were associated with an increasing likelihood of later stage diagnosis for 
breast cancer depicting a dose-response relationship. Results did not change when the 
age of each case was restricted to the ages associated with screening recommendations 
for each cancer or when analyses were limited to invasive cancers only (Gonzalez et al, 
2001). The authors also noted comorbidity may have had an unanticipated separate and 
opposing influence on screening. While the comorbidity index was highest for colorectal 
cancer (30%) and the majority of colorectal cancer cases were diagnosed at a later stage 
the effects of comorbidity on colorectal cancer were lower than any of the other three 
cancers examined in the study. The authors suggested the presence of one or more 
comorbidities may have increased the number of contacts with a primary health care 
provider and increased the number of opportunities for discussing or conducting 
screening while the absence of any comorbidity may have decreased the perceived 
importance of screening (Gonzalez et al., 2001). 
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Comorbid Conditions in Women with HIV Infection 
Major comorbid conditions may act as confounding or mediating variables 
between HIV infection and the completion or failure to complete preventive health care 
recommendations. Kiefe et al. (1998) examined the influence of chronic disease on 
breast and cervical cancer screening adherence. The retrospective cohort study of 1,764 
women aged 43 years and older revealed each one unit increase on the Charlson 
comorbidity index was associated with a 20% decreased likelihood of a participant 
completing a Pap smear (p = 0.002) and a 17% decreased likelihood of a participant 
completing a mammogram (p = 0.005) according to the USPSTF recommendations. 
While uncomplicated diabetes without end stage organ involvement was assigned a 
score of 1 on the Charlson index AIDS was assigned a score of 6 reflecting a three times 
greater likelihood of a woman with AIDS not having a Pap smear according to USPSTF 
recommendations (Kiefe et al., 1998).  
Though HIV infection is not always considered a disability HIV infection could 
result in disability due to medication side effects (Werth, Jr., Borges, McNally, Maguire, 
& Britton, 2008) and complications related to certain infections such as cytomegalovirus 
(CMV) which are more common in persons with HIV infection than the general public 
and could cause CMV retinitis resulting in decreased visual acuity or blindness (Sax et 
al, 2008). Yankaskas et al. (2010) noted women with disabilities were less likely to 
receive preventive care recommendations from their physicians and were less likely to 
complete breast cancer screening tests compared to women without disabilities and the 
more limitations a woman experienced including hearing, visual, and physical 
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impairments the greater the likelihood the woman did not complete breast cancer 
screening according to published recommendations. 
Summary 
Gaps in the literature associated with the completion of preventive health actions 
in women were identified and discussed throughout the review; the published literature 
contained limited knowledge related to the completion of preventive health actions in 
HIV seropositive women and the existing knowledge was based on only a few valid 
studies many of which lacked reliability since the studies could not be replicated due to 
the proprietary nature of the EMRs at each facility; omissions related to the exact 
information abstracted from the EMRs in each study may have been the result of 
publication space limitations and may not have reflected a lack of methodological rigor 
on the part of researchers; the lack of documentation related to methodology further 
limited the replication of existing studies and comparison between studies was made 
more difficult; even with these limitations certain factors were associated with the 
failure to complete preventive health care actions in women: (a) older age; (b) non-
White; (c) Hispanic; (d) unemployed or disabled; (e) less than high school education; (f) 
public insurance or no insurance; and (g) a lack of continuity of care. The study utilized 
variables commonly recorded in EMRs for medical care purposes to aid replication of 
the study in the future as well as to aid with the comparison of the study findings but the 
study focused on adding to the knowledge base associated with the completion of 
preventive health care actions by examining these variables in HIV seropositive women. 
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Chapter 3: Research Method 
Research Design and Approach 
The quantitative study used a cross sectional design to collect information on 
HIV seropositive women who completed or failed to complete recommended preventive 
health care actions for breast, cervical, and colorectal cancers; how the completion of 
screening tests by these women differed in the presence or absence of hypertension, 
obesity, diabetes, and depression and tobacco use. Data was abstracted from the EMRs 
of clients seen three or more times in the 12 months prior to data collection by an 
infectious disease specialist in an ambulatory care center in Newark, New Jersey. Data 
analysis included descriptive statistics for each variable; analyses determined which 
variables impacted the completion of or failure to complete preventive health care 
recommendations of HIV seropositive women.  
The presentation of material in Chapter 3 begins with information on the location 
and setting of the study; the population from which the sample was obtained; how the 
sample size was calculated; how the data abstraction instrument was developed from the 
EMR; the manual for completing the data abstraction instrument; how validity and 
reliability were established; how bias and confounding were limited; the analysis plan as 
related to the research questions; the plan for the dissemination of the research study 
results.  
Setting and Sample 
The CDC receives reports of HIV and AIDS cases from 33 states and five US 
dependent areas; point estimates of the total number of individuals living with HIV or 
AIDS are determined. At the end of 2003 the estimated number of individuals with HIV 
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or AIDS living in the US, the District of Columbia, and U.S. dependent areas ranged 
from 1,039,000 to 1,185,000 (CDC, 2008b). By the end of 2006 the estimated number of 
individuals in the US with diagnosed or undiagnosed HIV infection was 1.1 million.; in 
2008 the CDC changed the method in which new cases of HIV infection were estimated 
(CDC, 2009b). Using the new method the CDC estimated 56,300 new cases of HIV 
infection occurred in the US in 2006 which was significantly higher than the previous 
2006 estimate of 40,000 new cases derived using the old estimation method (CDC, 
2009c, 2009d). New Jersey is one of 33 states with confidential name-based HIV and 
AIDS reporting; New Jersey has some of the nation’s highest rates per 100,000 adult 
population for HIV and AIDS at 488.2 and 264.8 respectively (CDC, 2013c).  
Sampling frame. To ensure the existence of a large enough patient population 
from which to sample I accessed the EMR server: (a) acting in a consultant role; (b) 
under the direct supervision of an infectious disease specialist; (c) using a facility 
computer, (d) in a locked limited access office; (e) after obtaining permission from the 
University of Medicine and Dentistry of New Jersey (UMDNJ) which no longer existed 
at the time my study was initiated. A sampling frame was compiled from clients of 
infectious disease specialists seen in the ambulatory care center three or more times 
(n=1,959); during the previous twelve months (n = 1,496); females only (n = 684); and 
born in 1970 or earlier (n = 566). The EMR system did not allow for searches based on 
HIV status without special permission though ICD-9-CM codes were listed throughout 
the EMR on pages for intake, diagnoses, and problems; further review of the pages 
refined the number of eligible clients to 444 HIV seropositive women aged 40 years or 
older; first and last names of the 444 eligible females were entered alphabetically in the 
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sampling frame; names were replaced by medical records numbers (MRN) of EMRs 
corresponding to each name; a number from 1 to 444 (Appendix C) corresponding to the 
line number of the Excel spreadsheet (Microsoft®, 2010) containing the sampling frame 
was used to randomize the EMRs into the study and after the initial random selection 
was replaced by a patient identification number (PID; Appendix D).  
Sample size calculation. The Power and Sample Size Calculator (Lenth, 2011) 
with a recommended alpha of .05; one-tailed; power of .80; maximum 3 degrees of 
freedom to encompass the four possible levels of preventive health care completion--
completed on time, completed early, completed late, and not completed--was used to 
calculate a sample size of 52 which was considered adequate for chi square and logistic 
regression analyses. However Monte Carlo simulations indicated a need for a minimum 
of ten events per variable to reduce bias and improve precision in logistic regression 
(Peduzzi, Concato, Kemper, Holford, & Feinstein, 1996). The formula of N = 10k/p was 
used where k = number of independent variables expected in the regression model set a 
priori at three and p as the smallest proportion of cases in the population with the 
proportion estimated at 50% for maximum variability resulting in the smallest sample 
size of 60 for logistic regression (Peduzzi et al, 1996). Newton and Rudestan (1999) 
recommended a minimum sample size of 50 + 8k as a rule of thumb. Using this formula 
the sample size was increased to 50 + (8 x 3), or 74. However when calculating the 
significance for individual variables the same authors recommended 104 + k or a sample 
size of 110 (Newton & Rudestan, 1999). Another a priori power analysis for calculating 
total sample size was conducted using G*Power a free online statistics program (Faul, 
Erdfelder, Lang, & Buchner, 2007). The input parameters of a one-tailed test, alpha of 
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0.05, and power of 0.95 were used to calculate an odds ratio of 1.95 based on the 
proportions for the completion (58.8%) or the failure to complete (42.2%) colorectal 
cancer screening in a national sample (CDC, 2012). With a critical z score of 1.64 the 
actual power was estimated at 0.95 and the total sample size was 114. Rather than 
estimate a set number of additional EMRs to include in the study for possible attrition 
random sampling with replacement was conducted. From the initial 114 EMRs 
randomized for inclusion into the study ten EMRs were randomly selected for 
abstraction at two time periods to establish intra-rater reliability associated with the 
abstraction of data over the data collection time period.   
Using a sampling frame based on visits with an infectious disease specialist in 
the ambulatory care center eliminated the records of HIV seropositive women who did 
not receive their primary health care from an infectious disease specialist and controlled 
for differences arising from variations in HIV treatment including antiretroviral (ARV) 
therapy regimes since infectious disease specialists practicing in the ambulatory care 
center typically followed the ARV therapy regimes set forth by the Panel on 
Antiretroviral Guidelines for Adults and Adolescents (USDHHS, 2009, 2011).  
Instrumentation and Materials 
The data abstracted from the EMRs was limited to information collected for the 
purpose of medical care and the data abstraction instrument was based on the EMR used 
in the ambulatory care center at the time of the study. The data abstraction modules and 
accompanying manual (Appendix E) were organized according to the EMR information 
associated with the study variables related to the research questions discussed earlier in 
Chapter 1.  
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Description of Data Abstraction Instrument 
The data abstraction instrument was created directly from the screens and fields 
in the EMR so the order and categorization of the independent and dependent variables 
is different from the order and categories associated with the ecosocial theory as 
described earlier.  
Characteristic Variables 
Female gender was abstracted directly from the EMR for eligibility purposes and 
coded as female = 1 and not female = 0. All eligible EMRs had a code of 1 for gender. 
Date of birth was abstracted directly from the EMR and used to calculate the continuous 
variable of age that was recorded as a whole number. All eligible EMRs had a value for 
age of 40 or greater. Age was transformed into the discrete, ordinal variable of age 
cohort, in 10 year intervals, coded as: (a) 40-49 = 1; (b) 50-59 = 2; (c) 60-69 = 3; (d) 70-
79 =4; (e) 80-89 = 5; and (f) 90 years and older = 6. The discrete, ordinal variable of 
census age group was also calculated from the continuous age variables and was coded 
as: (a) 35-44 = 1; (b) 45-54 = 2; (c) 55-64 = 3; and (d) 65 years and older = 4. Only age 
cohort was analyzed while census age group existed for comparison to databases and 
studies. The discrete, nominal variable of race consisted of: (a) Black = 1; (b) White = 2; 
(c) Asian/Pacific Islander = 3; and (d) American Indian/Alaskan Native = 4. Only one 
choice for race was allowed. The discrete, nominal variable of ethnicity was limited to 
Hispanic = 1 and Non-Hispanic = 0. The discrete, nominal categories and codes for 
marital status were: (a) single or never married = 0; (b) married = 1; (c) partnered = 2; 
(d) separated = 3; (e) divorced = 4; and (f) widowed = 5. The discrete, nominal 
categories and codes for education included: (a) less than high school graduate = 1; (b) 
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high school graduate = 2; (c) some college = 3; and (d) college graduate = 4. 
Employment was limited to one response from the discrete, nominal categories: (a) 
unemployed = 0; (b) employed part time = 1; (c) employed full time = 2; (d) self-
employed = 3; (e) disabled = 4; (f) retired = 5; and (g) active military = 6. Insurance 
categories and codes included: (a) Medicare = 1; (b) Social Security Disability = 2; (c) 
Medicaid = 3; (d) private insurance = 4; (e) state HMO = 5; (f) charity care = 6; (g) self-
pay = 7; and (h) no insurance = 8. All the variables mentioned in this section included a 
response for other = 666, unknown = 888, and missing = 999.  
The earliest recorded date for HIV diagnosis in each EMR was abstracted as the 
continuous variable of HIV year and coded as a numeric value reflecting the year of the 
positive ELISA with WB for confirmation; all eligible EMRs had to have a valid year 
recorded for HIV year. The continuous variable of HIV time was calculated by 
subtracting HIV year from the year of data collection and was recorded as a continuous 
value reflecting the number of years with HIV infection. Data on ADCs including OIs 
for adults (Appendix A) was abstracted from the EMR and coded as Yes = 1 or No = 0. 
This information along with lowest CD4 cell count was used to determine HIV Stage 
which was coded: (a) A1 = 1; (b) A2 = 2; (c) A3 = 3; (d) B1 = 4; (e) B2 = 5; (f) B3 = 6; 
(g) C1 = 7; (h) C2 = 8; and (i) C3 = 9.   
Clinical Variables 
The independent variables of health care provider and health care facility were 
controlled by eligibility criteria so data related to these two variables was not abstracted. 
The number of miles to tenth of a mile between the residential zip code plus 4 in the 
EMR and the ambulatory care center zip code plus 4 was recorded; coded as a numeric 
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value for the continuous variable of distance; divided by the variable mean to create a 
discrete, ordinal form of the distance variable for analysis purposes. 
Comorbid Conditions 
Hypertension, diabetes mellitus, depression, and tobacco use were coded as: (a) 
never diagnosed or used = 0; (b) history of = 1; and (c) currently has or used = 2. The 
diagnostic code for obesity was abstracted directly from the EMR and was also 
determined by calculating the BMI from the height and weight recorded in the EMR 
(USDHHS, 2015) with obesity defined as a BMI of 30 or greater. As a data entry check 
a diagnosis of obesity from both sources was determined during data abstraction and all 
three variables: (a) obesity by ICD-9-CM code in the EMR; (b) obesity by BMI; and (c) 
obesity diagnosis from both sources were coded as No = 0 and Yes = 1.  
U.S. Preventive Services Task Force Recommendations 
Time intervals for the preventive health screening tests for breast cancer, cervical 
cancer, and colorectal cancer, were calculated from the date of birth; based on the dates 
on laboratory, radiological, and procedure reports for screening tests in the EMR coded 
as not completed = 0 or completed = 1. However for each preventive health screening 
interval with a completed screening test and based on the USPSTF recommendations 
current for the screening of each type of cancer at that time (Appendix B) a 
determination was made during data abstraction related to the timing associated with 
each interval and coded as: (a) not completed = 0; (b) completed on time = 1; (c) 
completed early = 2; and (d) completed late = 3. The method or type of screening test 
was not abstracted in the study.  
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Assessment of Reliability and Validity of Instrument 
Reliability. Yawn and Wollan (2005) examined the agreement at 5 time periods 
(1 month, 3 months, 6 months, 12 months, and 24 months) for data abstracted by 9 nurse 
data abstractors--only 6 at any one time--over 2.5 years from more than 1,200 medical 
records. Medical records information for ten years prior to the defining event 
(myocardial infarction) were examined and three types of data were identified for the 
determinations related to accuracy and agreement: a) demographic data or numerical test 
result; b) free-text data requiring the transcription of natural language; and c) 
information requiring a judgment on the part of the data abstractor. At one month 
agreement for demographic and laboratory result data, free-text data, and judgment data 
was rated as very good, good, and unacceptable resulting in retraining of all data 
abstractors. At three months after retraining agreement for demographic and laboratory 
result data, free-text data, and judgment data ranged from excellent to very good with 
demographic and laboratory result data having the highest agreement. The authors 
expressed agreement among the 6 nurses as a ratio of same responses to total responses 
instead of using kappa statistics which the authors determined were irrelevant to the 
study due to the large number of responses reviewed.   
As my study had a single data abstractor a variation of test-retest reliability was 
utilized to determine reliability. Data from the first 10 EMRs from which data was 
abstracted had data abstracted a second time near the end of the data collection process-- 
and the resulting data was compared for agreement between data collected at Time 1 and 
Time 2-- to determine the reliability associated with the data abstraction process.  
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To, Estrabillo, Wang, and Cicutto (2008) conducted a secondary medical records 
review study to determine reliability among 10 data abstractors at 15 study sites. Data 
abstractors were not allowed to re-abstract the data they collected originally at Time 1 
and the sample size for charts randomly selected for re-abstraction at Time 2 was 
calculated to allow the detection of a kappa statistic between 0.60 and 0.70. Time 1 was 
between September 2003 and June 2005 and Time 2 was between July 2005 and 
February 2006 near the close of the study; no time was allowed for retraining or 
adjustments in study procedures aimed at improving reliability.  
Data requiring the transcription of free-text language or a judgment by the data 
abstractor tended to be less reliable in the Yawn and Wollan (2005) study as evidenced 
by less agreement between abstractors over time. To improve reliability the data 
abstraction instrument for my study was designed to capture responses requiring less 
free-text or judgment-based data. 
Validity. In the study by Yawn and Wollan (2005)--discussed in the reliability 
section--the authors noted their study did not examine validity so while the ratio of same 
responses to total responses might be good (4/6) to very good (5/5) those high number of 
same responses used to determine reliability might all be incorrect data. To et al. (2008) 
added 8 simulated charts to the data re-abstraction at Time 2 in their study then 
compared the answers of the multiple data abstractors to the correct information in the 
simulated charts to address questions related to the validity of the abstracted data in 
addition to the kappa statistics calculated as a measure of reliability. The data abstracted 
from the simulated charts by the multiple data abstractors was also compared to the data 
abstracted from these same charts by an experienced abstractor who was considered the 
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data abstraction gold standard for the purpose of calculating sensitivity and specificity 
estimates (To et al., 2008). Other authors have supported the use of an experienced nurse 
as the gold standard for data abstraction from medical records (Bertelsen, 1981; Justice 
et al., 2006). 
By limiting data abstraction to a single site and a single abstractor with 
experience in the abstraction of data from medical records my study sought to establish 
high reliability by reducing variability related to different data abstractors (Bertelsen, 
1981; Yawn & Wollan, 2005; To et al., 2008); differences in medical records systems 
(Lemon, Zapka, Estabrook, & Benjamin, 2006; To et. al., 2008); different sources of 
information documented in the medical record (Tisnado et al., 2007).  
The use of control charts for monitoring adherence changes in clinical settings 
was found superior to the use of before and after study designs where data collected at 
two different time points was compared and analyzed for change (Peek, Goud, & Abu-
Hanna, 2008) but in a retrospective cohort study of mammogram adherence in 399 
women by Armstrong, Long, and Shea (2004) self-reporting of mammogram completion 
tended to over-report numbers possibly due to social desirability bias and recall errors, 
and while administrative and billing data bases were not subject to information biases 
billing data underreported mammogram completion often due to coding errors; in some 
cases billing data limited eligible participants to those with insurance (Armstrong et al., 
2004). The medical records review (MRR) was found to be the gold standard for 
measuring mammogram adherence; the two major sources of bias cited by the authors 
was missing or incomplete information and the existence of multiple records (Armstrong 
et al, 2004). 
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While reliability and validity were frequently not reported for studies utilizing 
EMRs both should have been reported along with measures of data quality; reliability 
should be calculated using kappa statistics (Engel, Henderson, Fergenbaum, & 
Colantonio, 2009) not just the percentage or ratio of agreement among abstractors or 
between time periods. Several best practice guidelines associated with the abstraction of 
data from EMRs were found during the review of the literature but focused on the 
standardization of processes associated with: (a) instrument development and testing; (b) 
data abstraction; (c) data recording; and (d) data analysis with the ultimate goal being a 
reliable and valid MRR study (Engel et al., 2009). My study sought to reduce the bias 
associated with self-report by determining adherence to preventive health care screening 
tests through the direct abstraction of data from laboratory, radiological, and procedure 
reports in the EMR; a manual was developed a priori to provide guidance during the 
data abstraction process; reduce the need for judgment by the abstractor; and to serve as 
a guidebook for future researchers. 
Instrument Completion 
Significant issues associated with the use of EMRs in research involve 
differences between the purpose of the research and the purpose of the database from 
which the data was abstracted (Engel et. al., 2009; VonKoss Krowchuk, Moore, & 
Richardson, 1995; Worster & Haines, 2004). During the development of the data 
abstraction instrument potential problems were identified and addressed in the manual 
(Appendix E) to allow the abstractor to determine where the data necessary for research 
purposes could be found in the EMR. For example a measureable clinical activity 
recorded in the EMR by more than one source was Pap smear; the date was recorded in 
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the Progress Notes as a procedure and in the Laboratory section as a Laboratory Result. 
The manual explicitly instructed the abstractor to obtain data from the Laboratory Result 
first followed by the information transcribed into the Progress Notes if no laboratory 
report was found. 
The greatest concerns associated with instrument completion for the study were 
conflicting data and missing data. The manual reduced the amount of conflicting data by 
providing guidelines that prioritized which information from each source to use for each 
variable. Dates associated with each completed preventive health care action were taken 
directly from laboratory, radiological, and procedure reports to reduce duplication 
associated with multiple information sources and allow the resolution of conflicts 
identified during data abstraction.  
Data was considered missing if none of the sources identified in the abstraction 
manual contained the information. Every effort was made to find information in the 
EMR such as in the case when a preventive health care screening test was ordered and 
documented in the Progress Notes but no result was found. If the abstractor had 
difficulty locating information in the EMR or found the information on source 
documents not listed in the abstraction manual this finding could have indicated a 
problem or lack of clarity with: (a) the development of the study; (b) the data abstraction 
instrument; or (c) the manual so this information was documented separately for review. 
As with other study methodologies, though, statistics were used to reduce the amount of 
missing data in the study. Case deletion and imputation were two methods for 
addressing missing data during the analysis phase of a study (Worster & Haines, 2004). 
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Case deletion is commonly used and involves deleting cases with missing 
observations from the analysis but the challenges of using this method include bias if 
those cases with missing data differed significantly from cases without missing data and 
would result in a reduced sample size (Worster & Haines, 2004). In my study case 
deletion was not used since the research purpose associated with the completion of 
preventive health care actions would involve the absence of data if an individual had not 
completed any preventive health care actions. Imputation used to address missing data in 
large databases (Worster & Haines, 2004) were described as using the average or the 
mode of all observations in a category to determine a value for missing data within the 
same category; sampling with replacement and imputation were used in my study to 
obtain a value for missing information not related to a preventive health care action to 
prevent a reduction in sample size. 
Data Collection and Analysis 
As discussed in several earlier sections of this paper, my study abstracted data 
recorded in hard copy format then transcribed into an electronic format or recorded in an 
electronic format from EMRs. The age of each client was used to create time intervals 
according to the USPSTF screening recommendations for breast, cervical, and colorectal 
cancers; the completion of the screening test--the dependent variable--was recorded as: 
(a) not completed; (b) completed on time; (c) completed early; or (d) completed late for 
each time interval associated with a preventive health care action. Information on 
gender, age, and HIV status was collected for eligibility criteria purposes. In an effort to 
control for continuity of care variability eligibility criteria restricted inclusion into the 
study to those EMRs associated with clients who had seen an infectious disease 
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specialist in a single ambulatory care center at least three times during the 12 months 
prior to data collection. The independent variables are detailed later in this chapter and 
included sociodemographic variables and the diagnoses of certain cormorbid conditions. 
Data Analysis Software 
The statistical analysis software was the Statistical Package for the Social 
Sciences (SPSS) version 21.0 (International Business Machines [IBM] Corporation, 
2012). SPSS was based on the measurement scale classifications of nominal, ordinal, 
interval, and ratio (Stevens, 1946) but SPSS analyzes continuous variables at the interval 
level only (IBM, 2012). Stevens' classification system (1946)--also known as Stevens' 
scale type theory--presents guidelines limiting the use of mathematical and statistical 
operations based on the properties associated with each measurement scale. Adherence 
to Stevens' scale classifications has been debated with the majority of arguments focused 
on: (a) inconsistencies in Stevens' theory (Gaito, 1980); (b) limitations associated with 
the appropriate use of parametric versus non-parametric statistics by measurement scale 
when a statistical assumption has not been met (Zumbo & Zimmerman, (1993); and (c) 
the danger of blind allegiance to the measurement scale classifications when theory 
should direct research studies and the statistics used to analyze the data (Velleman & 
Wilkinson, 1993). The study followed the guidelines described by Stevens (1946) since 
nominal, ordinal, and interval or scale determinations were necessary when the data was 
entered into the SPSS software. Violations related to the use of statistics by 
measurement scale and violations associated with the assumptions related to the use of 
parametric statistics are noted in this paper where appropriate. 
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Measurement and Classification 
To correctly enter the data for each EMR into SPSS each variable was labeled 
and defined by data type and measurement level. Appendix F lists each variable by the 
terminology used in the EMR; the SPSS label assigned to the term; numeric codes for 
each possible sublevel or value related to each independent and dependent variable; 
values associated with: (a) declined to answer; (b) unknown value as indicated in the 
EMR; (c) missing value; each variable was identified by the level or measurement for 
SPSS purposes as nominal, ordinal, or scale. 
Independent Variables 
Each variable was identified as an independent variable or a dependent variable 
and the levels of each variable were identified for interpretation of the data related to the 
research questions.   
Embodiment variables. Age calculated from date of birth was a continuous variable 
but was collapsed into 10-year intervals to create the additional variables of age cohort 
for analysis (Table 2) and census age group at discrete, ordinal levels for comparison to 
databases and other research studies. 
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Table 2  
Bivariate Analysis Plan for Embodiment Variables (N=114)a 
Variable/ 
Label 
Type/ 
Level 
Central 
Tendencyb 
 
 
 
Variability/ 
Dispersionc 
 
Inferential 
Statistics: 
Parametricd 
 
 
Sig (p)d 
 
Inferential 
Statistics: 
Non-
Parametrice 
 
Sig(p)e 
Age in years/ 
AGE 
Continuous 
Interval 
Mean 
 
Standard 
Deviation 
Independent 
Samples  
t test 
 
 
 
p<0.05,  
CI =95% 
 
Mann-Whitney  
U-test 
w/Hodges- 
Lehman 
estimate 
 
p<0.05,  
CI ~ 95% 
 
Age cohort/ 
COHORT    
40-49=1   
50-59=2   
60-69=3 
70-79=4 
80-89=5 
90+=6 
Categorical 
Ordinal 
Mode 
Median 
 
 
 
 
Range 
Independent 
Samples  
t test 
 
 
 
p<0.05,  
CI =95% 
Mann-Whitney  
U-test 
w/Hodges- 
Lehman 
estimate 
 
p<0.05,  
CI ~ 95% 
Notes. aData Check: frequencies for each variable = number of EMRs reviewed; bSkew 
(positive/right = mode/median < mean; negative/left = mode/median > mean) of sample; 
cAnalysis for assumption of normal distribution (SD = − 1 to 1 = 68%, SD = − 2 to 2 = 
95%, SD = − 3 to 3 = 99%); dNormal distribution; eNot a normal distribution  
α = 0.05, β = 0.20, power = 0.80, effect size = 0.80. 
 
Pathways of embodiment variables. Building upon Stevens' (1946) classifications the 
discrete, nominal variables associated with the pathways of embodiment construct were 
race, ethnicity, marital status, employment status, and insurance type while education 
level was measured at the discrete ordinal level (Table 3).  
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Table 3  
Bivariate Analysis Plan for Pathways of Embodiment Variables (N=114)a 
Variables/ 
Label 
Type/ 
Level 
Central  
Tendencyb 
 
 
 
Variability/ 
Dispersionc 
Inferential  
Statistics: 
Parametricd 
 
 
Sig (p)d 
Inferential 
Statistics: 
Non-
Parametrice 
 
Sig (p)e 
Patient’s race/ 
RACE 
Black=1 
White=2 
Asian/Pacific  
    Islander=3 
AIAN=4 
Other=666 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05, CI~ 
95% 
 
Patient 
ethnicity/ 
ETHNIC 
Non-
Hispanic=0 
Hispanic=1 
Declined=777 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05, CI~ 
95% 
 
Marital status/ 
MARITAL 
Single/Never     
   Married=0 
Married=1 
Partnered=2 
Separated=3 
Divorced=4 
Widowed=5 
Other=666 
Declined=777 
Unknown=888 
Missing=999 
 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05, 
 CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05, CI~ 
95% 
 
(table continues) 
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(table continues) 
 
Variables/ 
Label 
Type/ 
Level 
Central  
Tendencyb 
 
 
 
Variability/ 
Dispersionc 
 
Inferential  
Statistics: 
Parametricd 
 
 
Sig (p)d 
Inferential 
Statistics: 
Non-
Parametrice 
 
Sig (p)e 
Highest level 
of educational/ 
EDLEV 
<High 
   School=1 
High School  
   graduate=2 
Some 
college=3 
College  
  graduate=4 
Other=666 
Declined=777 
Unknown=888 
Missing=999 
 
Categorical 
Ordinal 
Median 
Mode 
 
 
 
 
 
Range 
Independent 
Samples  
t test 
 
 
 
 
p <.05,  
CI =95% 
 
Mann-Whitney  
U-test 
w/Hodges- 
Lehman 
estimate 
 
p < 0.05, CI ~ 
95% 
 
Employment 
status/ 
EMPLOY 
Unemployed=
0 
Part Time=1 
Full Time=2 
Self 
employed=3 
Disabled=4 
Retired=5 
Active  
   Military=6 
Other=666 
Declined=777 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05, CI~ 
95% 
 
(table continues) 
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(table continues) 
 
Variables/ 
Label 
Type/ 
Level 
Central  
Tendencyb 
 
 
 
Variability/ 
Dispersionc 
 
Inferential  
Statistics: 
Parametricd 
 
 
Sig (p)d 
Inferential 
Statistics: 
Non-
Parametrice 
 
Sig (p)e 
Insurance type/ 
INSURE 
Medicare=1 
SS 
Disability=2 
Medicaid=3 
Private 
  Insurance=4 
State HMO=5 
Charity Care=6 
Self-Pay=7 
Other=666 
Declined=777 
Unknown=888 
Missing=999 
 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05, CI~ 
95% 
 
Notes.aData Check: frequencies for each variable = number of EMRs reviewed; bSkew 
(positive/right = mode/median < mean; negative/left = mode/median > mean) of sample; 
cAnalysis for assumption of normal distribution (SD = −1 to 1 = 68%, SD = −2 to 2 = 
95%, SD = −3 to 3 = 99%); dNormal distribution; eNot a normal distribution 
α = 0.05, β = 0.20, power = 0.80, effect size = 0.80 
 
Cumulative interplay variables. Number of years since HIV diagnosis and distance 
between the residence and ambulatory care center were continuous variables which were 
collapsed and analyzed at the discrete, ordinal level (Table 4).  
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Table 4  
Bivariate Analysis Plan for Cumulative Interplay Variables (N=114)a 
Variable/ 
Label  
Type/ 
Level 
Central 
Tendencyb 
 
 
Variability/ 
Dispersionc 
 
Inferential 
Statistics: 
Parametricd 
 
Inferential 
Statistics: 
Non-
Parametrice 
Number of 
years with 
HIV/ 
HIVTIME 
Continuous 
Interval 
Mean 
 
 
 
 
Std Dev 
Independent 
samples t test 
 
 
p < 0.05,  
CI = 95% 
Mann-Whitney 
U-test 
w/Hodges- 
Lehmann 
estimate 
 
p < 0.05, CI ~ 
95% 
 
Distance 
between 
residence and 
health care 
facility 
DISTANCE 
Continuous 
Interval 
Mean 
 
 
 
 
Std Dev 
Independent 
samples t test 
 
 
p < 0.05,  
CI = 95% 
Mann-Whitney 
U-test 
w/Hodges- 
Lehmann 
estimate 
p < 0.05,  
CI ~ 95% 
 
CD4 cell count 
lowest 
LOWCD4, & 
interval 
INTCD4 
Continuous 
Interval 
Mean 
 
 
 
Std Dev 
Independent 
samples t test 
 
 
p < 0.05,  
CI = 95% 
 
Mann-Whitney 
U-test 
w/Hodgesehma
nn estimate 
p < 0.05,  
CI~ 95% 
Notes. aData Check: frequencies for each variable = number of eligible EMRs reviewed; 
bSkew (positive/right = mode/median < mean; negative/left = mode/median > mean) of 
sample; cAnalysis for assumption of normal distribution (SD = −1 to 1 = 68%, SD = −2 
to 2 = 95%, SD = −3 to 3 = 99%); dNormal distribution; eNot a normal distribution 
α = 0.05, β = 0.20, power = 0.80, effect size=0.8 
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Comorbid conditions—discrete, nominal variables--had dichotomous responses: (a) the 
absence of a comorbid condition; (b) history of or current diagnosis of a comorbid 
condition. The comorbid conditions my study were hypertension, obesity, diabetes 
mellitus, depression, and tobacco use. As a data check within each EMR the diagnosis of 
obesity by ICD-9-CM code in the EMR was compared to the presence of obesity via 
BMI calculated from height and weight recorded in the EMR and both measured as 
discrete, nominal variables (Table 5).  
Table 5  
Bivariate Analysis Plan for Cumulative Interplay - Comorbid Conditions (N=114)a 
Variable/ 
Label  
Type/ 
Level 
Central 
Tendencyb 
 
Variability/ 
Dispersionc 
Inferential 
Statistics: 
 
Parametricd 
Sig (p)d 
Inferential 
Statistics: 
 
Non-
Parametrice 
Sig (p)e 
 
Hypertension/ 
HTN 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
 
Categorical 
Nominal 
Mode 
 
 
 
Range 
Chi square 
 
 
 
p < 0.05,  
CI= 95% 
Fisher’s exact 
test 
 
 
p < 0.05,  
CI~ 95% 
Obesity in 
EMR/  
OBSEMR 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
p < 0.05,  
CI~ 95% 
 
(table continues) 
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(table continues) 
 
Variable/ 
Label  
Type/ 
Level 
Central 
Tendencyb 
 
Variability/ 
Dispersionc 
Inferential 
Statistics: 
 
Parametricd 
Sig (p)d 
Inferential 
Statistics: 
 
Non-
Parametrice 
Sig (p)e 
 
Obese per 
BMI/ 
OBSBMI 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
 
p < 0.05,  
CI~ 95% 
 
Obese in EMR 
and BMI/ 
OBSBOTH 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
Fisher’s exact 
test 
 
p < 0.05,  
CI~ 95% 
 
Diabetes 
mellitus 
diagnosis/ 
DMDX 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
Range 
Chi square 
 
p < 0.05,  
CI= 95% 
 
Fisher’s exact 
test 
p < 0.05,  
CI~ 95% 
 
Depression 
diagnosis/ 
DEPDX 
Never=0 
Hx of/Past=1 
Current=2 
Unknown=888 
Missing=999 
Categorical 
Nominal 
Mode 
 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
Fisher’s exact 
test 
 
p < 0.05,  
CI~ 95% 
(table continues) 
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(table continues) 
 
Variable/ 
Label  
Type/ 
Level 
Central 
Tendencyb 
 
Variability/ 
Dispersionc 
Inferential 
Statistics: 
 
Parametricd 
Sig (p)d 
Inferential 
Statistics: 
 
Non-
Parametrice 
Sig (p)e 
 
Tobacco use/ 
TOBUSE 
Never=0 
Hx of or 
Current=1 
Unknown=888 
Missing=999 
 
Categorical 
Nominal 
Mode 
 
 
Range 
Chi square 
 
 
p < 0.05,  
CI= 95% 
Fisher’s exact 
test 
 
p < 0.05,  
CI~ 95% 
Notes. aData Check: frequencies for each variable = number of EMRs reviewed; bSkew 
(positive/right = mode/median < mean; negative/left = mode/median > mean) of sample; 
cAnalysis for assumption of normal distribution (SD =	 −1 to 1 = 68%, SD =	 −2 to 2 = 
95%, SD = −3	 to 3 = 99%); dNormal distribution; eNot a normal distribution 
α = 0.05, β = 0.20, power = 0.80, effect size = 0.80 
 
Dependent Variables 
Dependent variables in the study were related to the completion of or failure to 
complete preventive health care actions: breast cancer screening mammography; 
cervical cancer screening Pap smear with or without HPV testing; and colorectal cancer 
screening by FOBT, sigmoidoscopy, or colonoscopy. The values associated with the 
three preventive health care actions were (a) not completed; (b) completed, on time; (c) 
completed early; and (d) completed late. If any cell number in the contingency tables 
created for the data analysis was less than five the categories were collapsed into the 
dichotomous response categories of not completed or completed without any 
consideration for the timeliness of the preventive health care action. 
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Data Analysis Process 
Data analysis began by checking the data entry accuracy and completeness. 
Column totals were calculated using SPSS and compared to the number of entries. Every 
EMR had a column entry and the number of entries equaled the number of EMRs 
determined from the sample size calculations. The study checked data abstraction 
accuracy over the length of the study period by reviewing ten EMRs twice; during the 
initial days of data abstraction; followed by the second review during the final days of 
data abstraction. Data from both abstraction times were compared for agreement using 
percent agreement and kappa statistics.  
Frequency distributions, histograms with normal curves, and scatterplots with fit 
lines were calculated to determine the presence of outliers, skew, and kurtosis to 
evaluate the normal distribution assumption. If a distribution appeared abnormal skew 
and kurtosis statistics, and stem-and-leaf plots were generated. All outliers were checked 
for accuracy of data entry but categorical variables were within the range of values 
determined a priori and listed in Appendix F. No further effort was made to collect 
missing data because a comparison of the abstracted data to the actual hard copy medical 
record was beyond the scope of my study and would have negated the use of the EMR 
as the primary source for data abstraction.  
Data entry was also checked through response categories. Obesity was 
determined by calculating BMI from height and weight measurements in the EMR and 
by the presence of a corresponding ICD-9-CM code listed in the EMR. A third variable 
was created to assess agreement between both methods for determining obesity and was 
used as a data check by coding responses as agreement = 1 and no agreement = 0. The 
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third variable described as obesity by BMI and in EMR could not have a response 
indicating agreement if only one of the obesity method variables had a response 
synonymous with no diagnosis of obesity.  
Summarizing the Data 
Summary analyses consisted of determining which single number best 
represented the data or the measure of central tendency and how much variability existed 
in the data.  
Central tendency. Mean, median, and mode were calculated for continuous, 
interval variables; discrete, ordinal variables were analyzed for median and mode; only 
mode was calculated for discrete, nominal variables. 
Variability. Range, variance, standard deviation, and interquartile range were 
calculated for continuous or scale variables. Since standard deviation and variance are 
sensitive to sample size the unbiased option in SPSS was selected. Discrete nominal and 
ordinal variables were analyzed for the range and distribution of observations associated 
with each variable and values with less than five observations were collapsed since five 
is the default cell count in SPSS below which analyses cannot be completed. 
Inferential Analyses  
The three assumptions associated with the use of parametric statistics were: (a) 
independent, unbiased sample; (b) normally distributed data; and (c) homogeneity of or 
equal variance. Independence and bias were addressed through random sampling and the 
study design. Analyses to evaluate normal distribution and homogeneity of variance 
were discussed earlier. The study used parametric statistics if the assumptions associated 
with their use were not violated. In the event one or more of the assumptions were 
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violated data was transformed in SPSS to comply with the assumptions or nonparametric 
statistics were used. If a parametric statistic was used when an assumption was violated 
the reason for using the statistic was provided in the Discussion section. 
Research Questions and Hypothesis Testing 
The purpose of the study was to determine if the variables associated with the 
constructs of embodiment, pathways of embodiment, and cumulative interplay--
identified and described earlier--differed significantly between HIV seropositive women 
who completed or failed to complete recommended preventive health care actions for 
breast cancer, cervical cancer, or colorectal cancer and if the findings from previous 
studies were applicable to HIV seropositive women who completed or failed to complete 
those same preventive health care actions with or without a diagnosis of one or more 
comorbid conditions of hypertension, obesity, diabetes mellitus, depression, or tobacco 
use when seen by an infectious disease specialist at the same health care facility three or 
more times during the 12 months prior to data collection. 
Analysis Plan 
Descriptive statistics. Frequencies and percentages were reported for each 
variable grouped by completion of preventive health care action and timeliness when 
cell counts allowed. As described in Appendix F, the completion and timeliness of 
preventive health care actions were coded in SPSS as: (a) not completed = 0; (b) 
completed on time = 1; (c) completed early = 2; and (d) completed late = 3. When the 
three completion groups were analyzed as a single group such as when the number of 
observations within one of the groups was less than five the codes were completed = 1; 
not completed = 0.  
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Comparing group differences. The unpaired or independent-samples t test was 
used to compare continuous independent variables such as age in years in HIV 
seropositive women who completed or failed to complete the preventive health care 
screening tests for each of the three cancers of interest. To determine if there is a 
statistically significant age difference between HIV seropositive women who completed 
their first mammogram compared to HIV seropositive women who failed to complete 
their first mammogram the variable age was selected as the test variable in SPSS and the 
grouping variable for the first breast cancer interval or the first time interval when a 
mammogram was recommended by the USPSTF was completed or not completed . The 
window for the first breast cancer interval ranged from 39 years 6 months of age to 40 
years 6 months of age. The confidence interval was set at 95%, one-tailed alpha of 0.05, 
and missing values were imputed on a case-by-case basis. For hypothesis testing the null 
hypothesis was no difference in the ages of the two groups of HIV seropositive women. 
SPSS produced two test statistics: Levene's test of equality of variances; t test for 
equality of means. The F statistic for the Levene’s test was used to determine the 
assumption of equal variances between the two groups. When the Levene’s test statistic 
for equal variances assumed was significant, the t test for equality of means for equal 
variances not assumed was used. The t test interpretation referred to the chance of 
observing a mean difference if the null hypothesis of no difference was true. The mean 
difference was the difference in the age by number of years between the two groups 
(IBM, 2012). If the sample data violated one or more parametric assumptions the Mann-
Whitney test was used instead of the independent samples t test.  
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Fisher's exact probability was used instead of chi-square to compare differences 
between categorical independent variables; Fisher's exact was preferred over chi-square 
because Fisher's produced an exact p value and could be used when the number of 
observations in one cell was small (IBM, 2012); with either test all observations had to 
be independent and the degree of freedom was 2 - 1 = 1. In SPSS either test could be 
calculated in the crosstabulation function which provided observed and expected counts 
and percentages within each of the four resulting cells. If the null hypothesis to be tested 
indicated no difference in the diagnosis of hypertension between the two groups of HIV 
seropositive women related to the completion or failure to complete breast cancer 
screening Fisher's exact test indicated immediately if there was a significant difference 
between the two groups. If the percentage of observations was higher in the cell 
corresponding to HIV seropositive women with a history of breast cancer and HIV 
seropositive women who completed a mammogram the Fisher's exact test indicated the 
mean associated with the completion of mammograms for HIV seropositive women who 
had hypertension was significantly different from the mean associated with the 
completion of mammograms for HIV seropositive women who did not have 
hypertension. The chi-square statistic was used with the Yates' continuity correction to 
make the p value associated with the chi square statistic more approximate (IBM, 2012). 
Contingency tables. To continue with breast cancer screening and hypertension as an 
example if 63 HIV seropositive women with hypertension had a mammogram and 24 
failed to have a mammogram and 14 HIV seropositive women without hypertension had 
a mammogram while 13 failed to have a mammogram when the data was entered into a 
2x2 table (Table 6) the result was determined as more HIV seropositive women with 
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hypertension completed a mammogram than HIV seropositive women without 
hypertension.  
Table 6  
Completion of Mammograms in HIV Seropositive Women with Hypertension 
Mammogram HTN – Yes 
(coded as 1) 
HTN – No 
(coded as 0) 
Totals 
Yes 
 
63 (a) 14 (b) 77 
No 
 
24 (c) 13 (d) 37 
Totals 
 
87 27 114 
 
The odds ratio (OR) associated with a hypertensive HIV seropositive woman completing 
a mammogram compared to an HIV seropositive woman without hypertension was 
calculated as follows: 
OR = (a/b)/(c/d) 
= (63/14)/(24/13) = 4.5/1.85 = 2.43 
 
or by using the crossproducts calculation as follows: 
 
OR = (a x d)/(b x c) 
= (63 x 13)/(14 x 24) = 819/336 = 2.43 
 
HIV seropositive women with hypertension were 2.43 times more likely to complete a 
mammogram compared to HIV seropositive women without hypertension. To test for 
the significance of the OR calculated in the example above Fishers exact ratio test was 
conducted for a 2 x 2 table as follows: 
p  =  (a + b)! (c + d)! (b + d)! 
n!a!b!c!d! 
 
where  
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p is the Fisher’s Exact Probability 
“a”, “b”, “c”, “d” represent individual cell counts 
“n” represents the total of the cell counts 
Continuing with the example the Fisher’s exact probability (p) was calculated as: 
p  =  (63 + 14)! (24 + 13)! (14 + 13)! 
114! 63!14!24!13! 
 
=  1.96/1.23  = 1.59 
 
To interpret Fisher’s exact probability a value greater than 1 indicated an event 
was more likely to occur and a value less than 1 indicated an event was less likely to 
occur. Interpretation of the Fisher’s exact probability calculated in the example (p = 
1.59) indicated HIV seropositive women with hypertension were more likely to have a 
mammogram compared to HIV seropositive women without hypertension. When the 
data no longer created a 2 x 2 table, chi-square was used instead of the Fisher’s exact 
ratio test.  
Analysis of variance (ANOVA). If the number of observations in each cell was 
10 or more four groups related to the timeliness of completed preventive health care 
actions were used for analysis of variance (ANOVA): (a) failed to complete = 0; (b) 
completed on time = 1; (c) completed early = 2; and (d) completed late = 4. The 
grouping variable that formed the four groups based on the completion and timeliness of 
preventive health care actions was known as the degree variable or factor (IBM, 2012). 
The assumptions associated with ANOVA were independent random samples from a 
normally distributed population with equal variances and the statistical test examined the 
variability between groups as well as within groups (IBM, 2012). The null hypothesis 
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tested was no difference in the estimated variability between or within each group. 
Degree of freedom was 4 –	 1 = 3 and the null hypothesis was rejected if the observed 
significance level was less than 0.05. The between-groups estimate of variance would 
only be true if the null hypothesis was true and if the between-groups estimate of 
variance was large the null hypothesis was usually not supported (IBM, 2012). The 
ANOVA table generated by SPSS displayed the sum of squares and mean square for 
between-groups variance and the sum of squares and mean square for within-groups 
variance as well as the total for the sum of squares. The F statistic was the ratio of the 
between-groups mean square to the within-groups mean square and was approximately 1 
when the null hypothesis was supported. If an assumption violation was noted the 
Kruskal-Wallis statistic was used (IBM, 2012). In addition to the analyses conducted on 
individual variables logistic regression was conducted for all variables significant at p < 
0.20 in univariate analyses and elimination based on the Hierarchial Principle 
(Kleinbaum & Klein, 2002) was conducted until a parsimonious model was identified 
which described the variables associated with the completion or failure to complete 
preventive health care screening tests for each of the three cancers in HIV seropositive 
women. A more thorough discussion of how logistic regression was used to answer the 
research questions is presented in the following sections. 
Regression Modeling  
Logistic regression was chosen as the mathematical modeling approach for 
several reasons: a) the dependent variable could be dichotomous; completed or not 
completed; b) a large number of independent variables could be used for logistic 
regression modeling especially using SPSS; c) the logistic function f(z) ranged from 0 to 
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1 and described the probability of completing or not completing the preventive health 
care action; and d) the logistic model created an S-shaped logistic model with a 
threshold which was applicable to the multivariate nature of epidemiologic research 
(Kleinbaum & Klein, 2002). Regression results in SPSS were presented in tables that 
used the same symbols common in logistic regression modeling where the dependent 
variable is termed the constant or intercept (⍺) and the term coefficient refers to the 
independent variable. The letter B in the SPSS coefficients table or the slope (β) 
represents an imaginary line drawn through each value of the dependent variable while 
the constant represents where a value of the independent variable intersects the slope of 
the line representing the dependent variable.  
Dummy variables and recoding. Dummy or binary variables were used to 
examine group differences on a variable. Categorical, nominal variables were recoded 
into binary variables indicating the presence (= 1) or absence (= 0) of a characteristic, 
comorbid condition, or screening test. The coefficient normally represents the change in 
the value of Y for every one-unit change in X but this interpretation can not be applied 
when dummy variables are used in the regression calculation because there is no change; 
there is only the presence or absence of a value or characteristic. Instead the value of the 
constant indicates the expected value of Y when X is zero. Ordinal variables were coded 
to reflect an increasing value such as age cohort or a more preferred value such as 
education level; ordinal variables could also be recoded to add a zero value where 
appropriate. Based on the literature review education level could be coded as the 
presence of a education beyond high school (= 1) versus the absence of education 
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beyond high school (= 0) the latter of which would also include women with less than a 
high school education. 
In my study sociodemographic variables identified in the literature review 
associated with women who were more likely to complete the preventive health action 
for breast cancer specifically a mammogram tended to be: younger; White; Non-
Hispanic; married; educated at a level higher than a high school graduate; employed; 
and have private insurance. To answer the research questions concerned with which 
embodiment and pathway of embodiment variables were associated with the completion 
of recommended preventive health actions for breast cancer each of these variables were 
recoded (Table 7). 
Table 7  
Recoding of Embodiment Variables for Regression Modeling 
 
Old SPSS Label New SPSS Label Recoded Values for SPSS 
COHORT DUMCOHORT 0 = Less than 40 years 
1 = 40-49 years 
2 = 50-59 years 
3 = 60-69 years 
4 = 70-79 years 
5 = 80-89 years 
6 = 90 years or older 
RACE DUMRACE 0 = Non-White 
1 = White 
ETHNICITY DUMETH 0 = Non-Hispanic 
1 = Hispanic 
MARITAL DUMMARI 0 = Non-/Never Married 
1 = Married 
EDLEV DUMEDLEV 0 = < High School 
1 = > High School 
EMPLOY DUMEMPLOY 0 = Not Employed 
1 = Employed and  
      Active Military 
INSURE DUMINSURE 0 = Non-Private 
1 = Private 
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Recoding dependent variables. Binary coding was already applied to the 
completion of the first mammogram where completed = 1 and not completed = 0. Using 
SPSS the values in the missing and unknown groups could have been classified as 
missing without further attempts to find the data and not used in ANOVA or logistic 
regression calculations. Since the study was also interested socioeconomic and clinical 
variables associated with the timing of completed preventive health care actions the first 
mammogram could have been recoded to incorporate both the completion of the first 
mammogram as well as the timing--on time, early, or late--according to the USPSTF 
recommendations. The initial coding associated with variable concerned with the timing 
of the first mammogram variable was: not completed = 0; complete on time = 1; 
completed early = 2; and completed late = 3. The variable was recoded so the values 
increased in relation to the ideal response: not completed = 0; completed late = 1; 
completed early = 2; and completed on time = 3.  
Regression Analysis  
When each of the dummy independent variables was regressed on the dependent 
variable SPSS created a coefficients table. A positive coefficient indicated a positive 
slope while the inverse was true for a negative coefficient. If the B coefficient had a 
negative value when the dummy variable for timing of the first mammogram was 
regressed on race this finding would indicate White HIV seropositive women differed 
from non-White HIV seropositive women on the timing of their first mammogram 
completion.  
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Significance and parsimony in regression modeling. When an independent 
variable was determined to be statistically significant I referred back to the literature 
review to guide the determination of which variables were clinically significant and 
should be used to develop the models to explain the differences observed in the 
dependent variables. Referring back to the original example where race, education level, 
and insurance were associated with the completion of breast cancer screening if these 
three independent variables were found to be statistically significant they could have 
been entered into the regression model. SPSS was allowed to determine if all three 
variables were needed to explain the difference in the completion of breast cancer 
screening or if two variables provided a similar or better explanation. A more 
parsimonious model can save time and expense related to future data collection 
especially for clinical or program evaluation purposes. 
Regression models for answering research questions. The first set of research 
questions asked which variables related to the constructs of embodiment, pathway of 
embodiment, and cumulative interplay in HIV seropositive women aged 40 years and 
older were associated with the completion or failure to complete the recommended 
preventive health care action for breast cancer. Regression modeling was used to answer 
the research questions and develop a model to determine whether the timing of 
screening completion for breast cancer screening was related to these variables. 
To create a model to explain the variables associated with the completion of the 
recommended preventive health care action for breast cancer in HIV seropositive 
women all statistically significant categorical variables including recoded dummy 
variables and continuous variables were used to create a regression model to answer 
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each research question. For example if the categorical variable DUMRACE and the 
continuous variable of years since HIV diagnosis were the only variables found to be 
statistically significant in SPSS the regression model explaining differences in the 
timing of the completion of the first mammogram for breast cancer screening purposes 
would be:  
where 
Y = Timing of the completion of first mammogram  
0 = Not Done 
1 = Completed, On-Time 
2 = Completed, Early 
3 = Completed, On Time 
 
X1 = Years since HIV diagnosis, or HIV Time 
 
X2 = DUMRACE 
0 = Non-White 
1 = White 
 
and 
 
ŷ = a + b1 x1 + b2 x2 
  
Hierarchial regression. Alternatively the order of variable entry into the 
multivariate regression model could be based on the literature review. While race might 
be a possible confounding variable the review of the literature indicated race was 
significantly related to failure to complete preventive health care actions: 1 in every 32 
Black women were HIV seropositive; breast cancer was the second most common cause 
of death in all races after adjusting for age but Black women were typically diagnosed at 
a later stage with invasive breast cancers; and non-White women were less likely to 
complete cancer screening tests.  
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Ethnicity could be the second variable entered in the regression model. One in 
every 106 Hispanic women had HIV the second highest incidence rate in U.S. female 
populations; breast cancer was the primary cause of cancer death in Hispanic women; 
colorectal cancer was the second leading cause of cancer death in Hispanic women; 
HPV-related cervical cancer was more common in Hispanic women; and fewer Hispanic 
women were screened for any type of cancer.  
No insurance was cited in several studies as a significant predictor of not 
completing cancer screening after adjusting for: (a) race; (b) age; (c) education level; (d) 
geographic region; (e) years of US residence; (f) and income. Having insurance was 
associated with higher rates of cancer screening test completion in women. Number of 
years since HIV diagnosis would be entered next into the model as more frequent 
contact with health care providers and a primary source of health care required for the 
management of HIV infection was associated with higher screening completion in 
women. However many HIV seropositive women require less intensive HIV 
management after their childbearing years or as they accommodate to their HIV disease 
so the number of contacts tend to decline over time resulting in less completion of 
preventive health care actions. Education level would be entered next into the model 
since education levels less than high school and high school graduation were significant 
predictors of lower screening completion in some studies. 
Marital status specifically: being single; not partnered; separated; divorced; or 
widowed were associated with lower screening completion in women. Being 
unemployed was also associated with lower screening completion in women. Failure to 
complete an initial cervical cancer screening test related to either age or onset of sexual 
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activity was positively associated with lower screening completion because cervical 
cancer screening typically begins at a younger age than breast and cervical cancer 
screenings and may indicate an individual’s willingness to comply with preventive 
health screening recommendations. 
The comorbid condition of obesity defined as a BMI of 30 or greater was 
associated with lower cancer screening completion in women. Current tobacco use and a 
history of tobacco use were both associated with lower screening rates in women. 
Diabetes mellitus and hypertension both require more frequent contact with health care 
providers and usually result in a primary source of health care for long-term 
management of both comorbid conditions. However while a diagnosis of diabetes 
mellitus was associated with higher screening completion rates in women, hypertension 
was more often undiagnosed and tended to result in fewer visits with a health care 
provider. Most studies in the literature review considered depression as a confounding 
variable. 
The initial breast cancer screening test though possibly occurring later in the 
lifespan when compared to the initial cervical cancer screening test was associated with 
higher screening completion rates possibly due to the availability of many free or low 
cost mammography programs in the inner city. The initial colorectal cancer screening 
test would be entered next into the regression model because the completion of one type 
of cancer screening test was found to improve the completion rates for other types of 
cancer screening. However the completion of colorectal cancer screening was not as 
predictive as breast cancer screening or cervical cancer screening because the 
preparation for sigmoidoscopy and colonoscopy screening methods was described in the 
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literature as intensive and uncomfortable and the preparation solution was often too 
expensive for low income women or women without health insurance. 
Regression models for interaction. Kleinbaum and Klein (2002) recommend a 
three-stage procedure using hierarchical modeling: variable specification; followed by 
the interaction assessment; a confounding and precision assessment. The initial model 
was created using all lower order variables. For the research questions associated with 
the diagnosis of one or more comorbid conditions of hypertension (V1), diabetes (V2), 
obesity (V3), depression (V4), and tobacco use (V5) reducing the likelihood a women with 
HIV infection would complete preventive health care action for breast cancer the 
dichotomous variable would become completed or not completed (E) for breast cancer 
screening and the initial model would be: 
EV1V2V3V4V5 
There were two levels for each of the comorbid diagnoses: a) has the diagnosis; 
i; b) no diagnosis, j. All levels of each component would be included so the complete 
initial model would be: 
EV1iV1jV2iV2jV3iV3jV4iV4jV5iV5j 
The second stage of the procedure was hierarchical backward elimination and 
involved statistical testing to identify interaction terms with the goal being a reduction in 
the number of redundant components in the model. This procedure did not test for 
confounding which was addressed later. If a higher level component was found to be 
insignificant the lower level component was likely be dropped from the model. However 
the hierarchy principle requires all lower level components of a statistically significant 
higher level component remain in the model (Kleinbaum & Klein, 2002). In the analysis 
143 
 
EV1iV1j would be analyzed before EV1 and nonsignificant components of the model 
would be eliminated. For instance if hypertension obesity and depression were found to 
be statistically significant for not completing the recommended preventive health care 
action for breast cancer the model would be comprised of the following components:  
EV1iV1j, EV2iV2j, EV4iV4j 
Once the revised model containing statistically significant components was 
identified Kleinbaum and Klein (2002) recommended a single chunk test on the 
components with a null hypothesis as follows: 
EV1V2, EV1V4, EV2V4 
H0: σ1 = σ2 = σ4 = 0 
Kleinbaum and Klein (2002) recommended using a likelihood ratio test 
involving a chi-square statistic with three degrees of freedom to compare the complete 
model to the revised model. If the chunk test was not significant all the terms were 
eliminated. However, if the chunk test was statistically significant some, but not 
necessarily all of the components would be retained in the model.  
Backward elimination was conducted one component (EV1, EV2, EV4) at a time 
to determine which components should remain in the final model and the researcher can 
decide to conduct the backward elimination procedure without conducting the chunk 
test. The least significant component was the first component to be considered for 
elimination from the model using the likelihood ratio chi-square test with one degree of 
freedom which compared the complete model to the model with the least significant 
component removed. To continue with the previous example if the component for 
depression was found to be the least significant then component EV4 would first be 
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eliminated and the likelihood ratio would compare the complete model to the reduced 
model without EV4: 
Complete model: EV1V2, EV1, EV2, EV4, V1, V2, V4, V1V2, V1V4 
Reduced model: EV1V2, EV1, EV2, V1, V2, V4, V1V2, V1V4 
If this backward elimination procedure found the component (EV4) to be 
statistically nonsignificant all levels of the component would be removed from the 
model. However if the component was significant all levels of the component would be 
retained in the final model. All remaining components were subsequently tested using 
the likelihood ratio chi-square test with one degree of freedom eliminating components 
in the order of least to most significant by comparing the complete model to the reduced 
model without the component being tested. 
Analyses to Identify Confounding 
Bivariate analysis could be used to identify confounding using the Cochran-
Mantel-Haenszel method. If 65 out of every 400 Black women living in Newark, New 
Jersey failed to complete initial breast cancer screening tests (0.1625) while 45 out of 
every 600 women of all other races combined failed to complete initial breast cancer 
screening tests the estimated relative risk (RR) for failing to complete initial breast 
cancer screening tests in Black women compared to all other races would be RR = 
0.1625/0.075 = 2.167 suggesting Black women in the Newark, New Jersey area were 
2.17 times less likely to complete initial breast cancer screening tests compared to 
women of all other races living in Newark, New Jersey. In this example where the crude 
RR = 1.79 the Cochran-Mantel-Haenszel method could be used to calculate an adjusted 
RR of 1.43. A change of 10% or more in the estimated measure of association would 
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suggest confounding was present so (1.79 – 1.43)/1.43 = 25%. Since 25% is greater than 
10%, confounding by race would exist. Similar calculations could be conducted to 
identify confounding among different combinations of embodiment variables, pathways 
of embodiment variables, and cumulative interplay variables including comorbid 
conditions found to be significant in bivariate testing. Confounding variables would not 
be entered into the initial model. Entry into the regression model would be based on 
highest to lowest prevalence--crude RR--for each independent variable associated with 
HIV seropositive women who had three or more visits within the 12 months prior to data 
collection with an infectious disease specialist in the ambulatory care center in Newark, 
New Jersey.  
Regression models for confounding. Kleinbaum and Klein (2002) identified 
those components without an exposure term (E) in the reduced model as confounders; 
that interaction occurred in those components involving exposure. For my study if the 
example using breast cancer screening was continued, the confounders would be: 
V1, V2, V4, V1V2, V1V4 
There is a lack of interaction components (EV1, EV2) including the one interaction 
component omitted because testing found depression (EV4) to be statistically 
nonsignificant. Kleinbaum and Klein (2002) indicated confounding can be easily 
assessed and confounding is determined before precision. The formula for assessing 
confounding in the absence of interaction terms for the complete model would be: 
Logit P(X) = ⍺ + βE + γ1V1 + γ2V2 + γ3V3 + γ4V4 + γ5V5 
An estimated odds ratio would be calculated and because there were no 
interaction terms could be interpreted as an adjusted estimate controlling for 
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confounding related to the comorbid conditions. This estimated odds ratio is known as 
the gold standard estimate and this gold standard is the estimated odds ratio to which all 
other estimated odds ratios calculated from the 15 subsets of variables included in the 
complete model would be compared. Once estimated odds ratios or point estimates are 
identified as being the same or similar to the gold standard a determination of precision 
using the confidence interval for each estimated odds ratio is made. The narrower the 
confidence interval the more precise the point estimate or estimated odds ratio. 
Kleinbaum and Klein (2002) noted when deciding whether to use the gold standard 
estimate which controls confounding for all variables in the model and is considered 
scientifically better versus a subset of the complete model a subset with the same 
estimated odds ratio as the gold standard but with better precision or a narrower 
confidence interval should be used to control for confounding. Automatically using the 
gold standard estimate without examining all subsets first could reduce validity; 
controlling for all variation without determining whether the variation is related to 
confounding could reduce validity. 
Assessing confounding in the presence of interaction can be done but is 
significantly more difficult (Kleinbaum & Klein, 2002). A complete model is created 
including the exposure variables (E) and all potential confounders (Vi and ViVj) but only 
the components found to be statistically significant interaction terms. For example if 
hypertension, obesity, and depression were found to be statistically significant 
interaction variables, the model would include: E1 to E5, V1 to V5; ten combinations of 
ViVj, EV1 to EV5; ten combinations of EViVj this complete model would be the gold 
standard model for comparisons of subset models in the presence of interaction. The 
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assessment of confounding in subsets was conducted using the likelihood ratio described 
earlier and comparing estimated odds ratios against the estimated odds ratio of the gold 
standard model. However Kleinbaum and Klein (2002) stipulate beginning with lower 
order components including Vi and ViVj,; if these are found to be statistically significant 
all related higher level components must be retained in the revised model due to the 
hierarchical principle. The retention or elimination of confounders in the model is 
subjective even when based on estimated odds ratios and the precision of the confidence 
interval; I retained all potential confounders even at a loss of precision; all steps and 
decisions were discussed to aid replication and generalizability.  
Analyses Related to Data Collection 
Inter-rater reliability. One individual abstracted data reliability associated with 
data collection; inter-related reliability was assessed through comparison of the data 
abstracted during the two time periods—early and late; Kappa statistics and percent 
agreement were calculated. 
Missing data. The percentage of missing data for each level of each variable was 
determined and reported along with any method used to correct for missing data, such as 
imputation and omission. 
Protection of Human Participants  
The study protocol including the data collection instrument and the data 
collection manual was be submitted to the IRB of Walden University; proof of the IRB 
approval (04-13-15-0050052) was forwarded to the infectious disease specialist. 
According to the University Hospital guidelines for studies involving the audit or 
collection of information from a client’s medical records individual consent forms were 
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not necessary as long as prescribed steps were taken to prevent the disclosure of any 
information that could result in the information being linked back to a specific client. 
Written approval from the Walden University IRB and the infectious disease specialist 
served as consent to access to EMRs associated with clients of the ambulatory care 
center. While my study did not involve direct contact with human participants sensitive 
health-related information was accessed. To maintain the confidential nature of the 
medical records a non-linked, random participant identification (PID) number was 
assigned using a two-stage method (Appendices B, C) to each record; all pages of the 
data collection instrument featured this random number and not the participant’s name, 
date of birth, or medical records number; this identifying information was recorded in a 
codebook which linked the identifying information to the random PID in case data 
verification was needed. The codebook remained in a locked cabinet in the limited 
access office of the infectious disease specialist in the ambulatory care center. 
During the study data extracted from the EMRs was entered into the fields of the 
electronic data abstraction modules with the exception of the PID Linking Page that was 
not in electronic format as discussed in the Methods section. The electronic data 
abstraction modules were located on a password-protected, single user laptop computer 
during the data collection period, and after the data was entered into the SPSS software 
program the data abstraction modules were stored on a password-protected, encrypted 
external hard drive (Seagate Maxtor Black Armor, Model 9HA2AH-500) and erased 
through serial deletion on the internal hard drive of the laptop computer. Completed hard 
copies of the PID linking page were not considered part of the data abstraction 
instrument; were not removed from the infectious disease clinic; hard copy versions 
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were converted to electronic versions and stored on a compact disk in a locked desk in a 
limited access office within the infectious disease clinic; electronic versions of the 
completed data abstraction instruments on the encrypted external hard drive will be 
stored for a 7 years after study closure prior to destruction. 
The code book was stored with the compact disk containing the PID linking 
pages but not with the encrypted external hard drive used to store the completed 
electronic versions of the data abstraction instrument, with the medical record numbers, 
or with billing information to prevent the accidental discovery of client information by 
individuals not associated with my study.  
If required reports will be completed in a timely manner and submitted to the 
Walden University IRB according to IRB requirements for the approved study (Walden 
University IRB 04-13-15-0050052). In the event of an actual breach of confidentiality 
the Walden University IRB would have been notified within 24 hours of the event; if the 
breach required a change in the study protocol data collection would have been delayed 
until the Walden University approved study protocol changes. At the completion of my 
study all data collected during the study was stored as described earlier and archived 
according to Walden University IRB requirements with an automatic destruction date of 
7 years from the date of study completion.  
Dissemination of Findings 
The results of the study will be disseminated through publication and 
presentation if the submitted manuscripts and poster abstracts are accepted by editorial 
boards and review committees respectively. A copy of the study findings will be 
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forwarded to the infectious disease clinic for application as needed, as well as to the 
ProQuest Dissertation database. 
Summary 
The cross sectional, descriptive study used observational methodology 
specifically data abstraction from EMRs to determine which variables associated with 
the concepts of embodiment, pathways of embodiment, and cumulative interplay from 
the ecosocial theory were significantly related to the completion of preventive health 
care screening tests for breast cancer, cervical cancer, and colorectal cancer in HIV 
seropositive women who received health care in an ambulatory care center in Newark, 
New Jersey. The identification of variables associated with the completion of preventive 
health care actions can be applied to programs aimed at maintaining or improving the 
health of HIV seropositive women through the improvement of screening test 
completion rates. Preventing disease conditions from existing or progressing in a manner 
which adversely affects the health and functioning of HIV seropositive women could 
require social change beyond the individual and facility levels but the expenditure in 
resources could be cost-effective over time. Since many of these HIV seropositive 
women were mothers, daughters, and significant others taking measures to ensure their 
continued health could result in healthier families and extend to all levels of society. The 
following chapter begins with a review of the research questions including research and 
null hypotheses and continues into the analysis of the data and presentation of the 
findings. 
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Chapter 4: Results 
Introduction 
The purpose of the cross sectional study was to describe, compare, and determine 
which variables differed significantly between HIV seropositive women who completed 
recommended preventive health care actions for breast cancer, cervical cancer, or 
colorectal cancer and HIV seropositive women who failed to complete those same 
preventive health care actions with or without a diagnosis of one or more comorbid 
conditions when seen by an infectious disease specialist at an ambulatory care center in 
Newark, New Jersey three or more times during the 12 months prior to data collection.  
Research Questions and Hypotheses 
Listing research questions and hypotheses by the preventive health care 
screening actions for breast cancer, cervical cancer, or colorectal cancer was done 
intentionally to acknowledge the limitations on data analysis related to low cell counts; 
the research questions and hypotheses are listed below in an abbreviated manner. 
The null hypotheses for all research questions was no difference between HIV 
seropositive women grouped by the timeliness and completion of preventive health care 
actions. When seen by an infectious disease specialist at the same ambulatory care 
center three or more times during the twelve months prior to data collection, did the 
completion of screening tests for breast cancer, cervical cancer or colorectal cancer by 
HIV seropositive women differ significantly: (a) RQ1 – by age cohort; H1 – did younger 
women complete more screenings than older women; (b) RQ2 – by race; H2 – did White 
women complete more screenings than Black women; (c) RQ3 – by ethnicity; H3 - did 
non-Hispanic women complete more screenings than Hispanic women; (d) RQ4 – by 
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marital status; H4 – did married women complete more screenings than other marital 
status categories; (e) RQ5 – by education level; H5 – did college graduates complete 
more screenings than women in other education categories; (f) RQ6 – by employment 
status; H6 – did employed women complete more screenings than other employment 
categories; (g) RQ7 – by type of insurance; H7 – did privately insured women complete 
more screenings than other insurance categories; (h) RQ8 – by length of time with HIV 
infection; H8 – did women living with HIV infection for shorter lengths of time 
complete more screenings; (i) RQ9 – by HIV stage; H9 – did women with HIV infection 
classified as non-AIDS complete more screenings; (j) RQ10 – by CD4 cell count; H10 –  
did women with CD4 cell counts of 500 cells/mm3 or more complete more screenings; 
(k) RQ11 – by distance between residence and health care facility; H11 – did women 
who lived a shorter distance from the health care facility complete more screenings; (l) 
RQ12 – by diagnosis of hypertension; H12 – did women without hypertension complete 
more screenings; (m) RQ13 - by diagnosis of obesity; H13 – did non-obese-underweight, 
normal weight, and overweight--women complete more screenings than obese women; 
(n) RQ14 - by diagnosis of diabetes mellitus; H14 – did women without diabetes mellitus 
complete more screenings; (o) RQ15 – by diagnosis of depression; H15 – did women 
without depression complete more screenings; (p) RQ16 by tobacco use; H16 – did 
women who used tobacco complete fewer screenings.  
As a result of high levels of missing data related to the variables of education 
level and employment status research questions five and six were not analyzed and will 
not be included in further discussions on hypothesis testing. Chapter 4 will continue with 
a description of the data collection process including: (a) discrepancies in the data 
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collection plan from the proposal; (b) description of the sample with comparisons to 
other populations of women particularly HIV seropositive women; (c) results of the data 
analysis; and (d) summary of the chapter information. 
Data Collection 
Recruitment and Eligibility 
The target population was HIV seropositive women aged 40 years and older who 
were seen by an infectious disease specialist in an infectious disease clinic, in an urban 
area three or more times during the 12 months prior to data collection. Recruitment of 
participants and obtaining of consents from participants was not applicable to the study 
since data was abstracted from EMRs.  
Eligibility for breast, cervical, and colorectal cancer was determined using the 
USPSTF recommendations. For timeliness related to the completion of preventive health 
care actions, the lowest cell count for the four levels of timeliness related to breast 
cancer screening was five; the late category for cervical cancer screening only had four 
cases; only six colorectal screenings were completed; as a result, cervical and colorectal 
cancer were only analyzed using two categories for not completed and completed; only 
breast cancer screening was analyzed for timeliness using four categories. Completion of 
preventive health care actions for breast cancer, cervical cancer, and colorectal cancer 
was 30.3%, 27.5%, and less than 1% respectively.  
Time Frame 
The data set for the study was compiled between October 2010 and November 
2010, and updated in October 2014 at the time the data abstraction instrument, the data 
abstraction manual, and the sampling frame were developed. The data abstraction 
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instrument was created directly from the screens of the EMR and incorporated the same 
response categories and continuous measures recorded by clinicians and hospital staff 
responsible for transcribing information from the hard copy medical record into the 
EMR. The data abstraction instrument was reviewed by an infectious disease specialist 
for completeness and logical flow according to the EMR. Data was abstracted from 10 
EMRs at two different times during the data collection period to assess intra-rater 
reliability. Abstraction of data from the data set occurred in April 2015 after study 
approval by the Walden University IRB. All EMRs in the data set including those 
designated as replacements for ineligible EMRs were used in the study for a total of 142 
EMRs. 
Omitted and Deceased Cases  
One client on the original sampling frame was incarcerated before data collection 
so the related EMR was not included in the study since the IRB application did not 
approve the study for use with prisoners; one case had significant outliers for age (65 
years), HIV time (26 years), and BMI (39.0); one case had a significant outlier for 
lowest CD4 cell count (1,206); one case had a significant outlier for distance (28.8 
miles) after correcting for inaccurate distance data. These cases were not omitted from 
the analysis because: the distribution for age could only be improved through 
transformation and not corrected; the abnormal distribution of BMI was not significant. 
Twenty-three cases (16%) included in the sampling frame were deceased by the time of 
data collection but each case had three or more appointments during the year prior to 
their deaths so an independent samples t test was conducted to compare the deceased 
women to women still alive at the time of data collection. There were no statistically 
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significant differences between the group means and variances for categorized age (F = 
2.72, p = 0.101; t = 0.20, p = − 0.147), distance without outliers (η 2 0.18, p = 0.671; t = 
− 0.40, p = 0.691), race (F = 1.85, p = 0.176; t = −0.70, p = 0.481), categorized distance 
(F = 0.015, p = 0.904; t =	 −0.447, p = 0.656), length of time with HIV infection (F = 
0.108, p = 0.743; t = −1.246, p = 0.215), and HIV stage (F = 3.35, p = 0.069; t = 0.591, p 
= 0.556). The variables with statistically significant variances but not means between 
deceased groups were ethnicity (F = 3.957, p < 0.05; t = − 1.035, p < 0.05), marital 
status (F = 9.289, p < 0.05; t = − 1.856, p = 0.074), and type of insurance (F = 7.016, p < 
0.05; t = 1.905, p = 0.067); the continuous variable age had a significant mean difference 
between the two groups (t =	 −3.02, p = 0.003) but the variances were not significantly 
different (F = 3.60, p = 0.060). A decision was made to leave the 23 deceased cases in 
the study but to add a category labeled deceased so these cases could be identified. 
Missing Data  
Case deletion and imputation were mentioned earlier as being two methods for 
addressing missing data during the analysis phase of a study (Worster & Haines, 2004). I 
used imputation; while no cases were deleted, two variables were not analyzed due to 
missing data. Six cases (4%) were missing the number of years with HIV so the mean 
number of years with HIV infection for the sample (M = 10.11) was rounded to 10 and 
substituted for the missing values. Three cases (2%) had missing marital status entries; 
the mode for marital status was 0 or single.; three cases had full time employment; three 
cases had part time employment; five cases were unemployed; the remaining 129 EMRs 
(91%) were missing entries for employment status. One case had an unknown education 
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level; one case had graduated from college; the remaining 140 EMRs (99%) were 
missing entries for education level; as a result the variables of education level and 
employment status could not be analyzed. 
Two cases (1%) were missing entries for the lowest CD4 cell count. The mean 
lowest CD4 cell count recorded as a whole number,(M = 155.19) was rounded to 155 
and substituted for the missing values. Eight cases (6%) were missing height entries so 
the mean height for each age cohort associated with each case was calculated and 
substituted for the missing values. One case (<1%) was missing an entry for weight. The 
height associated with the case was 66 inches so the mean weight for all women in the 
sample with a height of 66 inches was calculated (M = 178) and substituted for the 
missing value.  
Data Coding 
The original coding schema required changes including the addition of variables 
created by recoding. While the SPSS code book (Appendix F) for my study was updated 
to reflect the original and additional variables and their coding only changes to the 
original coding schema are discussed here. Age cohort had less than 5 cases in 3 of 6 
categories (70 to 79 years = 2, 80 to 89 = 0 and 90+ = 0) so age cohort was not used for 
analysis. The continuous variable of age was collapsed into a discrete, ordinal variable 
labeled age2 divided by the age cohort category nearest the mean (M = 53.3) for the 
discrete variable of age (40-49 = 1, 50-79 = 2) to replace age cohort and maintain 
comparison categories. Another discrete, ordinal variable labeled age3 divided the 
continuous variable of age at the mean (M = 53.3) and was used for analyses. 
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For the discrete, nominal variable of race two cases were listed as Italian and 
coded as other; these cases were recoded as White, non-Hispanic. Three of the nine cells 
for HIV Stage had case numbers less than 5 and were recoded into three additional 
discrete variables labeled Stage2, Stage3, and A_nonA. HIV stage was divided by CD4 
cell counts (less than 200 = 1, 200 to 499 = 2, and 500 or more = 3) to create the 
discrete, ordinal variables of Stage2; (b) divided by symptomatology (asymptomatic = 1, 
symptomatic = 2, and AIDS-defining condition = 3) to create the discrete, ordinal 
variable of Stage3; (c) divided by HIV stage classifications (A1/A2/B1/B2 = 0, and 
A3/B3/A1/A2/A3 = 1) to create the discrete, nominal variable of AIDS versus no AIDS 
or A_nonA. The continuous variable of BMI was recoded into the discrete, ordinal 
variable of BMI2 based on the BMI classification schema of the NHLI: underweight is 
14.9 to 18.4 = 1; normal weight is 18.5 to 24.9 = 2; overweight is 25.0 to 29.9 = 3; and 
obese is 30+ = 4; USDHHS, 2010).  
Outliers 
Histograms overlaid with normal curves indicated several variables might not 
have normal distributions: age; distance; HIV time; lowest CD4 cell count; and BMI so 
the presence of outliers was examined. Analysis using Mahalanobis distances (critχ2 = 
20.515, df = 5, p = 0.001,) identified three outliers for age; two outliers for HIV time; 
two outliers for distance; and two outliers for BMI (Meyers, Gamst, & Guarino, 2013; 
Table 8). After checking for data entry errors the variables of age, HIV time, lowest 
CD4 cell count, and BMI were analyzed for skew and kurtosis, which is discussed later.  
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Table 8 
 
Outliers for Cases with Significant Mahalanobis Distances (N=142) 
 
 Maha. 
Distance Age Distance HIV 
Time 
CD4 Cell 
Count BMI
b 
Case 1 
 
57.08 61 127.8 14 81 24.3 
Case 2 
 
42.22 60 4.8 19 1,206 26.3 
Case 3 
 
27.19 66 89.4 9 29 32.6 
Case 4 
 
25.42 52 3.3 26 204 39.0 
Case 5 
 
21.97 45 0.4 10 917 22.9 
Note. aMah. Distance = Mahalanobis distance; bBMI – body mass index; chi-square 
statistic = 20.515, df = 5, p = 0.001 
 
Data Collection Discrepancies  
Upon further examination of the outliers associated with the variable of distance, 
the data source identified eight inaccurate residential addresses; four on the coast of 
New Jersey, approximately 56, 73, 89 and 128 miles from the health care facility; the 
other four addresses were rehabilitation centers. The health care provider knew the eight 
clients stayed primarily with relatives in the Newark, New Jersey area due to their 
impaired health statuses. Rather than omit the data associated with each case, the sample 
mean for distance (M = 8.0 miles) was substituted for the four outlying values, as well as 
the four inaccurate addresses, a new variable was created containing the altered distance 
values (DISTA); the values in the discrete, ordinal distance variable were corrected. 
As noted earlier, age cohort was not used in the analysis because two categories 
(80-89 and 90+) contained no cases, and one category (70-79) contained only two cases. 
Deceased cases were included if the EMR reflected three visits during the year prior to 
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their death, which differs from the three visits in the twelve months prior to data 
collection; as mentioned earlier, education level and employment status could not be 
analyzed because more than 90% of the data was missing. The data set did not list a 
CD4 cell count for each interval, and an attempt to match the date of the CD4 cell counts 
in the data set to the screening intervals revealed more than 50% of the intervals lacked 
CD4 cell counts. Similarly, the lack of CD4 cell count results, in proportion to the 
number of screening intervals completed or due according to USPSTF recommendations 
prevent an updated HIV stage to be determined for each screening interval. Mileage, to 
the tenth of a mile, between residence and health care facility had already been 
calculated for the data set to avoid a possible confidentiality breach resulting from the 
release of a part of the residential address. Though outliers were identified and 
corrected, as described earlier, there is no reason to suspect the mileage values were 
calculated differently than planned. Finally, instead of using BMI tables, each BMI was 
calculated using the online BMI calculator from the same source (USDHHS, 2015).  
Timeliness related to the completion of preventive health care actions (0 = not 
completed, 1 = completed on time, 2 = completed early, 4 = completed late), and the 
results of the completed screening tests were originally two separate variables for each 
screening interval, but case numbers in one or more cells prohibited the analysis of 
completion timeliness for cervical cancer screening, and colorectal cancer screening, 
while breast cancer screening was analyzed in relation to completion timeliness. Due to 
low completion rates, and multiple outcomes related to the results of the screening tests, 
analysis of the results variable could not be conducted. The study protocol indicated the 
USPSTF recommendations relevant to each EMR would be used to determine 
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completion and timeliness, but several intervals had more than one completed test. Since 
additional tests within an interval could be follow up tests, and not screening tests, only 
information from the first test in the interval was abstracted for timeliness and results.  
Sample and Generalizability 
As mentioned in Chapter 1, over one-third of New Jersey’s HIV cases, and one 
third of the state’s AIDS cases, lived in Newark, New Jersey (NJDOH, 2013). Over 60% 
of the HIV seropositive females in New Jersey were non-Hispanic Black and over 40% 
were aged 40 to 49 years. In addition, 64% of HIV seropositive females in New Jersey, 
aged 50 years of age or older, were non-Hispanic Black (NJDOH, 2013). Women with a 
BMI of 25.0 to 29.9, also known as overweight, were significantly less likely to 
complete preventive health care actions for breast cancer, cervical cancer, and colorectal 
cancer (Ferrante et al., 2007). For the sample (N = 142), which included all available 
EMRs in the data set, the mean age was 53 years, and women in the sample tended to be 
Black (90.8%), non-Hispanic (92.3%), single (70.4%), with Medicaid (43.7%). After 
correcting for outliers, the mean distance between residence and health care facility was 
about eight miles, with values ranging from 0.3 miles to 28.8 miles. The average length 
of time the women had been living with HIV infection was about 10 years, and the 
majority of women were classified as HIV stage A3 (57.7%), had asymptomatic HIV 
infection (78.2%), and had CD4 cell counts less than 200 cells/mm3 (73.2%). The 
majority of the sample did not have hypertension (54.9%), diabetes mellitus (83.1%) or 
depression (71.8%), and did not use tobacco (54.9%). However, the majority of HIV 
seropositive women in the sample were overweight (28.2%) or obese (45.1%), according 
to BMI categories, while fewer (30.3%) were obese according to the ICD-9-CM codes 
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in the EMR. One EMR indicated a diagnosis of CMV retinitis, which had caused 
blindness. Similar to the findings of Werth et al. (2008) and Yankaskas et al. (2010), this 
case had not completed any preventive health care screenings. 
Statistical Assumption Evaluations 
The statistical assumptions associated with the use of parametric statistics were: 
(a) normality, linearity, and homoscedasticity.  
Normality Assumption 
A visual representation of each variable was created and overlaid with the 
normal curve, followed by Kolmogorov-Smirnov and Shapiro-Wilk normality tests for 
continuous variables, the results of which were presented later in the discussion on skew 
and kurtosis. The Embodiment variable of age violated the assumption of normality and 
was subjected to log10 transformation; the Pathways of Embodiment variables of 
distance, HIV time and lowest CD4 cell count violated the normality assumption, after 
three methods of transformation were attempted; the result of the normality test for the 
Cumulative Interplay variable of BMI was not significant. 
Skew and kurtosis. Examination of skew and kurtosis statistics indicated the 
variables: (a) age; (b) corrected distance; (c) HIV time; (d) CD4 cell count; (e) BMI 
were not normally distributed (Table 9). Kolmogorov-Smirnov and Shapiro-Wilk tests 
of normality were performed for each of the continuous variables, and the distribution of 
BMI was not found to be statistically significant (KS = 0.047, df = 142, p = 0.200; S-W 
= 0.986, df = 142, p = 0.177); the normality test statistics for the remaining variables 
were statistically significant, indicating the distributions had normality violations, which 
were confirmed by reviewing the Q-Q plots (Meyer, et al, 2013).  
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Table 9 
  
Skew and Kurtosis for Continuous Variables (N = 142) 
 
 Mean S.E. Skew 
Statistic 
 
95% C.I Kurtosis 
Statistic 
95% C.I. 
Age 
 
 
53.30 0.613 8.01* 0.063,  
0.859 
0.112 -0.68, 
0.904 
Distance 
 
 
8.01 1.36 4.676* 4.278,  
5.074 
26.494* 25.702,  
27.286 
Distance, 
Corrected 
 
4.90 0.46 2.31* 2.11, 
2.51 
5.52* 4.73, 
6.31 
HIV 
Time 
 
 
10.11 0.283 0.853* 0.455, 
1.251 
3.991* 3.199, 
4.783 
Lowest 
CD4 Cell 
Count 
154.62 14.18 3.261* 2.863, 
3.659 
14.177* 13.385,  
14.969 
BMI 
 
 
29.46 0.59 0.327 -0.071, 
0.725 
-0.57 -0.849, 
0.222 
Note. * - Significant for alpha of 0.05; skew standard error values (0.203), and 
kurtosis standard error values (0.404) were multiplied by 1.96 (0.398 and 0.792, 
respectively, to calculate the upper and lower limits of the 95% confidence 
interval for each variable. 
 
Linearity. Scatterplots were initially created as visual representations of possible 
linearity between all continuous independent variables. Base log10 transformed age and 
distance did not appear to be related; base log10 transformed age and HIV time, base 
log10 transformed age and BMI, HIV time and low CD4 cell count were positively 
related. Height appeared negatively related to BMI, while weight appeared positively 
related to BMI, and both height and weight appeared negatively related to base log10 
transformed age. A Pearson Product Moment Correlation, or Pearson r, was performed 
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on the log-transformed values for age and distance (r = -.036, p > 0.05), distance and 
HIV time (r = 0.41, p > 0.05), distance and BMI (r = 0.118, p > 0.05), and BMI and HIV 
time (r = 0.045, p > 0.05) confirmed the variables were not related. However, the 
correlations between the log-transformed values for age and HIV time (r = 0.250, p = 
0.03), as well as age and BMI (r = − 0.201, p = 0.016), were statistically significant, 
indicating a relationship between these two sets of variables (Table 10). As many of the 
variables appeared to violate the assumption of linearity, Kendall’s tau b was performed 
on the log-transformed values for age, as well as the other independent variables, in later 
bivariate analyses. 
Table 10 
Pearson Product Moment Correlation Results (N=142) 
 AgeLog10 Distance HIV Time BMI 
 r Sig r Sig r Sig r Sig 
Age 
Log10 
1 -- -.036 .674 .250** .003 -.201* .016 
Distan
ce 
-.036 .674 1 -- .041 .631 .118 .162 
HIV 
Time 
.250** .003 .041 .631 1 -- .045 .591 
BMI -.201* .016 .118 .162 .045 .591 1 -- 
Note: * - Correlation is significant p < 0.05 level, 2-tailed; ** - Correlation is significant 
p < 0.01, 2-tailed. 
 
Homoscedasticity. SPSS used the Levene statistic to test for homogeneity of 
variances (Meyer, 2013; IBM, 2012). The Levene statistic was significant for several 
independent variables across the levels of colorectal cancer screening (completed, not 
completed; Table 11).  
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Table 11 
Homogeneity of Variance: Significant Levene Statistic Results 
 
Dependent 
Variable 
Independent Variable Levene 
Statistic 
df df2 pa 
Breast Cancer 
Screening 
Time living with HIV, 
categorical 
13.314 1 140 0.000 
HIV stage by symptoms 9.426 2 139 0.000 
Diabetes Diagnosis 6.527 1 140 0.012 
Cervical Cancer 
Screening 
Distance, categorical 9.851 1 140 0.002 
HIV stage by CD4 count 5.673 2 139 0.004 
HIV stage by symptoms 8.303 2 139 0.000 
Colorectal Cancer 
Screening 
Age, categorical 1068.472 1 140 0.000 
Race 17.068 1 140 0.000 
Ethnicity 11.299 1 140 0.001 
Marital Status 7.544 3 138 0.000 
Insurance Type 6.473 6 135 0.000 
HIV stage by symptoms 12.030 2 139 0.000 
Hypertension Diagnosis 3.979 1 140 0.048 
BMI – obese or not obese 16.441 3 138 0.000 
Depression Diagnosis 8.757 1 140 0.004 
a Significance set a priori at p < 0.05 for analyses 
 
Fewer independent variables were associated with significant Levene statistics across 
the levels of breast cancer screening and cervical cancer screening, but all three 
dependent variables violated the assumption associated with homoscedasticity. 
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Data Transformations 
Log transformation. After log transformation, the skew (0.132) and kurtosis 
(−0.485) for age, and the skew (− 0.137) and kurtosis (0.056) for corrected distance were 
no longer significant (df = 142, p > 0.05). The skew (− 1.561) and kurtosis (4.923) for 
HIV time, and the skew (− 1.221) and kurtosis (3.247) for lowest CD4 cell count did not 
become more normally distributed; the skews for both variables became negative and 
the leptokurtic distributions remained significantly positive. For dependent variables, 
only log transformations created any change in the skew and kurtosis statistics, so 
dependent variables were only discussed here. Log transformation of the variables 
associated with screening test completion for breast cancer (BrCAScrng), cervical 
cancer (CVCaScrng), and colorectal cancer (CRCaScrng) made three significant Levene 
statistics non-significant (BrCaScrng X marital status, BrCaScrng X diabetes, 
CRCaScrng X hypertension); two non-significant Levene statistics to significant 
(BrCaScrng X race, BrCaScrng X ethnicity); four variables were improved, but 
remained significant; 16 were unchanged and significant.  
Square root transformations. Performed after log transformations for the 
variables of age, corrected distance, HIV time and lowest CD4 cell count. Again, the 
skew statistic for age was no longer significant, but the distribution became negatively 
leptokurtic while remaining insignificant. Skew and kurtosis statistics for corrected 
distance remained statistically significant, and, while the skew statistic for HIV time and 
lowest CD4 cell count became negative, and no longer significant, the kurtosis statistics 
remained statistically significant.  
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Reflected inverse transformation. Performed after log and square root 
transformations failed to correct statistically significant skew and kurtosis statistics, 
reflected inverse transformations on the variables of age, distance, and HIV time were 
preceded by dividing each value of age, corrected distance and HIV time for each case 
by 1 prior to performing the inverse transformations, giving the resulting values an 
expected positive value (Meyer, et al, 2013). However, the skew and kurtosis statistics 
for the transformed age variable became negative and, again, no longer significant. The 
skew and kurtosis statistics for corrected distance remained positive and statistically 
significant. The skew statistics for HIV time and lowest CD4 cell count became negative 
and remained statistically significant, like the positive values for the kurtosis statistic. 
To summarize the results of the transformations, the base 10 log transformations 
made the distributions more normal, and, while the direction of the skew statistics for 
HIV time and lowest CD4 cell count became negative, the skew statistics were no longer 
significant, though the kurtosis statistics remained significant (Table 12). The base 10 
log transformations lessened the statistical significance of the Levene statistics for the 
dependent variables, even though only three significant statistics became non-
significant, but the skew and kurtosis for all three dependent variables were improved. 
The square root and reflected inverse transformations had little impact on the shape of 
the distributions for each of the independent and dependent variables, so the base 10 log 
transformations were used for age, corrected distance, HIV time, and lowest CD4 cell 
count, and the three dependent variables. However, while improvements were made, 
violations continued so non-parametric statistical tests were used to analyze the data. 
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Table 12 
 
Correlation Results for Continuous Variables After Log Transformations (N=142) 
 
 Statistic AgeLog1
0 
DISTALog1
0 
TIMELog10 CD4Log10 BMI 
Age in years/ 
AGELog10 
Pearson r 
Sig (2-tailed) 
 
Kendall’s tau b 
Sig (2-tailed) 
 
1 
 
 
1 
0.102 
0.226 
 
0.051 
0.384 
.0.178* 
0.034 
 
0.210** 
0.001 
0.177* 
0.035 
 
0.142* 
0.014 
−.201* 
.016 
 
− 0.140* 
0.015 
Distance/ 
DISTALog10 
Pearson r 
Sig (2-tailed) 
 
Kendall’s tau b 
Sig (2-tailed) 
 
0.102 
0.226 
 
0.051 
0.384 
1 
 
 
1 
0.038 
0.656 
 
0.037 
0.541 
0.132 
0.117 
 
0.054 
0.346 
− 0.005 
0.954 
 
0.006 
0.916 
Years living 
with HIV 
infection/ 
TIMELog10 
Pearson r 
Sig (2-tailed) 
 
Kendall’s tau b 
Sig (2-tailed) 
 
.0.178* 
0.034 
 
0.201** 
0.001 
0.038 
0.656 
 
0.037 
0.541 
1 
 
 
1 
0.109 
0.196 
 
0.082 
0.170 
.045 
.591 
 
− 0.004 
0.952 
Lowest CD4 
cell count/ 
CD4Log10 
Pearson r 
Sig (2-tailed) 
 
Kendall’s tau b 
Sig (2-tailed) 
 
0.177* 
0.035 
 
 
0.142* 
0.014 
 
0.132 
0.117 
 
 
0.054 
0.346 
0.109 
0.196 
 
 
0.082 
0.170 
1 
 
 
 
1 
− 0.018 
0.836 
 
 
− 0.002 
0.968 
BMI Pearson r 
Sig (2-tailed) 
 
Kendall’s tau b 
Sig (2-tailed) 
 
−.201* 
.016 
 
− 0.140* 
0.015 
− 0.005 
0.954 
 
0.006 
0.916 
.045 
.591 
 
− 0.004 
0.952 
− 0.018 
0.836 
 
− 0.002 
0.968 
1 
 
 
1 
* - Correlation is significant at 0.05 (2-tailed) 
** - Correlation is significant at 0.01 (2-tailed). 
 
Analysis of Data 
Data was abstracted using the data abstraction instrument based on the 
proprietary EMR software in use at the health care facility at the time of the study. The 
data was coded into an Excel spreadsheet (Microsoft®, 2010) with the first row 
containing variable labels, and each column was summed to verify the correct number of 
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entries (N = 142), which served as a data entry check. The values for certain variables 
were created directly in the Excel program (Microsoft®, 2010): the value for the variable 
to assess agreement between an obesity diagnosis based on a BMI calculation from the 
height and weight measurements in the EMR; obesity diagnosis from the ICD-9-CM 
codes in the EMR (OBSBOTH). An obesity diagnosis was coded with a value of 1 and 
no obesity diagnosis was coded as 0 for the variable of obesity by BMI (OBSBMI), and 
for the variable of obesity by ICD-9-CM code in the EMR (OBSEMR). An Excel 
formula (Microsoft®, 2010) was developed to multiply the value of 0 or 1 in OBSBMI 
by the value of 0 or 1 in OBSEMR, and enter the result in the variable of OBSBOTH, 
where agreement would equal 1 and a lack of agreement would equal 0. Upon 
completion of the data entry, the data in the Excel (Microsoft®, 2010) spreadsheet was 
imported into the SPSS program (IBM, 2012) for analysis. 
Univariate Analysis 
Frequencies were analyzed and reported as percentages with 95% confidence 
intervals (CI) for each variable, grouped by the constructs of the ecosocial theory (Table 
13). Mean, median and mode were presented for continuous, interval variables, median 
and mode for discrete, ordinal variable, and only mode for discrete, nominal variables. 
Range was presented for discrete variables, while standard deviation was presented for 
continuous variables. Since standard deviation was sensitive to sample size, the unbiased 
option in SPSS was selected. The distribution of observations associated with discrete 
variables was analyzed, and values, or cells, with less than five observations were 
collapsed since five is the minimum default cell count in SPSS (IBM, 2012).  
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Table 13 
 
Univariate Analysis: Completion of Preventive Health Care Actions in HIV Seropositive 
Women 
Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
 
Embodiment 
 
Age (in years)/ 
 
 
53.30  
 
 
+ 7.3 
 
 
142   (100) 
  
 
52.10, 54.50 
 
Age, log10 
 
1.72 +0.59 142   (100) 
 
 
Age cohort 
40-49=1 
50-59=2 
60-69=3 
70-79=4 
 
 
2 
 
40-79 
 
 
50   (35.2) 
  92   (64.8) 
  27   (19.0) 
    2     (1.4) 
 
 
0.278, 0.434 
0.566, 0.722 
0.134, 0.263 
0.001, 0.053 
 
Age by mean 
40-53=1 
54-79=2 
 
1 
 
40-79 
 
 
73   (51.4) 
69   (48.6) 
 
 
0.433, 0.595 
0.405, 0.567 
Pathways of 
Embodiment 
Race 
Black=1 
White=2 
 
 
1 
 
1-2 
 
129   (90.8) 
  13     (9.2) 
 
0.849, 0.947 
0.053, 0.152 
Ethnicity 
Non-Hisp=0 
Hispanic=1 
 
 
0 
 
0-1 
 
131   (92.3) 
  11     (7.7) 
 
0.865, 0.958 
0.043, 0.135 
Marital status 
Single/Never  
Married=0 
Married=1 
Divorced=2 
Widowed=3 
 
 
0 
 
0-3 
 
100   (70.4) 
   
15   (10.6) 
  10     (7.0) 
  17   (12.0) 
 
0.624, 0.773 
 
0.064, 0.168 
0.037, 0.126 
0.037, 0.127 
 
(table continues) 
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(table continues) 
 
Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
 Marital status, 
Single 
Single=0 
All other=1 
 
 
 
0 
 
 
0-1 
 
 
100   (70.4) 
  42   (29.6) 
 
 
 
0.624, 0.773 
0.227, 0.376 
Marital status, 
Married 
Married=0 
All other=1 
 
 
 
0 
 
 
0-1 
 
 
15   (10.6) 
 127   (89.4) 
 
 
0.064, 0.168 
0.832, 0.936 
Insurance a,c,d 
Medicare=1 
SSD=2 
Medicaid=3 
Private 
Insurance=4 
State HMO=5 
Charity=6 
Self Pay=7 
 
 
3 
 
1-7 
 
23    (16.2) 
    6      (4.2) 
  62    (43.7) 
13      (9.2) 
     
6      (4.2) 
  15    (10.6) 
  17    (12.0) 
 
0.110, 0.232 
0.018, 0.091 
0.358, 0.519 
0.053, 0.152 
 
0.018, 0.091 
0.064, 0.168 
0.075, 0.184 
Insurance, 
Private 
Private Ins=1 
All other=2 
 
 
 
1 
 
 
1-2 
 
 
  129   (90.8) 
    13     (9.2) 
 
 
0.849, 0.947 
0.053, 0.152 
Insurance, 
Medicaid 
Medicaid=1 
All other=2 
 
 
 
2 
 
 
1-2 
 
 
    62   (43.7) 
    80   (56.3) 
 
 
0.358, 0.519 
0.481, 0.642 
Cumulative 
Interplay 
Distance bet 
residence and 
health care 
facility 
 
4.90 +5.48 142   (100) 4.002, 5.806 
(table continues) 
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(table continues) 
 
Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
Cumulative 
Interplay 
(continued) 
Distance, in 
miles, by mean 
0-4.9=1 
5.0-29.0=2 
 
 
1 
 
 
 
 
1-2 
 
 
104   (73.2) 
   38   (26.8) 
 
 
0.654, 0.799 
0.201, 0.346 
Number of years 
since HIV 
diagnosis 
 
10.11 +3.37 142   (100) 9.556, 10.665 
Years living with 
HIV, divided by 
mean 
2-10=1 
11-26=2 
 
 
 
 
1 
 
 
 
1-2 
 
 
 
89   (62.7) 
  53   (37.3) 
 
 
 
 
0.545, 0.702 
0.298, 0.455 
Lowest CD4 cell 
count 
 
154.62 +168.92 142   (100) 
    
126.835, 
182.404 
HIV Stage 
A1=1 
A2=2 
A3=3 
B1=4 
B2=5 
B3=6 
C1=7 
C2=8 
C3=9 
 
3 
 
1-9 
 
    7      (4.9) 
  22    (15.5) 
  82    (57.7) 
    1      (0.7) 
    2      (1.4) 
    9      (6.3) 
    1      (0.7) 
    5      (3.5) 
  13      (9.2) 
 
0.022, 0.100 
0.104, 0.224 
0.495, 0.656 
0.0001, 0.04, 
0.0006,0.053 
0.032, 0.118 
0.0001,0.042 
0.013, 0.082 
0.053, 0.152 
 
HIV Stage by 
CD4 cell count 
<200=1 
200-499=2 
>500=3 
 
 
1 
 
 
1-3 
 
 
104   (73.2) 
 29   (20.4) 
   9     (6.3) 
 
 
0.654, 0.797 
0.146, 0.278 
0.032, 0.118 
 
(table continues) 
  
172 
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Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
Cumulative 
Interplay 
(continued) 
HIV Stage by 
Symptoms 
Asymptom=1 
Symptom=2 
AIDS-
defining=3 
 
 
 
1 
 
 
1-3 
 
 
111   (78.2) 
  12     (8.5) 
  19   (13.4) 
 
 
0.706, 0.842 
0.048, 0.143 
0.087, 0.200 
HIV Stage by 
AIDS versus not 
AIDS 
Non-AIDS=0 
AIDS=1 
 
 
 
1 
 
 
 
0-1 
 
 
 
   32   (22.5) 
 110   (77.5) 
 
 
 
0.164, 0.301 
0.699, 0.836 
 
Hypertension 
Never 
Hx/Current 
 
 
1 
 
0-1 
 
64   (45.1) 
  78   (54.9) 
 
0.371, 0.533 
0.467, 0.629 
Body Mass 
Indexa 
 
29.462 +7.089 142   (100) 
 
28.296,30.628 
BMI by category 
Underweight=1  
(14.9-18.4) 
Normal 
weight=2 
(18.5-24.9) 
Overweight=3  
(25.0-29.9) 
Obese (30+)=4 
 
 
4 
 
1-4 
 
9      (6.3) 
  
  29    (20.4) 
    
  40    (28.2) 
   
64    (45.1) 
 
0.036, 0.107 
 
0.146, 0.278 
 
0.214, 0.361 
 
0.371, 0.533 
BMI, obese 
versus not obese 
Not Obese=0 
Obese=1 
 
 
 
0 
 
 
0-1 
 
 
  78    (54.9) 
   64    (45.1) 
 
 
0.467, 0.629 
0.371, 0.533 
(table continues) 
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(table continues) 
 
Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
Cumulative 
Interplay 
(continued) 
Obese per BMI 
Never=0 
Hx/Current=1  
 
 
0 
 
0-1 
 
64    (45.1) 
   78    (54.9) 
 
0.371, 0.533 
0.467, 0.629 
Obesity in EMR 
Never=0 
Hx/Current=1 
 
 
0 
 
0-1 
 
43    (30.3) 
   99    (69.7) 
 
0.233, 0.383 
0.617, 0.767 
Obese in EMR 
and by BMI 
Never=0 
Hx/Current=1  
 
 
 
0 
 
 
0-1 
 
 
    37   (26.1) 
  
105   (73.9) 
 
 
0.195, 0.339 
 
0.661, 0.805 
Diabetes mellitus 
diagnosis 
Never=0 
Hx/Current=1  
 
 
 
0 
 
 
0-1 
 
 
24   (16.9) 
 118   (83.1) 
 
 
0.116, 0.240 
0.760, 0.884 
Depression 
diagnosis 
Never=0 
Hx/Current=1  
 
 
 
0 
 
 
0-1 
 
 
   40   (28.2) 
102   (71.8) 
 
 
0.214, 0.361 
0.639, 0.786 
Tobacco use 
Never=0 
Hx/Current=1  
 
 
0 
 
0-1 
 
64   (45.1) 
   78   (54.9) 
 
0.371, 0.533 
0.467, 0.629 
Deceased 
No=0 
Yes=1 
 
 
0 
 
0-1 
 
 119   (83.8) 
    23   (16.2) 
 
0.768, 0.890 
0.110, 0.232 
 
(table continues) 
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(table continues) 
 
Ecosocial 
Theory 
Construct 
(IVs) or 
Dependent 
Variables 
Variable/ 
Coding 
Mean, 
Median, 
Modea 
Standard 
Deviation, 
Rangeb 
Frequency 
(Percentage)c 
95% 
Confidence 
Intervald 
Dependent 
Variables 
Breast Cancer 
Screening 
Not Completed 
Completed On  
Time 
Completed  
Early 
Completed  
Late 
Not Applicable 
 
 
 
0 
 
 
0-3,9 
 
 
92   (64.8) 
   20   (14.1) 
   
   16   (11.3) 
   
   13     (9.1) 
      
1     (0.7) 
 
 
 
0.571, 0.726 
0.093, 0.210 
 
0.070, 0.177 
 
0.054, 0.153 
 
Breast Cancer 
Screening 
Not Completed 
Completed 
Not Applicable 
 
 
 
0 
 
 
0-1,9 
 
 
92    (64.8) 
   49    (34.5) 
     1      (0.7) 
 
 
0.571, 0.726 
0.274, 0.429 
Cervical Cancer 
Screening 
Not Completed 
Completed 
Not Applicable 
 
 
 
0 
 
 
0-1,9 
 
 
102   (71.8) 
    39   (27.5) 
      1     (0.7) 
 
 
0.644, 0.791 
0.209, 0.356 
Colorectal 
Cancer 
Screening 
Not Completed 
Completed 
Not Applicable 
 
 
 
9 
 
 
0-1,9 
 
 
30   (21.1) 
     6     (4.2) 
 106   (74.6) 
 
 
0.677, 0.925 
0.749, 0.323 
 
Notes: Analysis for assumption of exhaustive categories; analysis for assumption of 
mutually exclusive categories; not a normal distribution; Fisher’s Exact is default for 
2x2 tables when number of observations in any one cell is less than 5. 
aMean, median, mode appropriate to level of measurement 
bStandard deviation, range appropriate to level of measurement 
cFrequencies for each variable based on valid number of EMRs reviewed 
dCI 95% calculated using modified Wald method, which is based on proportions 
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Bivariate Analysis 
Bivariate analysis was conducted to determine relationships between the 
dichotomous independent variables and the dependent variables: Kruskal-Wallis tests 
were used to compare discrete independent variables with continuous (base log 10 
transformations) and discrete, ordinal versions of the dependent variables since 
statistical assumptions were violated; Mann-Whitney U-tests were used to compare 
discrete independent variables in HIV seropositive women who completed, or failed to 
complete, the preventive health care screening tests for each of the three cancers of 
interest due to statistical assumption violations; cell observations were frequently less 
than five so Fisher’s Exact Test, the default reported by SPSS, was used instead of chi-
square. Using SPSS, a correlation matrix was constructed to examine relationships 
between variables (Table 14). Statistically significant independent variables for breast 
cancer screening were: age by cohort (40-49 and 50-79); log-transformed and discrete 
versions of time living with HIV infection; completion of cervical cancer screening. 
Statistically significant independent variables for cervical cancer screening were: log-
transformed and discrete versions of distance between residence and health care facility; 
log-transformation of lowest CD4 cell count; HIV stage by CD4 cell count; HIV stage 
by symptomatology; completion of breast cancer screening. Statistically significant 
independent variables for colorectal cancer screening were: age by mean; age by cohort; 
discrete version of marital status; dichotomous version of marital status comparing 
single to all other categories; dichotomous version of insurance comparing Medicaid to 
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all other categories; log-transformed version of lowest CD4 cell count; HIV stage by 
symptomatology. 
Table 14 
Bivariate Analyses: Kruskal-Wallis and Mann-Whitney U Tests for Completion of, or 
Failure to Complete, Preventive Health Care Screening Actions 
 
Independent 
Variablea,b 
Breast Cancer 
Screening 
Cervical Cancer 
Screening 
Colorectal Cancer  
Screening 
Statistica,b Sig 
(p)c 
Statistica,b Sig (p)c Statistica,b Sig (p)c 
Age, Log10 
Transformationa 
3.755 0.053 0.420 0.517 0.223 0.637 
Age, by Meanb 2087.00 0.403 1932.00 0.761 563.00 0.000* 
Age, by Groupb 1663.50 0.002* 1977.00 0.947 908.00 0.000* 
Distance, Log 
Transformationa 
2.804 0.094 5.708 0.017* 0.687 0.407 
Distance by 
Mean 
1916.00 0.057 1459.50 0.001* 1412.00 0.229 
Raceb 2067.50 0.125 1890.00 0.363 1463.00 0.191 
Ethnicityb 2055.00 0.064 1851.00 0.171 1493.00 0.281 
Marital Statusb 2232.00 0.905 1957.50 0.857 1200.50 0.010** 
Marital Status – 
Singleb 
2236.50 0.923 1962.00 0.875 1208.00 0.010** 
Marital Status – 
Marriedb 
2239.00 0.903 1908.00 0.485 1407.00 0.077 
Insuranceb 2091.50 0.460 1953.50 0.864 1397.50 0.291 
Insurance – 
Privateb 
2217.50 0.752 1890.00 0.363 1445.00 0.135 
Insurance – 
Medicaidb 
2222.00 0.872 1858.50 0.484 1264.00 0.046* 
HIV Time, Log 
Transformationa 
12.132 0.000* 0.554 0.457 0.202 0.653 
(table continues) 
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(table continues) 
 
Independent 
Variablea,b 
Breast Cancer 
Screening 
Cervical Cancer 
Screening 
Colorectal Cancer  
Screening 
Statistica,b Sig 
(p)c 
Statistica,b Sig (p)c Statistica,b Sig (p)c 
HIV Time, by 
Meanb 
1624.50 0.001* 1663.50 0.073 1509.00 0.609 
Low CD4, log 
Transformationa 
1.744 0.187 4.389 0.036* 5.552 0.018* 
HIV Stageb 2094.50 0.440 1854.00 0.486 1385.00 0.227 
AIDS versus not 
AIDSb 
2051.00 0.226 1696.50 0.063 1548.00 0.759 
HIV Stage by 
CD4 cell countb 
1996.00 0.150 1506.50 0.004* 1498.00 0.523 
HIV Stage by 
Symptomatology
b 
2250.00 0.981 1576.50 0.008* 1288.50 0.027* 
Hypertensionb 2246.50 0.231 1756.50 0.214 1470.00 0.464 
BMIa 1.433 0.340 0.000 1.000 2.084 0.149 
BMI, by 
categoryb 
2081.50 0.426 1963.00 0.898 1501.50 0.619 
Diabetesb 2183.00 0.613 1963.50 0.857 1527.00 0.611 
Depressionb 2035.50 0.226 1923.00 0.697 1344.00 0.097 
Tobacco Useb 2200.50 0.788 1948.50 0.828 1506.00 0.608 
Breast Cancer 
Screeninga 
N/A N/A 1288.00 0.000* 1479.50 0.490 
Cervical Cancer 
Screeninga 
1720.00 0.003* N/A N/A 1337.00 0.080 
Colorectal 
Cancer 
Screeninga 
2252.50 0.993 1820.50 0.302 N/A N/A 
a  Kruskal-Wallis test statistic 
b Mann-Whitney U test statistic 
c Significance: * p < 0.05; ** p < 0.01 
 
Kendall’s tau b correlation coefficient was used to examine relationships 
between log10 transformed variables and preventive health care actions (Table 15). 
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Kendall’s tau b, a nonparametric statistic, was used in the analysis due to outliers, which 
contributed to a violation of the normal distribution assumption (Meyer, et al. 2013; 
IBM, 2012). Significant relationships (one-tailed, p < 0.05) were noted between each of 
the preventive health care actions and several of the independent variables (Table 18). 
Using the more stringent tau b statistic: (a) breast cancer screening was significantly 
related to the log-transformed version of age, ethnicity (negatively), log-transformed 
version of length of time living with HIV infection, and the log-transformed version of 
lowest CD4 cell count; (b) cervical cancer screening was significantly related to the log-
transformed version of distance between residence and health care facility (negatively), 
the log-transformed version of lowest CD4 cell count, and the completion of breast 
cancer screening; (c) colorectal cancer screening was significantly and negatively related 
to the log-transformed version of age, marital status, and depression.  
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Table 15  
Bivariate Analysis: Kendall’s Tau B Correlation (N=142) 
 
Variable Breast Cancer 
Screening 
Cervical 
Cancer 
Screening  
Colorectal 
Cancer 
Screening  
Age (log10 trans) 
Sig.  
 
.135 
.021* 
NS -.578 
.000** 
Distance (log10 trans) 
Sig. 
  
NS -.173 
.007** 
NS 
Ethnicity 
Sig. 
 
-.135 
.045* 
NS NS 
Marital Status 
Sig.  
 
NS NS -.237 
.001** 
HIV Time (log10 trans) 
Sig.  
 
.250 
.000** 
NS NS 
CD4 Count (log10 trans) 
Sig. 
  
.109 
.048* 
.155 
.012* 
NS 
Hypertension 
Sig. 
  
NS NS NS 
Body Mass Index 
Sig. (1-tailed) 
 
NS NS NS 
Depression 
Sig. 
 
NS NS -.139 
.047* 
Mammogram–Completed 
Sig. 
 
1.00 .324 
.000** 
NS 
Note. Log10trans = log10 transformation; NS = not significant at p < 0.05 
* - Correlation significant at p < 0.05;  ** - Correlation significant at p < 0.01 level. 
 
Multivariate Analysis 
Analysis of variance (ANOVA) was used to examine associations between 
continuous independent variables and dependent variables. Assumptions associated with 
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ANOVA were independent random samples, from a normally distributed population 
with equal variances, and the statistical test examined the variability between groups, as 
well as within groups (IBM, 2012). The Kruskal-Wallis statistic was used instead of the 
F statistic due to statistical assumption violations (IBM, 2012), and the null hypothesis 
tested was no difference in the estimated variability between ranked groups (df = n, p < 
0.05). Breast cancer screening, which only had 5 or more observations for each category 
related to timing, was collapsed into two groups to comply with the higher number of 
observations (10) for each cell required for ANOVA, so the timeliness of the completed 
breast cancer screening was not analyzed. For breast cancer screening, significant 
independent variables were time living with HIV infection, and HIV stage, while 
significant independent variables for cervical cancer screening were distance between 
residence and health care facility, time living with HIV infection, and HIV stage, and the 
only statistically significant independent variable for colorectal cancer screening was 
age group (Table 16). 
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Table 16 
 
Ranked Group Differences in Variance: Significant Kruskal-Wallis Chi-Square Results  
 
Dependent 
Variable 
 
Independent 
Variable 
Kruskal-Wallis df Significancea 
Breast Cancer 
Screening  
 
Time living with 
HIV infection 
 
 
11.995 
 
1 0.001** 
HIV stage by 
classification 
schema 
25.174 8 0.001** 
HIV stage by 
CD4 cell count 
 
13.019 2 0.001** 
HIV stage by 
symptomatology 
 
10.330 2 0.006** 
Cervical Cancer 
Screening 
Distance 
 
 
10.495 1 0.001** 
Time living with 
HIV infection 
 
4.001 1 0.045* 
HIV stage by 
classification 
schema 
42.180 8 0.000*** 
HIV stage by 
CD4 cell count 
 
18.055 2 0.000*** 
HIV stage by 
symptomatology 
 
20.135 2 0.000*** 
Colorectal 
Cancer Screening 
Age divided by 
mean of 53.3 
 
44.584 1 0.000*** 
Note. aSignificance: * p < 0.05; ** p < 0.01; ***p < 0.001 
Due to the statistical assumption violations, ANOVA was conducted again using 
homogeneity of variance statistics and post hoc tests associated with equal variances 
(Bonferroni correction) and unequal variances (Tamhane’s T2) because, even after base 
log 10 transformations, violations remained (Meyer, 2012) for the three age variables 
(log transformed age, age by group, age by mean), as well as corrected distance, length 
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of time living with HIV infection, lowest CD4 cell count, breast cancer screening, and 
cervical cancer screening. Post hoc tests could only be conducted for colorectal cancer 
screening due to violations related to the minimum number of observations per cell 
(two). Bonferroni corrections were run for the same independent variables, and 
colorectal cancer screening, but only three independent variables (distance, lowest CD4 
cell count, and BMI) did not have significant homogeneity of variance statistics, and the 
statistics associated with the Bonferroni correction were not significant either.  
One-way ANOVA was executed a third time to examine mean differences using 
eta squared to determine the proportion of variance accounted for by main effects and 
interactions, as well as error (Tabachnick & Fidell, 2012). Only statistically significant 
variables were identified for discussion related to eta-squared (Table 17). For breast 
cancer screening, age cohort explained 6.6% of the variance, time living with HIV 
infection explained 7.3%, HIV stage by CD4 cell count explained 9%, HIV stage by 
symptomatology explained 13.5%, cervical cancer screening explained 13.5%, and HIV 
stage by classification schema explained 26.4%. For cervical cancer screening, time 
living with HIV infection explained 3%, distance between residence and health care 
facility explained 3.4%, breast cancer screening explained 5.3%, HIV stage by CD4 cell 
count explained 5.7%, HIV stage by symptomatology explained 7.3%, colorectal cancer 
screening explained 20.8%, and HIV stage by classification schema explained 25%. For 
colorectal cancer screening, breast cancer screening explained 5.6%, marital status 
explained 6.8%, age cohort explained 15.6%, and age divided by mean explained 32% 
of the variance based on the eta-squared statistics. 
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Table 17 
ANOVA – Significant Results for Completion of, or Failure to Complete, Screening for 
Breast, Cervical, and Colorectal Cancer Screening Independent	  Variables	   F	  (df)	   η 2	   F	   η 2	   F	   Sig	  (p)	   η 2	  Age	  Cohort	  	  	  	  	   9.836*	  (1,	  140)	   0.066	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   25.823***	  (1,	  140)	   	   0.156	  Age	  Group	  	  	  	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   65.905***	  (1,	  140)	   	   0.320	  Marital	  Status	  	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   3.375*	  (3,	  138)	   	   0.068	  Distance	  	  	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   4.862*	  (1,	  140)	   0.034	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  HIV	  Time	  	  	   11.051**	  (1,	  140)	   0.073	   4.256*	  (1,	  140)	   0.030	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	  HIV	  Stage	  	  	   5.976***	  (8,	  133)	   0.264	   5.554***	  (8,	  133)	   0.250	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	  HIV	  Stage,	  by	  CD4	  	   6.896**	  (2,	  139)	   0.090	   4.218*	  (2,	  139)	   0.057	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	   	  -­‐-­‐-­‐-­‐	  HIV	  Stage,	  by	  Symptoms	  	  	   10.829***	  (2,	  139)	   0.135	   5.502**	  (2,	  139)	   0.073	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  Breast	  Cancer	  Screening	  	  
-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   3.859*	  (2,	  139)	   0.053	   4.094*	  (2,	  139)	   0.019	   0.056	  
Cervical	  Cancer	  Screening	  	  	  
13.997***	  (2,	  139)	   0.168	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  Colorectal	  Cancer	  Screening	  	  
-­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   18.205***	  (2,	  139)	   0.208	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	   -­‐-­‐-­‐-­‐	  
Note: Significance: * p < 0.05; ** p < 0.01; *** p < 0.001 
 
As note above, several statistically significant variables contained the same 
information grouped differently, such the discrete variable of HIV stage, which created 
two additional discrete variables when grouped by CD4 cell count, and by 
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symptomatology, as well as two dichotomous variables. When more than one subgroup 
of a variable was significant, the resulting variable with the highest eta-squared was 
chosen for further analysis. Based on univariate and bivariate analyses, the following 
variables, in order of descending eta-squared statistics, were used to create the 
regression models: 
• For breast cancer screening 
• HIV stage, by classification schema (A1, A2, A3, B1, B2, B3, C1, C2, 
C3) 
! HIV stage, by symptomatology  
! HIV stage, by lowest CD4 cell count 
• Cervical cancer screening 
• Time living with HIV infection, divided by mean  
• Age cohort (40-49, 50-79) 
• For cervical cancer screening 
• HIV stage, by classification schema (A1, A2, A3, B1, B2, B3, C1, C2, 
C3) 
! HIV stage, by symptomatology  
! Lowest CD4 cell count  
• Colorectal cancer screening 
• Distance between residence and health care facility, divided by mean  
• Time living with HIV infection, divided by mean  
• Breast cancer screening 
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• For colorectal cancer screening 
• Age, divided by mean (40-53, 54-79) 
! Age cohort (40-49, 50-79) 
• Marital status  
• Breast cancer screening 
Logistic regression for the significant variables listed above was conducted using 
elimination based on the Hierarchial Principle (Kleinbaum & Klein, 2002) until a 
parsimonious model was identified, which described the variables associated with the 
preventive health care screening tests for breast cancer, cervical cancer, and colorectal 
cancer in HIV seropositive women. As mentioned in an earlier chapter, logistic 
regression was chosen as the mathematical modeling approach for several reasons: a) the 
dependent variable could be dichotomous, being completed or not completed; b) the 
logistic function f(z) ranged from 0 to 1 and described the probability of completing or 
not completing the preventive health care action; c) the logistic model created an S-
shaped logistic model with a threshold, which was applicable to the multivariate nature 
of epidemiologic research (Kleinbaum & Klein, 2002).  
Results of Hypothesis Testing 
The results of the analyses are discussed according to the research questions and 
hypotheses for each preventive health care action. For each research question, 
hypothesis and null hypothesis, the assumption was HIV seropositive women were seen 
by an infectious disease specialist at the same ambulatory care center three or more 
times, during the 12 months prior to data collection or death. Odds ratios were calculated 
from contingency tables; the p - value and 95% confidence intervals related to each odds 
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ratio were determined during bivariate analyses using Kendall’s tau b due to statistical 
assumption violations. The odds ratios for the variables retained for further analyses are 
presented in the next nine tables 
Breast Cancer Screening 
Research Question 1. Did the completion of breast cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women? The 
hypothesis, based on the literature review, stated HIV seropositive women in the 
youngest age cohort (40 to 49 years) would completed significantly more breast cancer 
screenings, compared to older HIV seropositive women, and the null hypothesis 
indicated no difference. More HIV seropositive women in the 50 to 79 year age cohort 
completed breast cancer screenings compared to women in the 40 to 49 years age 
cohort. However, failure to complete breast cancer was higher than completion in both 
women aged 40 to 49 years and women aged 50 to 79 years  (Table 18).  
Table 18 
 
Odds Ratio Using Kendall’s Tau B: Completion of Breast Cancer Screening by Age 
Group 
 
 Breast Cancer Screeninga  
 Completed Not Completed Totals 
Age Group   
   40-49 years 
 
9 
 
41 
 
50 
   50-79 years 40 51 91 
Totals 49 92 141 
Note: a (a/b)/(c/d) = (9/41)/(40/51) = 0.280 (CI95=0.1218, 0.643) 
χ2 = 0.024 (does not assume the null hypothesis) 
Tb = 0.000 (assumes the null hypothesis) 
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ANOVA results indicated a statistically significant relationship between age cohort and 
breast cancer screening (F = 9.836, df = 1, 140, p = 0.002, η 2 = 0.066). Based on the 
odds ratio calculated from the contingency table (OR = 1.00–0.280 = 0.72, CI95 = 
0.1218, 0.643), and using Kendall’s tau b for significance (Tb = 3.810, p = 0.000), since 
tau b is not sensitive to outliers, HIV seropositive women in the older age cohort of 50 to 
79 years, were 72% more likely to complete breast cancer screening, compared to HIV 
seropositive women in the younger age cohort of 40 to 49 years. While the null 
hypothesis of no difference was rejected, the hypothesis associated with the younger age 
group completing more breast cancer screenings was not supported, but the variable of 
age cohort was retained for further analysis 
Research Question 2. Did the completion of breast cancer screening differ 
significantly by the race of HIV seropositive women? The hypothesis, based on the 
literature review, stated White HIV seropositive women would complete significantly 
more breast cancer screenings, compared to Black or non-White HIV seropositive 
women, and the null hypothesis indicated no difference. The sample contained only 
Black and White HIV seropositive females. Black HIV seropositive women completed 
more breast cancer screenings (n=48), compared to White HIV seropositive females (n = 
2), but Black women also failed to complete more breast cancer screenings (n = 81), 
compared to White women (n = 11) in the study. Kruskal-Wallis and ANOVA did not 
indicate any statistically significant differences between Black and White HIV 
seropositive women and breast cancer screening. The odds ratio (OR = 3.2593, CI95 = 
0.6929, 15.3311) was not statistically significant by Kendall’s tau b (Tb = − 1.708, p = 
0.088) so the null of no difference was supported. 
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Research Question 3. Did the completion of breast cancer screening differ 
significantly by the ethnicity of HIV seropositive women? The hypothesis, based on the 
review of the literature, stated non-Hispanic HIV seropositive women would complete 
significantly more breast cancer screenings, compared to Hispanic HIV seropositive 
women, and the null hypothesis indicated no difference between the two groups. Non-
Hispanic HIV seropositive women completed more breast cancer screenings (n = 48) 
than Hispanic HIV seropositive women (n = 1). However, non-Hispanic women failed to 
complete more breast cancer screenings (n = 82), compared to Hispanic women (n = 10). 
Kruskal-Wallis and ANOVA were not statistically significant. The odds ratio (OR = 
5.8537; CI95 = 0.7267, 47.1515) was not statistically significant by Kendall’s tau b (Tb = 
− 1.911, p = 0.056), so the null hypothesis of no difference was supported. 
Research Question 4. Did the completion of breast cancer screening differ 
significantly by the marital status of HIV seropositive women? The hypothesis, based on 
the literature review findings, stated married HIV seropositive women would complete 
significantly more breast cancer screening tests, compared to single, partnered, divorced 
or widowed HIV seropositive women, and the null hypothesis indicated no difference. 
No women in the sample were categorized as partnered. More single HIV seropositive 
women completed breast cancer screenings (n = 35) than married, divorced or widowed 
women (n = 14), but failed to complete far more screenings (n = 65), compared to 
married, divorced or widowed (n = 27) in the study. In ANOVA, the Levene’s Test of 
Equality of Error Variances was statistically significant (F = 2.736, df = 3, 138, p = 
0.046) so the test was repeated using Tamhane’s T2 test (Meyer, et al, 2012), and the 
corrected model was not significant (F = 0.682, df = 3,138, p = 0.564). The odds ratio 
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comparing marital status and breast cancer screening (OR = 1.035, CI95 = 0.4831, 
2.2321) was not statistically significant (Tb = 0.309, p = 0.757), so the null hypothesis of 
no significant difference in the completion of breast cancer screening by marital status in 
HIV seropositive women was supported. 
Research Question 7. Did the completion of breast cancer screening differ 
significantly by the type of insurance in HIV seropositive women? The hypothesis, 
based on the review of the literature, stated HIV seropositive women with private or 
military insurance would complete significantly more breast cancer screenings, 
compared to HIV seropositive women with other types of insurance, including no 
insurance, self-pay, and charity care. The null hypothesis indicated no difference. No 
women in the sample had military insurance. HIV seropositive women with private 
insurance completed more breast cancer screenings (n = 45), compared to HIV 
seropositive with other types of insurance, as well as no insurance, self-pay, and charity 
care (n = 4), but privately insured women failed to complete more screenings (n = 83), 
compared to their counterparts (n = 9). The odds ratio associated with breast cancer 
screening and type of insurance (OR = 1.2199, CI95 = 0.3557, 4.1837) was not 
statistically significant (Tb = − 0.274, p = 0.784). The null hypothesis of no difference in 
breast cancer screening based on type of insurance was supported. 
Research Question 8. Did the completion of breast cancer screening differ 
significantly by the length of time the women were infected with HIV? The hypothesis, 
based on the literature review, stated women infected with HIV for the shortest category 
of time, which was 2 to 10 years, would complete significantly more breast cancer 
screenings, compared to women infected with HIV for a longer period of time, which 
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was 11 to 26 years in the study, and the null hypothesis indicated no difference between 
the two age groups. Breast cancer completion was similar between women who had 
lived with HIV infection for a shorter time, compared to women who had lived with 
HIV infection for a longer time. However, more women in the shorter time period failed 
to complete screenings, compared to their counterparts (Table 19).  
Table 19 
 
Odds Ratio Using Kendall’s Tau B: Completion of Breast Cancer Screening by Time 
Living with HIV Infection 
 
 Breast Cancer Screeninga  
 Completed Not Completed Totals 
HIV Time Group  
   2-10 years 
22 67 87 
   11-26 years 27 25 52 
Totals 49 92 141 
Note: a (a/b)/(c/d) = (22/67)/(27/25) = 0.304 (CI95=0.147, 0.6287) 
χ2 = 0.002 (does not assume the null hypothesis) 
Tb = 0.001 (assumes the null hypothesis) 
 
ANOVA using ranked groups was conducted due to statistical assumption violations, 
and was found to be significant (Kruskal-Wallis = 11.764, df = 1, p = 0.001). The results 
for breast cancer screening indicated significant variability between, or among, the ranks 
for time living with HIV infection. ANOVA was statistically significant (F = 8.672, df = 
1, 140, p = 0.004, η 2 = 0.087). Based on the odds ratio calculated from the contingency 
table (OR = 1.0-0.304, CI95 = 0.1423, 0.6042), and using Kendall’s tau b for significance 
(Tb = 3.421, p = 0.001), women living with HIV infection for a longer time, 11 to 26 
years, were 69.6% more likely to complete breast cancer screening, compared to women 
living with HIV infection for a shorter time, 2 to 10 years. While the null hypothesis of 
191 
 
no difference was not supported, the hypothesis of shorter time with HIV infection could 
not be supported either, but the relationship between breast cancer screening and a 
longer time with HIV infection was identified for further analysis. 
Research Question 9. Did the completion of breast cancer screening differ 
significantly by HIV stage in HIV seropositive women? The hypothesis, based on the 
literature review, stated HIV seropositive women with less progressed HIV infection 
would complete more breast cancer screenings than HIV seropositive women with more 
progressed HIV infection, and the null hypothesis was no difference. Four cells had five 
or fewer observations, so the ordinal variable of HIV stage by classification schema (A1, 
A2, A3, B1, B2, B3, C1, C2, C3) was collapsed into three three-category and three 
dichotomous variables based on: (a) symptomatology, where A was asymptomatic, B 
was symptomatic, but no AIDS-defining conditions, C was the diagnosis of an AIDS-
defining condition (StageSx3), and A and B were combined and compared to C 
(StageSx2); (b) CD4 cell count, where 1 referred to CD4 cell counts of 500 cells/mm3 or 
greater, 2 referred to CD4 cell counts between 200 and 499 cells/mm3, 3 corresponded to 
CD4 cell counts lower than 200 cells/mm3 (StageCD3), and 1 was compared to the 
combined 2 and 3 categories (StageCD2). In univariate analyses, one category in each of 
the three three-category variables had too few observations to comply with multivariate 
assumptions so these variables were not analyzed further. However, the three 
dichotomous variables had sufficient cell numbers. HIV disease progression was 
categorized according to symptomatology, where asymptomatic and symptomatic, but 
without an AIDS-defining condition, HIV infection was categorized as less progressed, 
while HIV infection with an AIDS-defining condition was categorized as more 
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progressed. Women with an AIDS-defining condition completed or failed to complete 
fewer screenings than women in the less progressed group (Table 20). The associated 
odds ratio (OR = 2.1916, CI95 = 0.6852, 7.0095) was not statistically significant (Tb = 
0.249, p = 0.804). The results for breast cancer screening indicated significant variability 
between, or among, the ranks for stage of HIV infection by symptomatology (Kruskal-
Wallis = 10.330, df = 2, p = 0.006).  
Table 20 
 
Odds Ratio Using Kendall’s Tau B: Completion of Breast Cancer Screening by Fewer 
Symptoms Related to HIV Infection 
 
 Breast Cancer Screeninga  
 Completed Not Completed Totals 
HIV Stage    
   Asymptomatic or  
      Symptomatic 
45 77 122 
   AIDS-defining 
Dx 
4 15 19 
Totals 49 92 141 
Note: a (a/b)/(c/d) = (45/77)/(4/15) = 2.192 (CI95 = 0.6852, 7.010) 
χ2 = 0.003 (does not assume the null hypothesis) 
Tb = 0.804 (assumes the null hypothesis) 
ANOVA was statistically significant for the ordinal variable of HIV stage, based on the 
classification schema (F = 5.976, df = 8, 133, p = 0.000), and the nominal variable of 
HIV stage, based on symptomatology (F = 10.829, df = 2, 139, p = 0.000). However, 
eta-squared for HIV stage by classification schema (η 2 = 0.264) was much larger, 
compared to HIV stage by symptomatology (η 2 = 0.135). Though the odds ratio was not 
significant using the more stringent Kendall’s tau, Kruskall-Wallis and ANOVA 
indicated a statistically significant difference, so, while the research hypothesis was not 
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supported, the variables of HIV stage by classification schema and symptomatology 
were retained for further analyses.  
Research Question 10. Did the completion of breast cancer screening differ 
significantly by CD4 cell count in HIV seropositive women? The hypothesis, based on 
the literature review, stated HIV seropositive women with CD4 cell counts of 500 
cells/mm3 or more would complete significantly more breast cancer screenings, 
compared to HIV seropositive women with CD4 cell counts less than 500 cells/mm3, 
and the null hypothesis indicated no difference. As mentioned in the previous section, 
the HIV classification schema was collapsed from a nine-category variable into 
dichotomous and three-category variables. For the resulting variable related to CD4 cell 
count, the lower category consisted of CD4 cell counts less than 500 cells/mm3, while 
the higher category included CD4 cell counts of 500 cells/mm3 or greater. HIV 
seropositive women with lower CD4 cell counts completed and failed to complete 
(n=90) more screenings than women with higher CD4 cell counts (Table 21). The results 
for breast cancer screening indicated significant variability between, or among, the ranks 
for stage of HIV infection by lowest CD4 cell count (Kruskal-Wallis = 13.029, df = 2, p 
= 0.001).  
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Table 21 
 
Odds Ratio Using Kendall’s Tau B: Completion of Breast Cancer Screening by CD4 
Cell Count >500mm3 
 
 Cervical Cancer Screeninga  
 Completed Not Completed Totals 
HIV Stage   
   >500mm3 
7 2 9 
   <500mm3  42 90 132 
Totals 49 92 141 
Note: a (a/b)/(c/d) = (7/2)/(49/92) = 0.133 (CI95 = 0.0266, 0.6695) 
χ2 = 0.000 (does not assume the null hypothesis) 
Tb = 1.264 (assumes the null hypothesis) 
 
While the odds ratio was not significant, analysis continued using the general linear 
model (Meyers, et al, 2012). The Levene’s Test of Equality of Error Variances was not 
significant in univariate analysis (F = 0.341, df = 2,139, p = 0.712). However, the 
between-subjects effect in the corrected model was significant (F = 6.896, df = 2,139, p 
= 0.001), as was the effect associated with the independent variable (F = 6.896, df = 2, 
139, p = 0.001, η 2 = 0.90). The Ryan-Einot-Gabriel-Welsch post hoc test indicated CD4 
cell counts of <200 cells/mm3 and 200 to 499 cells/mm3 did not differ significantly from 
one another, but values for these two groups did differ significantly from CD4 cell 
counts of 500 cells/mm3 or greater. Based on the additional analyses, the research 
hypothesis was not supported because the direction hypothesized was incorrect, but the 
variable was retained for analyses. 
Research Question 11. Did the completion of breast cancer screening differ 
significantly by distance between residence and health care facility in HIV seropositive 
women? The hypothesis, based on the literature review, stated HIV seropositive women 
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in the shortest distance in miles category would complete significantly more breast 
cancer screening tests compared to HIV seropositive women who live farther from the 
health care facility. In the study, the shortest distance category, divided by mean, was 0 
to 4.9 miles, while the farthest distance category was 5.0 to 29.0 miles. HIV seropositive 
women who lived a shorter distance from the health care facility completed more breast 
cancer screenings (n = 31), but failed to complete more screenings (n = 72), compared to 
women who lived farther away (n = 18 and 20, respectively). Kruskal-Wallis and 
ANOVA were not significant. The odds ratio (OR = 0.4784, CI95 = 0.223, 1.0264) was 
not statistically significant (Tb = 1.724, p = 0.085), so the null hypothesis of no 
difference was supported.  
Research Question 12. Did the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with hypertension, compared 
to HIV seropositive women without a diagnosis of hypertension? From the review of the 
literature, women with hypertension completed significantly fewer breast cancer 
screenings when compared to women without hypertension so the hypothesis stated 
there would be a significant difference in the completion of breast cancer screening by 
HIV seropositive women, but did not state which group would complete more 
screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women with hypertension and those without hypertension. 
The number of breast cancer screening completed by HIV seropositive women with 
hypertension (n = 22) was similar to completed screenings in women without 
hypertension (n = 27), as were the numbers for failure to completed screening (n = 41 
and 51, respectively). The odds ratio for breast cancer screening and hypertension (OR = 
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1.0136, CI95 = 0.5048, 2.0352) was not significant (Tb = 0.230, p = 0.818). No 
significant difference was noted in the analysis for ranked differences of variance or 
ANOVA, so the null hypothesis of no difference was supported. 
Research Question 13. Did the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with obesity, compared to 
HIV seropositive women without a diagnosis of obesity? From the review of the 
literature, women with obesity completed significantly fewer breast cancer screenings 
when compared to women without obesity so the hypothesis stated there would be a 
significant difference in the completion of breast cancer screening by HIV seropositive 
women, but did not state which group would complete more screenings. The null 
indicated no difference in the number of completed screenings between HIV 
seropositive women with obesity and those without obesity. For some analyses, the four 
BMI classifications (BMI <18.5 = underweight, 18.5-24.9 = normal weight, 25.0-29.9 = 
overweight, 30.0 or greater = obesity) were collapsed into two categories (obese = BMI 
of 30.0 or greater, not obese = BMI of less than 30.0). HIV seropositive women with 
obesity completed fewer breast cancer screenings (n = 20), compared to non-obese 
women (n = 29), but both groups failed to complete more screenings (n = 43 and 49, 
respectively) than were completed. The odds ratio (OR = 0.7859, CI95 = 0.3896, 1.5852) 
was not statistically significant (Tb = −0.470, p = 0.639). No significant difference was 
noted for Kruskal-Wallis or ANOVA, so the null hypothesis of no difference between 
the groups of HIV seropositive women, based on a diagnosis of obesity, was supported. 
Research Question 14. Did the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with diabetes mellitus, 
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compared to HIV seropositive women without a diagnosis of diabetes mellitus? From 
the review of the literature, women with diabetes mellitus completed significantly more 
breast cancer screenings when compared to women without diabetes, so the hypothesis 
stated there would be a significant difference in the completion of breast cancer 
screening by HIV seropositive women, but did not state which group would complete 
more screenings. The null indicated no difference in the number of completed 
screenings between HIV seropositive women with diabetes mellitus and those without 
diabetes mellitus. HIV seropositive women with diabetes mellitus completed fewer 
breast cancer screenings (n = 9), compared to HIV positive women without a diagnosis 
of diabetes mellitus (n = 40), but both groups failed to complete more screenings (n = 14 
and 78, respectively) than were completed. The odds ratio (OR = 1.2536, CI95 = 0.4995, 
3.1495) was not statistically significant (Tb = −0.470, p = 0.639). No significant 
difference was noted in ANOVA or in analysis for ranked differences of variance, so the 
null hypothesis of no difference between the groups of HIV seropositive women, based 
on a diagnosis of diabetes mellitus, was supported. 
Research Question 15. Did the completion of breast cancer screening differ 
significantly between HIV seropositive women diagnosed with depression, compared to 
HIV seropositive women without a diagnosis of depression? From the review of the 
literature, women with depression completed significantly fewer breast cancer 
screenings when compared to women without depression, so the hypothesis stated there 
would be a significant difference in the completion of breast cancer screening by HIV 
seropositive women, but did not state which group would complete more screenings. 
HIV seropositive women with a diagnosis of depression failed to complete more breast 
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cancer screenings (n = 23) than they completed (n = 17), and a similar trend was noted 
in HIV seropositive women without a diagnosis of depression (n = 69 and 32, 
respectively). The odds ratio (OR = 1.5938, CI95 = 0.7497, 3.388) was not significant (Tb 
= 1.070, p = 0.285). The null indicated no difference in the number of completed 
screenings between HIV seropositive women with depression, and those without a 
diagnosis of depression. No significant difference was noted in ANOVA or in analysis 
for ranked differences of variance so the null hypothesis of no difference between the 
groups of HIV seropositive women, based on a diagnosis of depression, was supported. 
Research Question 16. Did the completion of breast cancer screening differ 
significantly between HIV seropositive women who used tobacco, compared to HIV 
seropositive women who do not use tobacco? From the review of the literature, women 
who used tobacco completed significantly fewer breast cancer screenings when 
compared to women who abstained from tobacco use, so the hypothesis stated there 
would be a significant difference in the completion of breast cancer screening by HIV 
seropositive women, but did not state which group would complete more screenings. 
Fewer HIV positive women who used tobacco completed breast cancer screenings (n = 
23), compared to non-users (n = 26), but more non-users failed to complete breast cancer 
screenings (n = 51), compared to tobacco users (n = 41). The odds ratio (OR = 1.1004, 
CI95 = 0.5489, 2.2061) was not statistically significant (Tb = 0.107, p = 0.915). The null 
indicated no difference in the number of completed screenings between HIV 
seropositive women who used tobacco, and those who did not use tobacco. No 
significant difference was noted in ANOVA or in analysis for ranked differences of 
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variance, so the null hypothesis of no difference between the groups of HIV seropositive 
women, based on a tobacco use, was supported. 
Cervical Cancer Screening Research Questions 
Research Question 1. Did the completion of cervical cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women? The 
hypothesis, based on the literature review, stated HIV seropositive women in the 
youngest age cohort (40 to 49 years) would completed significantly more cervical cancer 
screenings, compared to older HIV seropositive women, and the null hypothesis 
indicated no difference. More HIV seropositive women in the 50 to 79 year age cohort 
completed cervical cancer screenings (n = 25) compared to women in the 40 to 49 years 
age cohort (n = 14). However, failure to complete breast cancer was higher than 
completion in both women aged 40 to 49 years (n = 36) and women aged 50 to 79 years 
(n = 66). Analysis of ranked differences associated with variance and ANOVA were not 
statistically significant. The odds ratio calculated from the contingency table (OR = 
1.0267, CI95 = 0.4753, 2.2175), was not statistically significant (Tb = 0.072, p = 0.943). 
As noted in the results section for breast cancer screening, Kendall’s tau b was used to 
test significance because tau b was not sensitive to outliers or unequal variances. The 
null hypothesis of no difference of in cervical cancer screening completion by age 
cohort was supported. 
Research Question 2. Did the completion of cervical cancer screening differ 
significantly by the race of HIV seropositive women? The hypothesis, based on the 
literature review, stated White HIV seropositive women would complete significantly 
more cervical cancer screenings, compared to Black or non-White HIV seropositive 
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women, and the null hypothesis indicated no difference. The sample contained only 
Black and White HIV seropositive females. Black HIV seropositive women completed 
more cervical cancer screenings (n = 34), compared to White HIV seropositive females 
(n = 5), but Black women also failed to complete more cervical cancer screenings (n = 
94), compared to White women (n = 8) in the study. Kruskal-Wallis and ANOVA did 
not indicate any statistically significant difference between Black and White HIV 
seropositive women and the completion of cervical cancer screening. The odds ratio (OR 
= 0.5787, CI95 = 0.1771, 1.8913) was not statistically significant by Kendall’s tau b (Tb = 
−0.776, p = 0.438). The null hypothesis of no difference in screening completion based 
on the race of HIV seropositive women was supported. 
Research Question 3. Did the completion of cervical cancer screening differ 
significantly by the ethnicity of HIV seropositive women? The hypothesis, based on the 
review of the literature, stated non-Hispanic HIV seropositive women would complete 
significantly more cervical cancer screenings, compared to Hispanic HIV seropositive 
women, and the null hypothesis indicated no difference between the two groups. Non-
Hispanic HIV seropositive women completed more cervical cancer screenings (n = 34) 
than Hispanic HIV seropositive women (n = 5). However, non-Hispanic women failed to 
complete more cervical cancer screenings (n = 96), compared to Hispanic women (n = 
6). The odds ratio (OR = 2.3529; CI95 = 0.6744, 8.2096) was not statistically significant 
by Kendall’s tau b (Tb = −1.138, p = 0.255) so the null hypothesis of no difference in 
cervical cancer screening completion associated with ethnicity was supported. 
Research Question 4. Did the completion of cervical cancer screening differ 
significantly by the marital status of HIV seropositive women? The hypothesis, based on 
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the literature review findings, stated married HIV seropositive women would complete 
significantly more cervical cancer screening, compared to single, partnered, divorced or 
widowed HIV seropositive women, and the null hypothesis indicated no difference. No 
women in the sample were categorized as partnered. More single HIV seropositive 
women completed cervical cancer screenings (n=27) than married, divorced or widowed 
women (n=12), but failed to complete far more screenings (n=72), compared to married, 
divorced or widowed (n=30) in the study. Analysis for ranked differences of variance 
and ANOVA were not statistically significant. The odds ratio comparing marital status 
and cervical cancer screening (OR = 0.9375, CI95 = 0.4202, 2.0914) was not statistically 
significant (Tb = 0.035, p = 0.972), so the null hypothesis of no difference in screening 
completion based on marital status was supported. 
Research Question 7. Did the completion of cervical cancer screening differ 
significantly by the type of insurance in HIV seropositive women? The hypothesis, 
based on the review of the literature, stated HIV seropositive women with private or 
military insurance would complete significantly more cervical cancer screenings, 
compared to HIV seropositive women with other types of insurance, including no 
insurance, self-pay, and charity care. The null hypothesis indicated no difference. No 
women in the sample had military insurance. HIV seropositive women with private 
insurance completed more cervical cancer screenings (n = 34), compared to HIV 
seropositive with other types of insurance, as well as no insurance, self-pay, and charity 
care (n = 5), but privately insured women failed to complete more screenings (n = 94), 
compared to their counterparts (n = 8). Analysis for ranked differences of variance and 
ANOVA were not statistically significant. The odds ratio associated with cervical cancer 
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screening and type of insurance (OR = 0.5787, CI95 = 0.1771, 1.8913) was not 
statistically significant (Tb = −0.089, p = 0.438). The null hypothesis associated with no 
difference in screening completion based on type of insurance was supported.   
Research Question 8. Did the completion of cervical cancer screening differ 
significantly by the length of time the women were infected with HIV? The hypothesis, 
based on the literature review, stated women infected with HIV for the lowest, or 
shortest, category of time, which was 2 to 10 years, would complete significantly more 
cervical cancer screenings, compared to women infected with HIV for a longer period of 
time, which was 11 to 26 years in the study, and the null hypothesis indicated no 
difference between the two age groups. Analysis for ranked group differences in 
variance between length of time living with HIV infection and cervical cancer screening 
indicated significant variability between, or among, the ranks of time living with HIV 
infection (Kruskal-Wallis = 4.001, df = 1, p = 0.045). ANOVA was statistically 
significant (F = 4.256, df = 1, 140, p = 0.041, η 2 = 0.030). The odds ratio (OR = 0.5034, 
CI95 = 0.2372, 1.0685) was not significant (Tb = 1.948, p = 0.051). However, given the 
statistically significant results for ranked group differences and ANOVA, and the near-
significant results for the stringent Kendall’s tau b associated with the odds ratio, the 
variable of length of time living with HIV infection was included in modeling, but, 
based on the outcome of the odds ratio, the null hypothesis of no difference was 
supported.   
Research Question 9. Did the completion of cervical cancer screening differ 
significantly by HIV stage in HIV seropositive women? The hypothesis, based on the 
literature review, stated HIV seropositive women with less progressed HIV infection 
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would complete more cervical cancer screenings than HIV seropositive women with 
more progressed HIV infection, and the null hypothesis was no difference. In the study, 
HIV disease progression was determined by HIV stage and was categorized according to 
symptomatology. Analysis for ranked group differences in variance indicated cervical 
cancer screening had significant variability between, or among, the ranks for stage of 
HIV infection by classification schema, and stage of HIV infection by symptomatology 
(Kruskal-Wallis = 20.135, df = 2, p = 0.000). ANOVA was statistically significant for 
HIV stage based on classification schema (F = 5.554, df = 8, 133, p = 0.000) and HIV 
stage based on symptomatology (F = 5.502, df = 2, 139, p = 0.005), but the effect size 
for HIV stage based on classification schema (η 2 = 0.250) was larger than the effect size 
for HIV stage based on symptomatology (η 2 = 0.073). Based on the odds ratio calculated 
from the contingency table, using Kendall’s tau b for significance (Table 22), HIV 
seropositive women who were asymptomatic, or had symptoms not associated with an 
AIDS-defining condition, were 6.8 times more likely to complete cervical cancer 
screening, compared to HIV seropositive women with an AIDS-defining condition. The 
research hypothesis indicating a difference in screening completion based on HIV 
disease progression was supported. 
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Table 22 
 
Odds Ratio Using Kendall’s Tau B: Completion of Cervical Cancer Screening by Fewer 
Symptoms Related to HIV Infection 
 
 Cervical Cancer Screeninga  
 Completed Not Completed Totals 
HIV Stage    
   Asymptomatic or  
      Symptomatic 
89 34 123 
   AIDS-defining 
Dx 
5 13 18 
Totals 94 47 141 
Note: a (a/b)/(c/d) = (89/34)/(5/13) = 1.0068 (CI95 = 0.336, 3.0383) 
χ2 = 0.000 (does not assume the null hypothesis) 
Tb = 2.646 (assumes the null hypothesis) 
 
Research Question 10. Did the completion of cervical cancer screening differ 
significantly by CD4 cell count in HIV seropositive women? The hypothesis, based on 
the literature review, stated HIV seropositive women with CD4 cell counts of 500 
cells/mm3 or more would complete significantly more cervical cancer screenings, 
compared to HIV seropositive women with CD4 cell counts less than 500 cells/mm3, 
and the null hypothesis indicated no difference. Analysis for ranked group differences in 
variance indicated significant variability between, or among, the ranks for stage of HIV 
infection by CD4 cell count for cervical cancer screening (Kruskal-Wallis = 18.055, df = 
2, p = 0.000). ANOVA was statistically significant (F = 4.218, df = 2, 139, 0.017, η 2 = 
0.057). Based on the odds ratio calculated from the contingency table using Kendall’s 
tau b for significance, HIV seropositive women whose lowest CD4 cell count was less 
than 500mm3 were 26 times more likely to complete cervical cancer screening, 
compared to HIV seropositive women whose lowest CD4 cell count was 500mm3 or 
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greater (Table 23). The null hypothesis of no difference could not be rejected, even 
when statistical results were found due to the direction of research hypothesis, where 
HIV seropositive women with lowest CD4 cell counts of 500mm3 or greater would 
complete more screening tests. 
Table 23 
 
Odds Ratio Using Kendall’s Tau B: Completion of Cervical Cancer Screening by CD4 
Cell Count >500mm3 
 
 Cervical Cancer Screeninga  
 Completed Not Completed Totals 
HIV Stage   
   >500mm3 
8 1 9 
   <500mm3  31 101 132 
Totals 39 102 141 
Note: a (a/b)/(c/d) = (8/1)/(31/101) = 26.065 (CI95 = 3.1364, 216.6024) 
χ2 = 0.000 (does not assume the null hypothesis) 
Tb = 0.006 (assumes the null hypothesis) 
 
Research Question 11. Did the completion of cervical cancer screening differ 
significantly by distance between residence and health care facility in HIV seropositive 
women? The hypothesis, based on the literature review, stated HIV seropositive women 
in the shortest distance in miles category would complete significantly more cervical 
cancer screening tests compared to HIV seropositive women who live farther from the 
health care facility. In the study, the shortest distance category was 0 to 4.9 miles, while 
the farther distance category was 5.0 to 29.0 miles. HIV seropositive women who lived a 
shorter distance from the health care facility completed more cervical cancer screenings 
(n = 36), compared to women who lived farther (n = 3), but women who lived a shorter 
distance away failed to complete more screenings (n = 67), compared to women in the 
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farther distance group (n = 35). Analysis of ranked group differences in variance 
indicated significant variability between, or among, the ranks for distance between 
residence and health care facility, and cervical cancer screening (Kruskal-Wallis = 
10.495, df = 1, p = 0.001). The odds ratio (OR = 6.2687, CI95 = 1.8019, 21.8084) was 
statistically significant (Tb = −4.054, p = 0.000), so the research hypothesis was 
supported. 
Research Question 12. Did the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with hypertension, compared 
to HIV seropositive women without a diagnosis of hypertension? From the review of the 
literature, women with hypertension completed significantly fewer cervical cancer 
screenings when compared to women without hypertension so the hypothesis stated 
there would be a significant difference in the completion of cervical cancer screening by 
HIV seropositive women, but did not state which group would complete more 
screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women with hypertension and those without hypertension. 
The number of cervical cancer screening completed by HIV seropositive women with 
hypertension (n = 21) was similar to completed screenings in women without 
hypertension (n = 18), as were the numbers for failure to completed screening (n = 43 
and 59, respectively). The odds ratio for breast cancer screening and hypertension (OR = 
1.6008, CI95 = 0.7621, 3.3624) was not significant (Tb = 1.053, p = 0.292). No 
significant difference was noted in ANOVA or in analysis for ranked differences of 
variance so the null hypothesis of no difference was supported. 
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Research Question 13. Did the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with obesity, compared to 
HIV seropositive women without a diagnosis of obesity? From the review of the 
literature, women with obesity completed significantly fewer cervical cancer screenings 
when compared to women without obesity so the hypothesis stated there would be a 
significant difference in the completion of cervical cancer screening by HIV seropositive 
women, but did not state which group would complete more screenings. The null 
indicated no difference in the number of completed screenings between HIV 
seropositive women with obesity and those without obesity. As mentioned in relation to 
cervical cancer screening, for some analyses, the four BMI classifications were 
collapsed into two categories (obese = BMI of 30.0 or greater, not obese = BMI of less 
than 30.0). HIV seropositive women with obesity completed fewer cervical cancer 
screenings (n = 16), compared to non-obese women (n = 23), but both groups failed to 
complete more screenings (n = 48 and 54, respectively) than were completed. The odds 
ratio (OR = 1.6521, CI95 = 0.7826, 1.6521) was not statistically significant (Tb = −0.067, 
p = 0.946). No significant difference was noted in ANOVA or in analysis for ranked 
differences of variance so the null hypothesis of no difference between the groups of 
HIV seropositive women, based on a diagnosis of obesity, was supported. 
Research Question 14. Did the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with diabetes mellitus, 
compared to HIV seropositive women without a diagnosis of diabetes mellitus? From 
the review of the literature, women with diabetes mellitus completed significantly more 
cervical cancer screenings when compared to women without diabetes, so the hypothesis 
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stated there would be a significant difference in the completion of cervical cancer 
screening by HIV seropositive women, but did not state which group would complete 
more screenings. The null indicated no difference in the number of completed 
screenings between HIV seropositive women with diabetes mellitus and those without 
diabetes mellitus. HIV seropositive women with diabetes mellitus completed fewer 
cervical cancer screenings (n = 7), compared to HIV positive women without a diagnosis 
of diabetes mellitus (n = 32), but both groups failed to complete more screenings (n = 17 
and 85, respectively) than were completed. The odds ratio (OR = 1.0938, CI95 = 0.4148, 
2.8839) was not statistically significant (Tb = −0.810, p = 0.418). No significant 
difference was noted in ANOVA or in analysis for ranked differences of variance so the 
null hypothesis of no difference between the groups of HIV seropositive women, based 
on a diagnosis of diabetes mellitus, was supported. 
Research Question 15. Did the completion of cervical cancer screening differ 
significantly between HIV seropositive women diagnosed with depression, compared to 
HIV seropositive women without a diagnosis of depression? From the review of the 
literature, women with depression completed significantly fewer cervical cancer 
screenings when compared to women without depression, so the hypothesis stated there 
would be a significant difference in the completion of cervical cancer screening by HIV 
seropositive women, but did not state which group would complete more screenings. 
The null indicated no difference in the number of completed screenings between HIV 
seropositive women with depression, and those without a diagnosis of depression. HIV 
seropositive women with a diagnosis of depression failed to complete more cervical 
cancer screenings (n = 28) than they completed (n = 12), and a similar trend was noted 
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in HIV seropositive women without a diagnosis of depression (n = 74 and 27, 
respectively). The odds ratio (OR = 1.1746, CI95 = 0.524, 2.6329) was not significant (Tb 
= 0.267, p = 0.790). The null indicated no difference in the number of completed 
screenings between HIV seropositive women with depression, and those without a 
diagnosis of depression. No significant difference was noted in ANOVA or in analysis 
for ranked differences of variance so the null hypothesis of no difference between the 
groups of HIV seropositive women, based on a diagnosis of depression, was supported. 
Research Question 16. Did the completion for cervical cancer screening differ 
significantly between HIV seropositive women who used tobacco, compared to HIV 
seropositive women who do not use tobacco? From the review of the literature, women 
who used tobacco completed significantly fewer cervical cancer screenings when 
compared to women who abstained from tobacco use, so the hypothesis stated there 
would be a significant difference in the completion of cervical cancer screening by HIV 
seropositive women, but did not state which group would complete more screenings. 
The null indicated no difference in the number of completed screenings between HIV 
seropositive women who used tobacco, and those who did not use tobacco. Fewer HIV 
positive women who used tobacco completed cervical cancer screenings (n = 18), 
compared to non-users (n = 21), but more non-users failed to complete breast cancer 
screenings (n = 57), compared to tobacco users (n = 45). The odds ratio (OR = 1.0857, 
CI95 = 0.5175, 2.2779) was not statistically significant (Tb = 0.418, p = 0.676). The null 
indicated no difference in the number of completed screenings between HIV 
seropositive women who used tobacco, and those who did not use tobacco. No 
significant difference was noted in ANOVA or in analysis for ranked differences of 
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variance so the null hypothesis of no difference between the groups of HIV seropositive 
women, based on a tobacco use, was supported. 
Colorectal Cancer Screening Research Questions 
Research Question 1. Did the completion of colorectal cancer screening differ 
significantly by the embodiment variable of age cohort in HIV seropositive women? The 
hypothesis, based on the literature review, stated HIV seropositive women in the 
youngest age cohort would completed significantly more colorectal cancer screenings, 
compared to older HIV seropositive women, and the null hypothesis indicated no 
difference. In the study, for minimum cell numbers to be realized, the original six age 
cohorts were collapsed into two cohorts, specifically 40 to 49 years and 50 to 79 years. 
Since the USPSTF did not recommend colorectal cancer screening for women until 50 
years of age, the continuous variable of age was divided by the variable mean of 53.3 
years to form two age groups, 40 to 53 years and 54 to 79 years, for the hypothesis 
testing of age related to colorectal cancer screening. Of the 142 HIV seropositive women 
in the sample, only 36 met the USPSTF preventive health screening recommendations 
for colorectal cancer screening. The older age group of 54 to 79 years did not complete 
any colorectal cancer screenings (n = 0), while the younger age group of 40 to 53 years 
completed a few more (n = 6) and failed to completed significantly more (n = 29). 
Analysis for ranked group differences in variance indicated statistically significant 
variability between age group, divided by the mean of the continuous age variable, and 
colorectal cancer screening (Kruskal-Wallis = 44.584, df = 1, p = 0.000). ANOVA was 
statistically significant for age cohort, or ages 40 to 49 years and 50 to 79 years, and age 
group by mean, specifically 40 to 53 years and 54 to 79 years (F = 25.823, df = 1, 140, p 
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= 0.000 and F = 65.905, df = 1, 140, p = 0.000, respectively), but the eta-squared was 
higher for age group divided by mean (η 2 = 0.320), compared to age cohort (η 2 = 0.156). 
The odds ratio and confidence intervals were not interpretable due to the zero value in 
one cell, but the associated Kendall’s tau b statistically significant (Tb = −7.956, p = 
0.000). As noted in the results sections for breast and cervical cancer screening, 
Kendall’s tau b was used to test significance because tau b was not sensitive to outliers 
or unequal variances. The null hypothesis of no difference in colorectal cancer screening 
by age was not supported.  
Research Question 2. Did the completion of colorectal cancer screening differ 
significantly by the race of HIV seropositive women? The hypothesis, based on the 
literature review, stated White HIV seropositive women would complete significantly 
more colorectal cancer screenings, compared to Black or non-White HIV seropositive 
women, and the null hypothesis indicated no difference. The sample contained only 
Black and White HIV seropositive females, and, as mentioned before, only 36 HIV 
seropositive women met the USPSTF preventive health screening recommendations for 
colorectal cancer screening. Black HIV seropositive women completed more colorectal 
cancer screenings (n = 6), compared to White HIV seropositive females (n = 0), but 
Black women also failed to complete more cervical cancer screenings (n = 29), 
compared to White women (n = 1) in the study. Initial univariate analyses did not 
indicate any statistically significant difference between Black and White HIV 
seropositive women and cervical cancer screening. Results from the analysis for ranked 
group differences in variance and ANOVA were not significant. The odds ratio was not 
interpretable due to the zero value in one cell, and was not statistically significant by 
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Kendall’s tau b (Tb = 1.954, p = 0.051). The null hypothesis of no difference in 
screening completion based on the race of HIV seropositive women was supported. 
Research Question 3. Did the completion of colorectal cancer screening differ 
significantly by the ethnicity of HIV seropositive women? The hypothesis, based on the 
review of the literature, stated non-Hispanic HIV seropositive women would complete 
significantly more colorectal cancer screenings, compared to Hispanic HIV seropositive 
women, and the null hypothesis indicated no difference between the two groups. Of the 
142 HIV seropositive women in the sample, only 36 met the USPSTF preventive health 
screening recommendations for colorectal cancer screening. Non-Hispanic HIV 
seropositive women completed more colorectal cancer screenings (n = 6) than Hispanic 
HIV seropositive women (n = 0). However, non-Hispanic women failed to complete 
more colorectal cancer screenings (n = 29), compared to Hispanic women (n = 1). 
Results from the analysis for ranked group differences in variance and ANOVA were 
not significant. The odds ratio (OR = 0.000; CI95 = 0.000, NaN) was not interpretable 
due to an absence of cases in one cell, and was not statistically significant by Kendall’s 
tau b (Tb = −1.588, p = 0.112) so the null hypothesis of no difference in cervical cancer 
screening completion associated with ethnicity was supported. 
Research Question 4. Did the completion of colorectal cancer screening differ 
significantly by the marital status of HIV seropositive women? The hypothesis, based on 
the literature review findings, stated married HIV seropositive women would complete 
significantly more colorectal cancer screening tests, compared to single, partnered, 
divorced or widowed HIV seropositive women, and the null hypothesis indicated no 
difference. No women in the sample were categorized as partnered, and only 36 met the 
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USPSTF preventive health screening recommendations for colorectal cancer screening. 
ANOVA indicated a statistically significant difference between the categories of marital 
status (F = 3.375, df = 3, 138, p = 0.020, η 2 = 0.068), in relation to colorectal cancer 
screening, and the odds ratio was statistically significant for single versus other marital 
status (Table 24), while the odds ratio for married versus other marital status was not 
interpretable due to an absence of cases in one cell, and was not significant (Tb = −1.281, 
p = 0.200).  
Table 24 
 
Odds Ratio Using Kendall’s Tau B: Completion of Colorectal Cancer Screening by 
Marital Status, Single Versus Others 
 
 Colorectal Cancer Screeninga  
 Completed Not Completed Totals 
Marital Status  
   Single 
2 16 18 
   Married, 
Divorced,    
      Widowed 
4 14 
18 
Totals 6 30 36 
Note: a (a/b)/(c/d) = (2/16)/(4/14) = 0.438 (CI95 = 0.0693, 2.7623) 
χ2 = 0.005 (does not assume the null hypothesis) 
Tb = 2.747 (assumes the null hypothesis) 
2 n = 36; 106 cases were not applicable to USPSTF recommendations for colorectal 
cancer screening 
 
The null hypothesis of no difference was supported by default because the research 
question hypothesized being married would be associated with colorectal cancer 
screenings. However, the marital status associated with never been married, or single, 
was used in later analyses. 
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Research Question 7. Did the completion of colorectal cancer screening differ 
significantly by the type of insurance in HIV seropositive women? The hypothesis, 
based on the review of the literature, stated HIV seropositive women with private or 
military insurance would complete significantly more colorectal cancer screenings, 
compared to HIV seropositive women with other types of insurance, including 
insurance, self-pay, and charity care. The null hypothesis indicated no difference. No 
women in the sample had military insurance, and only 36 met the USPSTF preventive 
health screening recommendations for colorectal cancer screening. More HIV 
seropositive women with private insurance completed colorectal cancer screenings (n = 
6), compared to women with other types of insurance, including no insurance, self-pay 
and charity care (n = 0). However, more women with private insurance failed to 
complete colorectal cancer screening (n = 25), when compared to other insurance, no 
insurance, self-pay and charity care (n = 5). The odds ratio associated with private 
insurance and colorectal cancer screening was not interpretable due to a zero value in 
one cell, and was not significant (Tb = −1.077, p = 0.281). Though an odds ratio could be 
calculated when the eligible HIV seropositive women (n = 36) were categorized by 
Medicaid, the most frequently reported type of insurance, and other insurances, no 
insurance, self-pay and charity care (OR = 5.5, CI95 = 0.8389, 36.0598), the odds ratio 
was not significant (Tb = 1.691, p = 0.091). The null hypothesis of no difference in type 
of insurance and colorectal cancer screening completion was supported.  
Research Question 8. Did the completion of colorectal cancer screening differ 
significantly by the length of time the women were infected with HIV? The hypothesis, 
based on the literature review, stated women infected with HIV for the lowest, or 
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shortest, category of time, which was 2 to 10 years, would complete significantly more 
colorectal cancer screenings, compared to women infected with HIV for a longer period 
of time, which was 11 to 26 years in the study, and the null hypothesis indicated no 
difference between the groups. To review, the USPSTF recommendations for colorectal 
cancer screening only applied to 36 HIV seropositive women. HIV seropositive women 
in the shortest time group completed fewer screenings (n = 2), and failed to complete 
more screenings (n = 18), compared to women in the longer time group (n = 4 and 12, 
respectively). Analyses for ranked group differences in variance between length of time 
living with HIV infection and colorectal cancer screening, as well as ANOVA, were not 
statistically significant. The odds ratio (OR = 0.3333, CI95 = 0.0525, 2.1155) was not 
significant (Tb = −0.870, p = 0.385). The null hypothesis of no difference between time 
living with HIV infection, and colorectal cancer screening completion was supported.   
Research Question 9. Did the completion of colorectal cancer screening differ 
significantly by HIV stage in HIV seropositive women? The hypothesis, based on the 
literature review, stated HIV seropositive women with less progressed HIV infection 
would complete more colorectal cancer screenings than HIV seropositive women with 
more progressed HIV infection, and the null hypothesis was no difference. In the study, 
HIV disease progression was determined by HIV stage and was categorized according to 
symptomatology. The USPSTF recommendations for colorectal cancer applied to only 
36 HIV seropositive women in the sample; HIV seropositive women in the 
asymptomatic and symptomatic group completed more colorectal cancer screenings (n = 
4), and failed to complete more screenings (n = 29), compared to women in the AIDS-
defining condition group (n = 2 and 1, respectively).  
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Table 25 
 
Odds Ratio Using Kendall’s Tau B: Completion of Colorectal Cancer Screening by 
Fewer Symptoms Related to HIV Infection 
 
 Colorectal Cancer Screeninga  
 Completed Not Completed Totals 
HIV Stage 
Asymptomatic or  
Symptomatic 
4 29 33 
AIDS-defining Dx 2 1 3 
Totals 6 30 36 
 
Note: a (a/b)/(c/d) = (4/29)/(2/1) = 14.5 (CI95 = 1.0575, 198.8211) 
χ2 = 0.119 (does not assume the null hypothesis) 
Tb = 0.023 (assumes the null hypothesis) 
n = 36; 106 cases were not applicable to USPSTF recommendations for colorectal 
cancer screening. 
 
Analyses for ranked group differences in variance and ANOVA were not statistically 
significant for HIV stage based on classification schema or classification by 
symptomatology; the odds ratio for HIV symptomatology groupings was significant 
(Table 25). Based on the odds ratio, the null hypothesis of no difference was not 
supported for HIV stage by symptomatology and colorectal cancer screening.   
Research Question 10. Did the completion of colorectal cancer screening differ 
significantly by CD4 cell count in HIV seropositive women? The hypothesis, based on 
the literature review, stated HIV seropositive women with CD4 cell counts of 500 
cells/mm3 or more would complete significantly more colorectal cancer screenings, 
compared to HIV seropositive women with CD4 cell counts less than 500 cells/mm3, 
and the null hypothesis indicated no difference. USPSTF recommendations applied to 
only 36 HIV seropositive women in the sample. HIV seropositive women with CD4 cell 
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counts of 500 cells/mm3 or more completed fewer screenings (n = 1) and failed to 
completed fewer screenings (n = 2), compared to women with CD4 cell counts less than 
500 cells/mm3 (n = 5 and 28, respectively). Analyses for ranked group differences in 
variance and ANOVA were not statistically significant. The odds ratio (OR = 2.8, CI95 = 
0.217, 37.0345) was not statistically significant (Tb = 0.018, p = 0.985). The null 
hypothesis of no difference for CD4 cell count and colorectal cancer screening was 
supported. 
Research Question 11. Did the completion of colorectal cancer screening differ 
significantly by distance between residence and health care facility in HIV seropositive 
women? The hypothesis, based on the literature review, stated HIV seropositive women 
in the shortest distance in miles category would complete significantly more colorectal 
cancer screening tests compared to HIV seropositive women who live farther from the 
health care facility. In the study, the shortest distance category was 0 to 4.9 miles, while 
the farther distance category was 5.0 to 29.0 miles, and the USPSTF recommendations 
for colorectal screening only applied to 36 HIV seropositive women. HIV seropositive 
women in the shorter distance group completed more colorectal cancer screenings (n = 
6), but failed to complete more screenings (n = 19), compared to women who lived 
farther away (n = 0 and 11, respectively). Analyses for ranked group differences in 
variance and ANOVA were not statistically significant. The odds ratio was not 
interpretable due to the lack of observations in one cell, and the Kendall’s tau b was not 
statistically significant (Tb = −0.752, p = 0.452), so the null hypothesis of no difference 
was supported. 
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Research Question 12. Did the completion of colorectal cancer screening differ 
significantly between HIV seropositive women diagnosed with hypertension, compared 
to HIV seropositive women without a diagnosis of hypertension? From the review of the 
literature, women with hypertension completed significantly fewer colorectal cancer 
screenings when compared to women without hypertension so the hypothesis stated 
there would be a significant difference in the completion of colorectal cancer screening 
by HIV seropositive women, but did not state which group would complete more 
screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women with hypertension and those without hypertension. 
USPSTF recommendations for colorectal screening only applied to 36 HIV seropositive 
women. Failure to complete screening was the same for both groups (n = 15), while HIV 
seropositive women with hypertension completed more screenings (n = 4), compared to 
women without a diagnosis of hypertension (n = 2). Analyses for ranked group 
differences in variance and ANOVA were not statistically significant. The odds ratio 
(OR = 2.0, CI95 = 0.317, 12.6198) was not statistically significant (Tb = −0.983, p = 
0.326) so the null hypothesis of no difference was supported. 
Research Question 13. Did the completion of colorectal cancer screening differ 
significantly between HIV seropositive women diagnosed with obesity, compared to 
HIV seropositive women without a diagnosis of obesity? From the review of the 
literature, women with obesity completed significantly fewer colorectal cancer 
screenings when compared to women without obesity so the hypothesis stated there 
would be a significant difference in the completion of colorectal cancer screening by 
HIV seropositive women, but did not state which group would complete more 
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screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women with obesity and those without obesity. USPSTF 
recommendations for colorectal screening only applied to 36 HIV seropositive women. 
Only one HIV seropositive woman had completed colorectal cancer screening, while 
five without obesity had completed screening. Women with obesity failed to complete 
fewer screenings (n = 11), compared to women with obesity (n = 19). Analyses for 
ranked group differences in variance and ANOVA were not statistically significant. The 
odds ratio (OR = 0.3455, CI95 = 0.0356, 3.35) was not statistically significant (Tb = 
1.564, p = 0.118) so the null hypothesis of no difference was supported. 
Research Question 14. Did the completion of colorectal cancer screening differ 
significantly between HIV seropositive women diagnosed with diabetes mellitus, 
compared to HIV seropositive women without a diagnosis of diabetes mellitus? From 
the review of the literature, women with diabetes mellitus completed significantly more 
colorectal cancer screenings when compared to women without diabetes, so the 
hypothesis stated there would be a significant difference in the completion of colorectal 
cancer screening by HIV seropositive women, but did not state which group would 
complete more screenings. The null indicated no difference in the number of completed 
screenings between HIV seropositive women with diabetes mellitus and those without 
diabetes mellitus. USPSTF recommendations for colorectal screening only applied to 36 
HIV seropositive women. HIV seropositive women with diabetes completed fewer 
screenings (n = 1) and failed to complete fewer screenings (n = 6), compared to women 
without diabetes mellitus (n = 5 and 24, respectively). Analyses for ranked group 
differences in variance and ANOVA were not statistically significant. The odds ratio 
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(OR = 0.8, CI95 = 0.0781, 8.1895) was not statistically significant (Tb = −0.470, p = 
0.638) so the null hypothesis of no difference in colorectal screening completion based 
on a diagnosis of diabetes mellitus was supported. 
Research Question 15. Did the completion of colorectal cancer screening differ 
significantly between HIV seropositive women diagnosed with depression, compared to 
HIV seropositive women without a diagnosis of depression? From the review of the 
literature, women with depression completed significantly fewer colorectal cancer 
screenings when compared to women without depression, so the hypothesis stated there 
would be a significant difference in the completion of colorectal cancer screening by 
HIV seropositive women, but did not state which group would complete more 
screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women with depression, and those without a diagnosis of 
depression. USPSTF recommendations for colorectal screening only applied to 36 HIV 
seropositive women. HIV seropositive women with depression completed fewer 
screenings (n = 2) and failed to complete fewer screenings (n = 12), compared to women 
without a diagnosis of depression (n=4 and 18, respectively). Analyses for ranked group 
differences in variance and ANOVA were not statistically significant. The odds ratio 
(OR = 0.75, CI95 = 0.1182, 4.7599) was not statistically significant (Tb = −1.573, p = 
0.116), so the null hypothesis of no difference was supported. 
Research Question 16. Did the completion of colorectal cancer screening differ 
significantly between HIV seropositive women who used tobacco, compared to HIV 
seropositive women who do not use tobacco? From the review of the literature, women 
who used tobacco completed significantly fewer colorectal cancer screenings when 
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compared to women who abstained from tobacco use, so the hypothesis stated there 
would be a significant difference in the completion of colorectal cancer screening by 
HIV seropositive women, but did not state which group would complete more 
screenings. The null indicated no difference in the number of completed screenings 
between HIV seropositive women who used tobacco, and those who did not use tobacco. 
USPSTF recommendations for colorectal screening only applied to 36 HIV seropositive 
women. Of the HIV positive women who used tobacco, 4 completed colorectal cancer 
screenings, and 12 failed to complete screenings, while women who abstained from 
tobacco completed 2 screenings, but failed to complete 18 colorectal cancer screenings. 
Analyses for ranked group differences in variance and ANOVA were not statistically 
significant. The odds ratio (OR = 3.0, CI95 = 0.4727, 19.0395) was not statistically 
significant, so the null hypothesis of no difference in the completion of colorectal cancer 
screening based on tobacco use was supported. 
Additional Research Questions 
In the study of 142 HIV seropositive women, 34.8% completed breast cancer 
screening, 27.7% completed cervical cancer screening, and 16.7% completed colorectal 
cancer screening when laboratory, radiological and procedure reports were compared to 
screening intervals based on the USPSTF recommendations. During the review of the 
literature, questions arose pertaining to whether completing one type of preventive 
health care screening might increase or decrease the completion of other screening tests 
in HIV seropositive women. Data was analyzed to determine if a statistically significant 
difference in completion, or failure to complete, screening tests existed between breast 
cancer screening and cervical cancer screening, breast cancer screening and colorectal 
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cancer screening, and cervical cancer screening and colorectal cancer screening in HIV 
seropositive women. In binomial and one-sample chi-square tests, statistically 
significant differences were noted between the two groups, completed and failed to 
complete, in each variable associated with preventive health care screenings for the 
breast cancer (χ2 = 13.113, p < 0.000), cervical cancer (χ2 = 16.00, p < 0.000), and 
colorectal cancer (χ2 = 16.00, p < 0.000). Kruskal-Wallis and ANOVA using Kendall’s 
tau b were conducted to examine relationships between the three cancer screenings, and 
the results are reported below. 
Research Question A1. Did the completion, or failure to complete, breast cancer 
screening increase or decrease the likelihood of cervical cancer screening? Kruskal-
Wallis indicated a statistically significant difference in breast cancer screening between 
the different levels of cervical cancer screening (χ2 = 8.881, df = 1, p = 0.003), and the 
Kendall’s tau b was also statistically significant (Tb = 0.323, 1-tailed, p = 0.000) 
Research Question A2. Did the completion, or failure to complete, breast cancer 
screening increase or decrease the likelihood of colorectal cancer screening? Kruskal-
Wallis and Kendall’s tau b did not indicate statistically significant differences in breast 
cancer screening and colorectal cancer screening. 
Research Question A3. Did the completion, or failure to complete, cervical 
cancer screening increase or decrease the likelihood of breast cancer screening? Kruskal-
Wallis and Kendall’s tau b indicated statistically significant differences in cervical 
cancer screening between the different levels of each breast cancer screening variable: 
(a) breast cancer screening, by timeliness (χ2 = 14.553, df = 1, p = 0.000; Tb = 0.925, 1-
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tailed, p = 0.000); (b) breast cancer screening, dichotomous (χ2 = 9.039, df = 1, p = 
0.003; Tb = 0.267, 1-tailed, p = 0.001). 
Research Question A4. Did the completion, or failure to complete, cervical 
cancer screening increase or decrease the likelihood of colorectal cancer screening? 
Kruskal-Wallis and Kendall’s tau b did not indicate statistically significant differences 
in cervical cancer screening and colorectal cancer screening. 
 Research Question A5. Did the completion, or failure to complete, colorectal 
cancer screening increase or decrease the likelihood of breast cancer screening? Kruskal-
Wallis indicated a statistically significant difference in colorectal cancer screening 
between the different levels of breast cancer screening, by timeliness (χ2 = 5.895, df = 1, 
p = 0.015), but Kendall’s tau b was not statistically significant. For the dichotomous 
variable of breast cancer screening, Kruskal-Wallis and Kendall’s tau b were not 
statistically significant. 
Research Question A6. Did the completion, or failure to complete, colorectal 
cancer screening increase or decrease the likelihood of cervical cancer screening? 
Kruskal-Wallis indicated a statistically significant difference in colorectal cancer 
screening between the different levels of cervical cancer screening (χ2 = 13.413, df = 1, p 
= 0.000), but Kendall’s tau b was not statistically significant. 
Results of Regression Modeling 
Variables used in the three regression models were examined for violations of 
regression assumptions. Casewise diagnostics was used to remove outliers from the 
variables, and Durban-Watson statistics were calculated to determine independence.  
Stepwise forward regression modeling began by entering the significant independent and 
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dependent variables for each preventive health care screening test, established by η2 
statistics, in descending order. Some variables were not related to a statistically 
significant change, and some significant variables, such as age and time living with HIV 
infection, had more than one statistically significant form, so the form of the variable, 
which created the greatest change, was left in the model. When a variable was entered, 
which did not result in a statistically significant change, the addition of variables ended.  
Breast Cancer Screening Model 
Confounding and interaction were assessed before the regression model was 
finalized. For breast cancer screening, previous bivariate analyses identified HIV stage 
by classification schema, HIV stage by symptomatology, HIV stage by CD4 cell count, 
cervical cancer screening, time living with HIV infection, and age cohort (40-49 years) 
as statistically significantly related. As expected, statistically significant covariance was 
noted amount HIV stage by classification schema, HIV stage by symptomatology, and 
HIV stage by CD4 cell count. According to the analysis plan outlined earlier, sublevels 
of variables could be removed if not significant in the model, but, if sublevels were 
significant, the main variable must be retained (Kleinbaum & Klein, 2002). HIV stage 
by CD4 cell count had a greater effect (partial η2 = 0.111), compared to HIV stage by 
symptomatology (partial η2  = 0.001), when examined together, and HIV stage by CD4 
cell count indicated a statistically significant interaction with HIV stage by 
symptomatology (p < 0.001), while HIV stage by symptomatology was no longer 
statistically significant (p = 0.778). When cervical cancer screening was added to the 
model, statistically significant interaction was noted between the HIV stage by CD4 cell 
count and cervical cancer screening (p < 0.001) and the effect increased (η2 = 0.182, or 
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18.2%). When HIV time, or the number of years living with HIV infection, was added, 
HIV stage by CD4 cell count was no longer statistically significant in the model, but the 
adjusted η2statistic increased (0.182 to 0.254). Upon further examination, HIV stage by 
CD4 cell count and HIV time were statistically significantly related (p < 0.001), and the 
combination of HIV stage by CD4 cell count, HIV time, and cervical cancer screening 
explained less of the variance in breast cancer screening (η2 = 0.253) than just HIV time 
and cervical cancer screening (η2 = 0.254) so HIV stage by CD4 cell count was replaced 
by HIV stage by classification schema. HIV stage by classification schema was not 
statistically significant, as was the interaction between cervical cancer screening and 
HIV time, so HIV stage by classification schema, as well as the subgroups of HIV stage 
by symptomatology and HIV stage by CD4 cell count, was removed from the model to 
lessen interaction among the predictor variables and increase the variance explained by 
the total model. Log10 transformed age was added, and the eta-squared statistic 
increased, η2 = 0.286, but the prior statistical significance for each variable in the model 
became non-significant, while the sublevels of age group and age cohort, increased to η2 
= 0.268 and η2 = 0.306, respectively, without confounding. 
The regression model, which best explained the completion of breast cancer 
screening in HIV seropositive women, was comprised of age by cohort (40-49 and 50-79 
years), HIV time (2-26 years), and cervical cancer screening (0-1). Age cohort, F(1, 
140) = 6.467, p = 0.012, cervical cancer screening, F(2, 138) = 7.615, p = 0.001, and 
HIV time, F(18, 123) = 15.161, p = 0.000, explained 56.1% of the variance in breast 
cancer screening, adjusted R2 = 0.355 (Table 26). 
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Table 26 
 
Regression Model for Completion of Breast Cancer Screening in HIV Seropositive 
Women (N=142) 
 
Variable R Square 
(Adj R Sq) 
 
Odds Ratio CI95 F-Statistic P-Value 
Age Cohort 0.279 
(0.258) 
 
8.0633 1.0226, 
63.5801 
6.467 0.012 
Cervical 
Cancer 
Screening 
0.187 
(0.175) 
48.630 6.0884, 
388.415 
7.615 0.001 
Time Living 
with HIV 
Infection 
0.248 
(0.232) 
0.4066 0.1328, 
1.245 
15.161 0.000 
Note: R2 = 0.561; adjusted R2 = 0.355 
 
Cervical Cancer Screening Model 
For confounding and interaction assessment, the log10 transformation of age, age 
cohort, and age, divided by mean, were not statistically significantly related to marital 
status, marital status, single versus others, or marital status, married versus others. The 
variables in the regression model, which best explained the completion of cervical 
cancer screening in HIV seropositive women, were the completion of breast cancer 
screening, distance between residence and health care facility, HIV stage by CD4 cell 
count, and HIV stage by symptomatology (Table 27). The completion of breast cancer 
screening, F(1, 140) = 27.776, p < 0.001, explained 16% of the variance in cervical 
cancer screening. Distance between residence and health care facility, F(1, 139) = 
23.009, p < 0.000, explained another 7.8%, while HIV stage by CD4 cell count, F(1, 
138) = 18.623, p < 0.000, and HIV stage by symptomatology, F(1, 137) = 16.079, p < 
0.000, explained 3.5% and 2.7%, respectively. The total model explained 31.9% of the 
variance in cervical cancer screening completion, adjusted R2 = 0.273. 
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Table 27 
 
Regression Model for Completion of Cervical Cancer Screening in HIV Seropositive 
Women (N=142) 
 
Variable R Square 
(Adj R Sq) 
 
Odds Ratio CI95 F-Statistic P-Value 
Breast Cancer 
Screening 
0.166 
(0.160) 
 
2.9365 1.3581, 
6.3492 
27.776 0.000 
Distance 
 
 
0.249 
(0.238) 
6.2687 1.8019, 
21.8084 
23.009 0.000 
HIV Stage by 
CD4 
 
0.288 
(0.273) 
0.0384 0.0046, 
0.3188 
18.623 0.000 
HIV Stage by 
Symptom 
 
0.319 
(0.319) 
0.9933 0.3291, 
2.9975 
16.079 0.000 
Note: R2 = 0.319; adjusted R2 = 0.273 
 
Colorectal Cancer Screening Model 
Confounding and interaction were assessed before creating the regression model. 
The variables of age group, divided by mean, and marital status, single verses others, 
were identified earlier as being statistical significantly related to colorectal cancer 
screening. Interaction by age, divided by mean, was statistically significant, F(1, 141) = 
56.439, p > 0.05, for colorectal cancer screening, but the interaction of marital status, 
single versus others, was not statistically significant, F(1, 140) = 0.457, p > 0.000, so the 
interaction of age group, divided by mean, is not dependent on marital status, single 
versus others. A third variable, breast cancer screening, previously found to be 
statistically significantly related to colorectal cancer screening, was not statistically 
significant, F(1, 139) = 1.154, p < 0.000, lowered the effect of the model, and was 
eliminated as a possible confounding variable. After adjusting for marital status, single 
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versus others, there was a statistically significant difference in colorectal cancer 
screening by age group, divided by mean.  
The two variables of age group, divided by mean, coded as 1 for ages 40 to 53 
years and 2 for ages 54 to 79 years, and marital status, single, coded as 1, versus others, 
including married, divorced and widowed, coded as 0, best explained the completion of 
colorectal cancer screening in HIV seropositive women (Table 28). Age, divided by 
mean, F(1, 140) = 65.905, p < 0.000, explained 31.5% of the variance in colorectal 
cancer screening, while single marital status, F(1, 139) = 35.949, p < 0.000, explained 
an additional 1.6% of the variance. The total model explained 33.2%, adjusted R2, of the 
variance in colorectal cancer screening completion.  
Table 28 
 
Regression Model for Completion of Colorectal Cancer Screening in HIV Seropositive 
Women (N=142) 
 
Variable R Square 
(Adj R Sq) 
 
Odds Ratio CI95 F-Statistic P-Value 
Age, divided 
by Mean 
 
0.320 
(0.315) 
N/A1 N/Aa 65.905 0.000 
Marital 
Status, Single 
 
0.341 
(0.331) 
0.4375 0.0693, 
2.7623 
35.949 0.000 
Note: a one cell had zero observations so OR and CI95 could not be calculated; R2  =  0.332; adjusted R2 =  
0.323. 
 
Summary of Findings 
For breast cancer screening, HIV seropositive women in the older age cohort (50 
to 79 years), who lived longer with HIV infection (11 to 26 years), had more progressed 
HIV infection, and their lowest CD4 cell count was less than 499 cell/mm3 were likely 
to complete more breast cancer screening tests. For cervical cancer screening, HIV 
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seropositive women, who had lived a shorter length of time with HIV infection (2 to 10 
years), had more progressed HIV infection, a lowest CD4 cell count of 499 cell/mm3 or 
less, and lived a shorter distance from the health care facility completed significantly 
more cervical screening tests. For colorectal cancer, HIV seropositive women in the 
younger age group (40 to 53 years), who were single, were more likely to complete 
colorectal screening tests. The independent variables of race, ethnicity, type of 
insurance, and the comorbid diagnoses of hypertension, obesity and diabetes mellitus, as 
well as tobacco use, were not significantly related to the completion of screenings tests 
for breast cancer, cervical cancer or colorectal cancer.  
Breast cancer screening was related to cervical cancer screening, but not 
colorectal cancer screening. Cervical cancer screening was related to breast cancer 
screening, but not colorectal cancer screening. Colorectal cancer screening was related 
to breast cancer screening, but not cervical cancer screening. Possible reasons for the 
asymmetrical relationship between colorectal cancer screening and breast cancer 
screening are discussed in the following chapter, as part of the interpretation of findings, 
implications for public health and clinical practice, and recommendations for future 
research. 
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Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of the quantitative study was to describe, compare and determine 
which independent variables differed significantly between HIV seropositive women 
who completed, or failed to complete, recommended preventive health care actions for 
breast cancer, cervical cancer or colorectal cancer, with or without a diagnosis of one or 
more comorbid conditions. Based on the ecosocial theory (Krieger, 2008), the cross 
sectional study used observational methodology to collect and analyze information 
extracted from the EMRs of 142 patients, who received health care services from an 
infectious disease specialist in an ambulatory care center in Newark, New Jersey, three 
or more times during the 12 months prior to data collection or death. Identification of 
variables related to the completion of, or failure to complete, cancer screening tests over 
the lifespans of HIV seropositive women could indicate a need for practice and policy 
changes at individual, agency/institutional, local, and regional levels, aimed at positive 
social change for the prevention of disease and disability, which can negatively impact 
these women, their families and their communities. 
Summary of Findings 
The findings of the study were summarized by the constructs of the ecosocial 
theory. 
Embodiment Variables 
Age cohort was found to be statistically significant for breast cancer screening, 
but not as hypothesized. HIV seropositive women in the older cohort, aged 50 to 79 
years were 72% more likely to complete breast cancer screening, compared to HIV 
seropositive women, aged 40 to 49 years. Age, age group, and age cohort were not 
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significantly related to the completion of, or failure to complete, cervical cancer 
screening in HIV positive women. For colorectal cancer screening, HIV seropositive 
women in the younger age cohort (40 to 49 years) and younger age group (40 to 53 
years) completed significant more screening tests, compared to older HIV seropositive 
women. However, age group accounted for more of the variance between the completion 
of, or failure to complete, colorectal cancer screenings in HIV seropositive women. 
Pathway of Embodiments Variables 
More Black HIV seropositive women completed more breast, cervical and 
colorectal cancer screenings, compared to White HIV seropositive women, but race was 
not significantly related to breast, cervical or colorectal cancer screenings by the HIV 
seropositive women in the study. Non-Hispanic HIV seropositive women completed 
more breast, cervical and colorectal cancer screenings, but ethnicity was not found to 
significantly effect cancer screenings by the HIV seropositive women in the study. The 
study hypothesized married women would complete more breast, cervical and colorectal 
cancer screenings, but more single women completed screenings. Marital status was not 
significantly related to breast or cervical cancer screening in HIV seropositive women in 
the study. However, while not in the hypothesized direction, marital status, specifically 
married, was significantly associated with colorectal cancer screening in HIV 
seropositive women. Education level and employment status could not be assessed in the 
study due to missing information. As hypothesized, more HIV seropositive women with 
private insurance completed breast, cervical and colorectal cancer screenings, compared 
to women with other types of insurance, including no insurance, self-pay and charity 
232 
 
care, but the difference between type of insurance and screening completion was not 
statistically significant. 
Cumulative Interplay Variables 
Length of time living with HIV infection was statistically significant for breast 
cancer screening, but not as hypothesized, which stated women living with HIV 
infection for a shorter period of time would complete more breast cancer screenings. 
According to the study, women who had lived a longer period of time with HIV 
infection, which was 11 to 26 years, completed significantly more breast cancer 
screenings. While the hypothesized direction of the relationship between length of time 
living with HIV infection and the completion of breast cancer screenings was not 
supported, the inverse direction was statistically significant, so the variable of HIV time 
was retained for further analysis. Length of time living with HIV infection was not 
significant for cervical cancer screening, but, as hypothesized, HIV seropositive women, 
who had lived with HIV infection for a shorter length of time completed significantly 
more colorectal cancer screenings, compared to women who had lived with HIV 
infection for a longer period of time. As mentioned earlier, the nine-category HIV 
staging classification schema was collapsed into several additional variables. HIV stage 
by classification schema, and HIV stage by symptomatology were statistically 
significant in some analyses, the research hypothesis, but not in the direction 
hypothesized. HIV seropositive women, who were asymptomatic or had symptoms, but 
not an AIDS-defining condition, were 2.2 times more likely to complete breast cancer 
screening, compared to HIV seropositive women with an AIDS-defining condition. HIV 
stage by classification schema, and HIV stage by symptomatology were significantly 
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related to cervical cancer screenings. HIV stage by symptomatology was significantly 
related to colorectal cancer screenings in HIV seropositive women in the study. 
 In the analyses to examine the relationship between lowest CD4 cell count, and 
breast or cervical cancer screenings, the additional analyses, which included post hoc 
tests, supported the research hypothesis of a difference between CD4 cell counts and 
screening completion. However, the research hypothesis stated HIV seropositive women 
with CD4 cell counts of 500 cells/mm3 or greater would complete more cancer 
screenings than HIV seropositive women with CD4 cell counts less than 500 cells/mm3, 
and these hypothesized relationships were not supported; in the study, HIV seropositive 
women with CD4 cell counts of 499 cells/mm3 or less completed more breast, cervical 
and colorectal cancer screenings. Distance between residence and health care facility 
was measured to the tenth of a mile, and the research question hypothesized HIV 
seropositive women, who lived a shorter (0.3 to 10 miles) distance from the health care 
facility, would complete more breast cancer screenings, compared to women who lived a 
longer (11 to 29 miles) distance away. For breast cancer screening, the null hypothesis 
was supported, as no difference associated with distance between residence and health 
care facility was found. However, for cervical cancer screening, HIV seropositive 
women who lived a shorter distance from the health care facility did complete more 
screenings. There was no statistically significant difference in the distance between 
residence and health care facility and the completion of, or failure to complete, 
colorectal cancer screenings in HIV seropositive women. 
No statistically significant difference was found for breast, cervical or colorectal 
cancer screening completion between HIV seropositive women with hypertension, 
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compared to HIV seropositive women without hypertension. Obesity, defined as a BMI 
of 30.0 or greater, was not significantly related to the completion of breast, cervical or 
colorectal cancer screenings in HIV seropositive women in the study. A diagnosis of 
diabetes mellitus was not significantly related to the completion of breast, cervical or 
colorectal cancer screenings in HIV seropositive women in the study. Likewise, a 
diagnosis of depression was not significantly related to the completion of, or failure to 
complete, breast, cervical or colorectal cancer screenings in HIV seropositive women in 
the study. Tobacco use was not significantly related to the completion of, or failure to 
complete, breast, cervical or colorectal cancer screenings in HIV seropositive women in 
the study. 
Interpretation of the Findings 
The findings were interpreted according to the constructs of the ecosocial theory, 
including embodiment, pathways of embodiment, and cumulative interplay. 
Embodiment Variables  
The independent variables associated with the embodiment were age, as a 
continuous variable, the ordinal variable of age cohort, and the dichotomous variables of 
age cohort (40-49 years and 50-79 years), and age group (40-53 years and 54-79 years). 
Previous studies found conflicting results, suggesting the completion of preventive 
health care screening for breast, cervical and colorectal cancers declines with increased 
age (Shenson et al., 2005), and women aged 50 years to 64 years were more likely to be 
screened for cervical cancer than women in younger or older age categories, (Guilfoyle, 
et al., 2007). For age group, older age was related to completion of breast cancer 
screening, while younger age in both the age group and age cohort variables were related 
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to colorectal cancer screening, suggesting HIV seropositive women may complete the 
baseline colorectal cancer screening, or the colorectal procedures completed and 
recorded in the EMR were not for screening purposes. In addition, since the USPSTF 
recommendations are age-based, variables other than age, or not just age, may influence 
the completion of preventive health care actions. 
Pathway of Embodiment Variables  
The independent variables associated with societal arrangements, biological 
constraints, and the trajectories of biological and social development included race, 
ethnicity, marital status, and type of insurance. As noted earlier, in 2009, the rate of new 
HIV cases was fifteen times greater in Black women, compared to White women, and 
over three times the rate, compared to Hispanic women (CDC, 2011c). Over 90% of the 
HIV seropositive women were Black, and almost 8% were Hispanic. While colorectal 
screening rates improved between 2000 and 2005, after adjusting for multiple factors, 
colorectal screening rates did not improve in non-Hispanic and Hispanic females, and 
insurance was identified as a predictor of screening behavior independent of income 
(Trivers et al., 2008). From BRFSS data, non-adherence to breast cancer, cervical cancer 
and/or colorectal cancer screening was associated with not being married, and/or a lack 
of health insurance (Bazargan et al., 2004; Coughlin et al., 2004; Sabatino et al., 2008; 
Trivers et al., 2008). A systematic literature review on cervical cancer screening in 
African American and Hispanic women found a lack of health care insurance, or having 
insurance which required a copay, was associated with a lesser likelihood of completing 
cervical cancer screening (Ackerson & Gretebeck, 2007). The majority of HIV 
seropositive women in the study were younger, Black, non-Hispanic, had Medicaid, and 
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over 70% of the HIV seropositive women were single, or never married, while almost 
11% were married.  
Cumulative Interplay Variables  
The independent variables associated with exposure, susceptibility and resistance 
were the year of HIV diagnosis, stage of HIV disease, the lowest CD4 cell count, the 
distance between the residence and the health care facility, and the presence of one or 
more comorbid conditions limited to hypertension, obesity, diabetes mellitus, and 
depression, as well as tobacco use. In the study, obesity was determined by the height 
and weight recorded in the EMR, as well as the ICD-9-CM code, to check for agreement 
between the two methods. A previous study suggested the effects of race and ethnicity 
on the completion of preventive health care screenings were made non-significant when 
the individual had one or more comorbid conditions (Kiefe et al., 1998). In addition, the 
presence of one or more comorbidities was thought to have increased the number of 
contacts with a health care provider, which increased the number of opportunities for 
discussion and screening (Gonzalez et al., 2001). Obesity and tobacco use have been 
associated with failure to complete preventive health screenings for breast and cervical 
cancer (Coughlin et al., 2004). From an earlier study, HIV infection, while not 
considered a disability, could result in disability related to medication side effects or 
complications from AIDS-defining conditions or opportunistic infections, and having a 
disability was associated with a reduced likelihood of completing preventive health care 
screenings (Werth, Jr. et al., 2008; Yankaskas et al., 2010).  
In my study, the diagnosis of one or more comorbid conditions was not related to 
the completion of, or failure to complete, preventive health care screenings in HIV 
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seropositive women. However, having HIV infection for fewer years (2 to 10 years) was 
associated with a greater likelihood of failing to complete breast cancer screening, while 
living a shorter distance (0.3 to 10 miles) from the health care facility, having a CD4 cell 
count of less than <500mm3, and asymptomatic HIV infection was associated with a 
greater likelihood of failing to complete cervical cancer screening. Older age (50 to 79 
years), and single marital status were associated with a greater likelihood of failing to 
complete colorectal cancer screening. 
Accountability and agency variables. The independent variables associated 
with the entities responsible for creating, contributing or rectifying disparities in health 
will be controlled by limiting the inclusion of EMRs in the study to those of patients 
seen by an infectious disease specialist in the ambulatory care center, and only the 
preventive health care recommendations published by the USPSTF will be used for the 
study. The lack of a primary health care provider or usual source of health care, having 
not seen a physician in the past year, and continuity of care were examined in previous 
studies (O’Malley et al., 2002; Bazargan et al., 2004; Coughlin et al., 2004; Ackerson & 
Gretebeck, 2007; Litaker & Tomolo, 2007), and region of the country was a variable in 
an earlier study (Trivers et al., 2008). These variables were controlled in the study by 
limiting eligibility to the EMRs of HIV seropositive women seen three or more times 
during the 12 months prior to data collection at a single facility in the northeastern 
United States. 
Dependent Variables 
According to the findings of a study examining BRFSS data, never having had 
either a mammogram or a Pap smear was associated with a lack of other preventive 
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health screening tests (Coughlin et al., 2004). In the study, dependent variables were 
related to the completion of, or failure to complete, preventive health care actions, 
specifically breast cancer screening mammography, cervical cancer screening Pap 
smears, with or without HPV testing, or colorectal cancer screening by FOBT, 
sigmoidoscopy or colonoscopy. Each dependent variable was analyzed separately, as 
well as together.  
Breast cancer screening. In an earlier study, 90% of the respondents had a 
mammogram for breast cancer screening, the mean age of respondents was 74 years, and 
one-fourth were married (Levy-Storms et al., 2004). In the current study, the mean age 
calculated from the date of birth recorded in the EMRs was 53 years, one-tenth of the 
women were married, and having HIV infection for fewer years (2 to 10 years) was 
associated with a greater likelihood of failing to complete breast cancer screening. Over 
34% of the HIV seropositive women in the study completed breast cancer screening, 
and, of those completed breast cancer screenings, 14% were on time, 11% were early, 
and 9% were late, according to the screening intervals developed for study purposes. 
Cervical cancer screening. In the current student, living a shorter distance (0.3 
to 10 miles) from the health care facility, having a CD4 cell count of less than <500mm3, 
and asymptomatic HIV infection was associated with a greater likelihood of failing to 
complete cervical cancer screening. Earlier studies have noted a statistically significant 
positive relationship between the completion of breast cancer screening and cervical 
cancer screening, where the completion of one type of screening test increased the 
likelihood another type of screening test would be completed (Coughlin, et al., 2004; 
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Gregory-Mercado et al., 2007), and this statistically significant relationship was found in 
the current study. 
Colorectal cancer screening. Unlike the synergistic relationship between breast 
and cervical cancer screening completion, colorectal screening rates tend to fall well 
below those for breast and cervical cancer screening (Trivers et al., 2008), and Black 
women have a greater risk of being diagnosed with colorectal cancer, as well as a higher 
mortality rate, compared to other racial groups (Smith-Bindman et al., 2006). In the 
current study, over 90% of the EMRs had Black checked for racial group. In addition, 
older age (50 to 79 years), and single marital status were associated with a greater 
likelihood of failing to complete colorectal cancer screening in the current study.  
Limitations of the Study 
Previous studies have mentioned the possibility of race and ethnic categories 
failing to capture the influence of culture, religion, preferred language, birthplace, 
citizenship status, years of US residence, and external locus of control issues related to 
the completion of preventive health screenings and examinations (Ackerson & 
Gretebeck, 2007; Ackerson et al., 2008; Bazargan et al., 2004; Guilfoyle et al., 2007; 
Trivers et al., 2008). The current study was not able to obtain information related to 
these factors, as the information was not routinely recorded in the EMR, though EMR 
screens contained areas to record the most of the information when reported by a patient. 
In addition, income information was not recorded in the EMR, and the data set only 
included distance in miles, to the tenth of a mile, between residence and the health care 
center, and not an address and/or zip code from which a census tract block could be 
determined, and used to estimate household income. Lower education, lower household 
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income and shorter length of time having insurance were associated with nonadherence 
to breast and cervical cancer screening recommendations in earlier studies (Ackerson & 
Gretebeck, 2007; Coughlin et al., 2004; Litaker & Tomolo, 2007; Trivers et al., 2008); 
these variables could not be examined in the current study due to missing information. 
Generalizability 
As mentioned earlier, breast, cervical, and colorectal cancer incidence in women 
was higher in New Jersey, compared to almost all other states, and the mortality 
associated with breast and colorectal cancer in women in New Jersey was higher when 
compared to other states (CDC, 2011e). While data related to cancer incidence and 
prevalence in these HIV seropositive women was not abstracted, the statistics reported 
by the CDC emphasize the need for breast, cervical, and colorectal cancer screening in 
this population of women.  
Due to the specialized structure of EMRs across various facilities, and the 
specialized nature of the instruments designed from those EMRs, the data abstraction 
instrument, as well as the findings of the study, may have limited generalizability. 
However, many previous studies have lacked documentation related to methodology, 
making comparison to, and replication of, those studies difficult. The methodology used 
to design the data abstraction instrument and the data abstraction manual from the EMR 
can be adapted for use at most facilities providing patient care and preventive health 
services. The independent and dependent variables, as well as the categories within the 
variables, should allow for replication and comparison across departments and facilities, 
as well as local and national agencies.  
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Reliability and Validity 
The data abstraction instrument was designed to capture information from the 
EMR not recorded in a free-text or judgment-based format because the abstraction of 
free-text information, as well as information regarding a judgment by the abstractor, 
resulted in less reliable data (Yawn & Wollan, 2005). A data abstraction manual was 
developed a priori to provide guidance during the data abstraction process, and reduce 
judgment by the abstractor. As noted earlier, by limiting data abstraction to a single site 
and a single abstractor with MRR experience, the study sought to establish high 
reliability by reducing variability related to different data abstractors (Bertelsen, 1981; 
To et al., 2008; Yawn & Wollan, 2005), differences in medical records systems (Lemon 
et al., 2006; To et. al., 2008), and differences associated with the source of information 
documented in the medical record (Tisnado et al., 2007), while the MRR was the gold 
standard for measuring adherence to preventive health care recommendations 
(Armstrong et al, 2004). Obesity, calculated using the height and weight recorded in the 
EMR, as well as the ICD-9-CM code, served as a check for agreement between the two 
methods. 
Reliability. The first ten EMRs from which data was abstracted (Time 1) had 
data abstracted a second time on the last day of data abstraction (Time 2). The abstracted 
data was compared for information accuracy, and the accuracy of completion 
information (completed = 1, not completed = 0) assigned to a preventive health care 
action interval. Agreement between Time 1 and Time 2 was used to determine the 
reliability associated with the data abstraction process. Unlike the secondary MRR study 
(To et al., 2008), where data abstractors were not allowed to re-abstract the data they 
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collected originally at Time 1, this study had only one abstractor, and, while retraining 
for improved reliability occurred in the aforementioned study (To et al., 2008), the study 
discussed in this paper did not incorporate added time for retraining or review of the 
data abstraction process. In addition to the percentage of agreement between time 
periods, kappa statistics were calculated for reliability (Engel et al., 2009). 
In the current study, there were sixteen data points associated with variables for 
embodiment, pathways of embodiment and cumulative interplay constructs, as well as 
five calculations for age from date of birth, HIV stage from lowest CD4 cell count and 
diagnosis of AIDS-defining conditions, BMI from height and weight, and a 
determination of agreement related to obesity by BMI versus obesity recorded in the 
EMR. In addition, breast cancer screening had a maximum of fourteen time intervals, 
cervical cancer screening had a maximum of seven time intervals, and colorectal cancer 
screening had a maximum of four time intervals. Information added to the EMRs 
between Time 1 and Time 2 was not included in the calculations. However, data 
abstracted at Time 1 and corrected at Time 2 was coded as an error in data collection. A 
total of six data abstraction errors or discrepancies were found across the ten charts for 
the forty-one possible data points per EMR, and were found in two categories: (a) 
earliest date of HIV infection; (b) height. Percent agreement was 98.5% between Time 1 
and Time 2. The kappa statistic for agreement between Time 1 and Time 2 was -0.970, 
indicating strong agreement (Meyers, 2013), and was not statistically significant so the 
null hypothesis was not supported. 
Validity. The use of an experienced research nurse, such as the doctoral student, 
has been supported as the gold standard for data abstraction from medical records 
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(Bertelsen, 1981; Justice et al., 2006). Agreement and accuracy between data collection 
times were compared using percent agreement and kappa statistics. At the time the study 
was conducted, hard copy medical records were being transferred into electronic format 
across all departments, and the information may not been uniformly transferred. While 
missing data was limited, the study was designed to minimize the amount of missing 
data, such as the assignment of a code for not completed to a screening interval when no 
laboratory, radiological or procedure report was available. Over the time period for data 
collection, additional information was transferred into the electronic record, explaining 
why the amount of information abstracted at Time 2 was greater than at Time 1 for the 
ten EMRs, which were abstracted twice.    
Recommendations 
The ecosocial theory was helpful in emphasizing the level of measurement, and 
measurement over time (Krieger, 1999). Future studies on the preventive health actions 
in HIV seropositive women may benefit from a prospective design and additional data 
abstractors, as well as comparisons between the EMR and hard copy medical record, 
especially for information documented on a screen or sheet other than a laboratory, 
radiological or procedure note, such as a physician’s order. 
When transcribing information from the hard copy medical record to the EMR, a 
log of information transcribed might be useful, particularly related to laboratory, 
radiological and procedure reports, so an assessment can be made as to the portion of the 
medical record transcribed, as well as the earliest date of care contained in both records. 
A prospective design would avoid problems associated with an absence or the 
inaccuracy of transcribed information in the EMR. A prospective design could be used 
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to test the incorporation of a separate screen for the surveillance of preventive health 
care actions, including the date and type of test ordered, if the test was ordered for 
screening or due to a problem, the date the test was completed, and the results of the 
screening test. 
Comparing the hard copy medical record to the EMR was beyond the scope of 
the study since the doctoral student was the only data abstractor and there was no 
funding to cover the increased manpower needed to locate and re-file each of the hard 
copy medical records at the study facility. However, future studies should abstract 
information from the hard copy of the medical record, as well as the EMR, to assess the 
level of transfer, as well as the accuracy of the information transfer, within the facility 
during the data collection time.  
Implications for Positive Social Change 
Establishing the prevalence or proportion of women who were referred for 
screening, compared to women not referred, would be desirable for identifying facility- 
or provider-related factors, but this information would most likely be found in the 
progress notes or on a document used to record health care provider orders. Again, 
comparison between the EMR and the hard copy medical record would be useful, and a 
future study with more data abstractors and/or more time could compare the completion 
of preventive health care screenings based on the number of orders for the screening 
tests, as documented in the EMR.  
If certain health care providers are not ordering the preventive health care 
screening tests, improvements at the agency or institutional level associated with the 
provision of preventive health care services, as well as changes to facilitate the 
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completion of preventive health care actions, might be necessary to improve cancer 
screening rates in specific groups, such as older adults and racial or ethnic minorities 
(Shenson et al., 2005), to improve continuity of care or coordination of services across 
different departments (O’Malley et al., 2002), or provide the foundation necessary to 
support the use of non-physician health care providers, such as nurse practitioners 
(Ackerson & Gretebeck, 2007).   
As noted earlier, in the current study, fewer years (2 to 10 years) with HIV 
infection was associated with a greater likelihood of failing to complete breast cancer 
screening. Living a shorter distance (0.3 to 10 miles) from the health care facility, 
having a CD4 cell count of less than <500 cells/mm3, and having asymptomatic HIV 
infection was associated with a greater likelihood of failing to complete cervical cancer 
screening. Older age (50 to 79 years), and single marital status were associated with a 
greater likelihood of failing to complete colorectal cancer screening. Determining which 
groups of HIV seropositive women have a greater likelihood of failing to complete age-
appropriate preventive health care screenings could assist program planners at agencies, 
including health departments, as well as health care facilities, in the development of new 
programs, and the expansion or revision of existing programs. Identifying variables, 
which can impact the completion of preventive health care actions, would allow 
surveillance personnel to incorporate these factors into routinely collected information, 
so adverse trends could be identified quickly and addressed before an impact on 
individual, family, and community health is realized.  
Finally, the Patient Protection and Affordable Care Act, which became effective 
on March 23, 2010, was incorporated into health care practice during the time frame of 
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the study, and may account for the absence of a statistically significant relationship 
between private insurance and the completion of preventive health care actions. Future 
researchers are advised to assess and/or comment on similar legislative and policy 
changes, which may positively or negatively impact, not only the findings of their study, 
but the findings of previous studies, since, unlike most earlier studies, private insurance 
was not statistically significantly related to preventive health care actions in the study.  
Conclusion 
Preventive health care recommendations must be incorporated into the provision 
of services to groups with chronic illnesses, such as HIV infection, but the value of those 
services, as well as the cost of not providing preventive health care services, may need 
to be established at the societal level, and not just at the institutional level, where the 
main focus may be on cost-effective delivery of services. Research identifying 
geographical areas and subpopulations, where population health has been neglected or 
has remained at a sub-optimal level for one or more generations, can provide the data 
necessary to support the enactment of policies aimed at positive social change, 
expressed as improved population, group and individual health.  
Preventive health care screening procedures and tests should be made available to all 
groups in all geographic areas, across the lifespan. However, resources related to those 
services, remain limited, so identifying factors that facilitate, not just those which inhibit 
or prevent, optimal health across the lifespan could result in the development of social 
policy with a positive effect on population health outcomes. If an individual is to attain 
optimal health, the factors facilitating the attainment of optimal health must be 
incorporated into every level of society across the individual’s lifespan.   
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Appendix A: AIDS-Defining Conditions for Adults 18 Years or Older 
Candidiasis of bronchi, trachea, or lungs  
Candidiasis of esophagus 
Cervical cancer, invasive 
Coccidioidomycosis, disseminated or extrapulmonary  
Cryptococcosis, extrapulmonary  
Cryptosporidiosis, chronic intestinal (duration longer than 1 month)  
Cytomegalovirus disease (other than liver, spleen, or nodes), onset at greater than 1 
month of age 
Cytomegalovirus retinitis (with loss of vision) 
Encephalopathy, HIV-related  
Herpes simplex: chronic ulcers (duration greater than 1 month) or bronchitis, 
pneumonitis, or esophagitis (onset at greater than 1 month of age)  
Histoplasmosis, disseminated or extrapulmonary  
Isosporiasis, chronic intestinal (duration longer than 1 month)  
Kaposi sarcoma  
Lymphoma, Burkitt (or equivalent term)  
Lymphoma, immunoblastic (or equivalent term)  
Lymphoma, primary, of brain  
Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary 
Mycobacterium tuberculosis of any site, pulmonary, disseminated, or 
extrapulmonary 
Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary 
Pneumocystis jirovecii pneumonia 
Pneumonia, recurrent 
Progressive multifocal leukoencephalopathy  
Salmonella septicemia, recurrent  
Toxoplasmosis of brain (onset at greater than 1 month of age) 
      Wasting syndrome attributed to HIV  
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Appendix B: USPSTF A and B Recommendations by Publication Month and Year 
 Breast cancer 
screening 
Cervical cancer 
screening 
Colorectal cancer 
screening 
October 1989 Women over 40 
years – annual 
clinical breast 
exam (CBE); 
mammography 
every 1-2 years 
beginning at age 50 
and concluding at 
age 75 in absence 
of pathology; 
mammography 
before age 50 for 
women at high risk 
for breast cancer 
 
Pap smear with 
onset of sexual 
activity; repeat 
every 1-3 years; 
discontinue at age 
65 if previous Pap 
smears were 
consistently normal 
Insufficient 
evidence to 
recommend for or 
against fecal occult 
blood testing 
(FOBT) or 
sigmoidoscopy in 
asymptomatic men 
and women 
1989 Mammography 
alone or with 
annual CBE every 
1-2 years for 
women ages 50-69 
 
Pap smear with 
onset of sexual 
activity in women 
with a cervix; 
repeat at least 
every 3 years 
All persons ages 50 
and older – annual 
FOBT or 
sigmoidoscopy or 
both (periodicity 
unspecified 
2002 Mammography 
with or without 
CBE every 1-2 
years for women 
ages 40 years and 
older 
 
USPSTF strongly 
recommends Pap 
smear for sexually 
active women with 
a cervix 
USPSTF strongly 
recommends 
women 50 years 
and older be 
screened 
2003 USPSTF strongly 
recommends 
mammography with or 
without CBE every 1-2 
years for women ages 
40 and older 
 
USPSTF strongly 
recommends Pap smear 
for sexually active 
women with a cervix 
 
USPSTF strongly 
recommends women 
50 years and older be 
screened 
October 
2008 
  USPSTF recommends 
FOBT, sigmoidoscopy 
or colonoscopy 
beginning at age 50 
years and concluding at 
age 75 
November 
2009 
USPSTF recommends 
film mammography 
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every 2 years in 
women ages 50-74  
August 
2010 
Affordable Care Act 
implemented using 
2002 recommendations 
  
March  
2012 
 USPSTF recommends 
Pap smear every 3 
years in women ages 
21 to 65; to lengthen 
screening interval, Pap 
smear with HPV 
testing every 5 years in 
women ages 30-65  
 
October 
2012 
 Pap smear every 3 
years for women ages 
21 to 65; Pap smear 
with HPV testing every 
5 years for women ages 
30 to 65 
 
Note: 1984 – establishment of the United States Preventive Services Task Force by the 
US Department of Health and Human Services for the development of clinical 
preventive services recommendations based on evidence from published clinical 
research studies. 
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Appendix C: Random Numbers Table: Assignment By Line Number 
Initial 114: 
179 214 435 216 312 259 416 390 141 328 093 026 437 092 237 364 103 441 078 280 
236 043 059 337 065 111 181 090 361 438 443 428 027 225 283 345 160 271 264 402 
433 013 386 155 285 221 086 375 395 127 370 409 084 054 351 022 239 240 029 102 
209 005 173 440 201 354 131 356 008 400 112 413 163 024 116 166 133 233 378 060 
125 138 218 421 376 183 199 034 087 252 321 231 057 016 021 007 050 365 424 041 
182 411 405 098 012 035 408 178 425 244 226 071 418 149  
 
Order for Sampling with Replacement: 
067 432 106 195 048 045 380 381 169 242 349 146 313 136 342 051 154 052 031 422 
135 109 304 164 256 307 274 373 074 083 266 278 359 117 399 206 340 174 228 392 
017 371 198 157 162 147 190 062 002 064 323 108 427 121 152 176 105 318 122 384 
249 212 114 290 207 128 247 335 188 185 076 403 192 383 046 168 010 159 038 073 
294 193 171 119 275 250 444 187 397 003 414 070 097 223 406 419 055 140 095 347 
036 197 368 089 040 394 220 297 302 288 330 202 143 204 019 130 124 261 293 316 
245 015 144 081 389 234 255 430 230 269 387 032 211 326 217 100 332 079 068 309 
150 299 219 388 412 110 358 004 350 039 282 404 246 429 407 355 042 423 189 305 
333 291 331 272 324 276 186 094 080 366 053 037 317 222 061 268 118 336 315 091 
415 006 227 208 377 329 262 156 339 314 072 279 295 129 301 153 263 075 137 396 
056 177 391 077 322 167 362 320 258 265 338 001 241 367 148 348 205 260 352 369 
025 170 296 374 113 023 257 243 215 277 203 196 334 200 018 385 303 224 431 284 
281 172 372 134 287 096 099 165 310 319 058 151 353 191 442 132 410 020 184 253 
434 393 426 298 238 300 115 343 270 341 401 306 145 420 175 030 011 180 346 142 
235 363 213 104 066 101 028 251 123 248 325 232 047 158 289 344 273 417 014 360 
107 327 120 308 139 311 292 398 082 379 267 033 229 382 194 161 088 085 044 049 
069 210 439 126 063 436 009 254 286 357 
 
Note: This table of random numbers was generated according to the following 
specifications - numbers were randomly selected from within the range of 1 to 444. 
Duplicate numbers were not allowed. Each random number generated in this table, and 
not in numerical order, will be used to replace the Excel spreadsheet line number 
associated with the alphabetically-ordered sampling frame. Once the line number has 
been replaced with a random number, a new list will be generated in numerical order 
prior to assigning a patient identification number (PID). 
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Appendix D: Random Numbers Table: Assignment by Non-Linked PID 
Initial 114: 
5556445 5550905 5552213 5553601 5559436 5551933 5551758 5554883 5555590 
5559124 5554522 5559329 5552253 5550824 5557767 5554283 5554736 5558688 
5554176 5555056 5557727 5557060 5553749 5556338 5551225 5551251 5556485 
5558128 5550544 5555951 5559730 5555738 5550371 5553815 5558795 5553855 
5556018 5554843 5558367 5555137 5559516 5553678 5558448 5559583 5558835 
5551078 5554349 5557192 5558662 5558942 5550758 5555310 5554308 5559970 
5550330 5556592 5557807 5551505 5553067 5551038 5557126 5556205 5556312 
5555992 5556953 5554069 5555377 5556765 5559944 5555097 5554949 5558047 
5556098 5556632 5555030 5559837 5555417 5551332 5550931 5557447 5555244 
5559196 5557340 5555564 5558235 5550224 5556912 5556846 5554389 5554415 
5559649 5551292 5553708 5559115 5552894 5558901 5553535 5556979 5559303 
5557019 5556526 5555351 5558876 5558301 5552680 5559542 5551612 5552747 
5551999 5554242 5557513 5557701 5551826 5552106  
 
Remainder for Sampling with Replacement: 
5554745 5551826 5551478 5553494 5559756 5556098 5552922 5558474 5554817 
5550971 5557192 5558942 5553067 5551332 5557019 5556526 5555351 5558876 
5552680 5552747 5551478 5553494 5559756 5550374 5553472 5554179 5554713 
5553111 5557917 5550842 5559413 5556355 5552871 5553324 5557276 5552764 
5553645 5556315 5558304 5552337 5554926 5552470 5559840 5555074 5559372 
5559133 5554540 5550974 5554326 5551615 5552403 5557383 5552444 5554606 
5553431 5556956 5556381 5550761 5554967 5559693 5558171 5557424 5559667 
5552937 5555781 5559906 5557530 5559346 5553899 5552897 5558558 5558919 
5555181 5559052 5550094 5551656 5559626 5555715 5557450 5557556 5557236 
5558197 5552657 5553965 5555354 5551188 5553685 5553538 5556635 5557343 
5557877 5556275 5551081 5554006 5552577 5559519 5556035 5556488 5550440 
5555928 5556809 5559479 5558812 5555501 5558090 5552978 5553004 5558238 
5559880 5552297 5557704 5551483 5557490 5552123 5555567 5550547 5555608 
5557770 5556595 5550120 5556890 5551269 5558131 5550201 5551335 5550588 
5552831 5556101 5558945 5550414  
 
 
Note: This table of random numbers was generated on June 18, 2011, using StatTrek 
(2011), according to the following specifications - numbers were randomly selected 
from within the range of 5550000 to 5559999. Duplicate numbers were not allowed. 
Each random number generated in this table is a non-linked patient identification 
number (PID) and will be used to replace the medical records number (MRN) linked to 
each electronic medical record (EMR). 
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Appendix E: Manual for Electronic Medical Records (EMR) Review 
Completion of Recommended Preventive Health Care Actions by 
Women with HIV/AIDS 
 
Manual for Electronic Medical Records (EMR) Review 
 
Primary Information Source: Citrix Centricity (AKA Logitian) Physician Office EMR 
 
Purpose(s) of EMR: (1) Determine the completion rates for preventive health care 
actions associated with breast cancer screening, cervical cancer screening and colorectal 
cancer screening in HIV seropositive women aged 40 years and older; (2) Determine 
whether HIV seropositive women aged 40 years and older are completing the preventive 
health care actions associated with breast cancer screening, cervical cancer screening 
and colorectal cancer screening early, late or on-time. 
 
Study List Linking PID with Patient Identifiers 
 
Participant Identification Number (PID): 9-digit non-linked number assigned during 
randomization of eligible patients from frame created during the initial EMR screening 
phase. List of PIDs linked to patient first and last names, as well as medical record 
number, must be maintained and stored in locked file cabinet within the Infectious 
Disease specialist’s office in the ambulatory care center affiliated with University 
Hospital. This linked list must never be removed from the office and must reflect all 
current participants including those later found to be ineligible. PIDs cannot be 
reassigned from an ineligible participant to an eligible participant; for this reason, more 
PIDs exist than eligible participants. 
 
Patient Identifier 1 - Patient First Name and Last Name: Must be obtained from 
Home Page screen, Summary tab. 
 
Patient Identifier 2 - Medical Records Number (MRN): Must be obtained from 
Home Page screen, Summary tab, and checked for consistency across all screen 
elements (pages, laboratory reports, flow sheets, etc.) 
 
Patient Identifier 3 - Date of Birth (DOB): Must be obtained from Home Page screen, 
Summary tab, and converted to age in years at time of data collection. 
 
Zip Code – Must be obtained from Home Page screen, Summary tab. Information must 
include the entire zip code (first 5 digits and plus-four). 
 
NOTE: The three Patient Identifiers are recorded on both the linked Study List 
and on the PID Linking Page only; none of the Patient Identifiers are to be 
recorded on the data collection modules. Zip code plus 4 information should be 
transferred to the appropriate section of the PID Linking Page and then 
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transferred to the appropriate section on the data collection module for 
Characteristics. 
 
PID Linking Page 
 
The Study List linking PID numbers with Patient Identifiers, described above, lists 
patient identification information by PID number. In the event additional information is 
required, or data recorded on a module during data collection needs to be confirmed or 
clarified, the data abstractor may prefer locating the participant’s medical record number 
by last name. The PID Linking Page is specific to a single eligible patient and is 
alphabetized by last name. 
 
PID: Must be obtained from the Study List linking PID numbers and recorded on the 
first page of the data collection module, which is the Characteristics Module. 
 
Medical Records Number (MRN): Must be obtained from the Study List linking PID 
numbers, which was obtained from the Home Page Screen and checked for consistency 
across all screen elements (pages, laboratory reports, flowsheets, etc.) 
 
Patient Last Name: Must be obtained from the Study List linking PID numbers, which 
was obtained from the Home Page screen, Summary tab 
 
Patient First Name: Must be obtained from the Study List linking PID numbers, which 
was obtained from the Home Page screen, Summary tab 
 
Date of Birth (DOB): Must be obtained from the Study List linking PID numbers, 
which was obtained from the Home Page screen, Summary tab, and converted to age in 
years at time of data collection. 
 
****NOTE: The three Patient Identifiers must be recorded on the Study List and 
on the PID Linking Page only; the Patient Identifiers must not be recorded on the 
data collection modules. 
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Data Collection Modules 
 
Instructions: Complete the data collection modules using black or blue permanent ink 
only, using capital letters, and entering one capital letter or number in each space 
provided on the module. Dates should be formatted as MM/DD/YYYY. Only 
standardized abbreviations (see separate page) should be used.  
 
If an error is made, cross out the error with a single line completely through the 
information recorded in error and initial the error on the right end of the single line. 
Write the correct information on the next data entry line.  
 
If the number of individual data entries exceeds the number of lines on the module, use a 
new module page and add lower case letters next to the page numbers printed on each 
module page. For example, page 1 of 2 would become page 1a of 2 and 1b of 2. 
 
Modules are arranged in the order of the information contained in the electronic medical 
record to aid in data collection. The order of data collection should not be changed 
because necessary data may be accidentally omitted and would increase the amount of 
missing data. 
 
Characteristics Module 
 
NOTE: The data recorded on the Characteristics Module will be used to confirm study 
eligibility. 
 
PID: Recorded at the time the PID Linking Page was completed. After completion of 
the Characteristics Module, and confirmation of study eligibility, the abstractor is 
advised to enter the PID on all remaining study module pages in order to avoid or reduce 
errors associated with incorrect module page completion, particularly errors involving 
the recording of one participant’s information in another participant’s module. 
 
Gender: Obtained from the Home Page screen, Summary tab. For study eligibility, the 
participant’s gender should be female.  
 
Age: Calculated from the DOB on the PID Linking Page, the age, in years, should be 
recorded as the participant’s age at the time of data collection. For study eligibility, the 
participant’s age should be 40 years or older. 
 
Race: Only categories from the Home Screen Page screen, Summary tab are included, 
along with a line for “Other” and “Unknown”. Do not record ethnicity in this section, 
only race.  
 
Ethnicity: Record ethnicity from the Home Screen Page screen, Summary tab. 
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Marital Status: Only categories from the Home Screen Page screen, Summary tab are 
included, along with a line for “Other” “None” and “Unknown” If an individual’s 
marital status has changed, record the most recent. 
 
Education Level: Only categories from the Home Screen Page screen, Summary tab are 
included, along with a line for “Unknown” If an individual’s education level has 
changed, record the most recent. 
 
Employment Status: Only categories from the Home Screen Page screen, Summary tab 
are included, along with a line for “Unknown” If an individual’s employment status has 
changed, record the most recent. 
 
Insurance: Obtained from the Home Page screen, Summary tab. The majority of 
insurance and payment options accepted by the ambulatory care center, as well as 
University Hospital, are captured on the Characteristic Module. There are two spaces 
provided for insurance or payment options not listed on the module page.  
 
Distance: The distance from the patient’s zip code plus 4 (recorded in the previous 
section) to the ambulatory care center zip code plus 4 should be recorded in tenths of a 
mile in this section of the Characteristic Module. 
 
Diagnostic Coding Module 
 
Instructions: Data recorded on the Diagnostic Coding Module should be obtained from 
the Home Page screen, Problems tab, and listed by ICD-9-CM or ICD-10-CM code 
format. A list of ICD-9-CM codes commonly used in the ambulatory care center and 
University Hospital is listed on the module page. However, a more complete list of ICD-
9-CM codes for study purposes can be found in the appendices at the end of this manual. 
There are blank spaces provided for other ICD-9-CM codes not listed on the module 
page, but the use of these spaces should be limited. Date should be recorded in 
MM/DD/YYYY format. 
 
HIV Status: The ICD-9-CM or ICD-10-CM code for HIV infection should be obtained 
from the Home Page screen, Problems tab. Only patients with a positive HIV ELISA test 
and a Western Blot test for confirmation are eligible for study participation. The 
patient’s HIV classification stage will be recorded later in this study module. 
 
Opportunistic Infections (OIs): The ICD-9-CM or ICD-10-CM code for Category B 
Symptomatic Conditions or Category C AIDS Defining Conditions, also known as OIs, 
should be obtained from the Home Page screen, Problems tab. This information, along 
with CD4 cell counts, will be used to determine the individual’s HIV Stage 
Classification in the event a cancer is detected during screening. A list of Category B 
Symptomatic Conditions and Category C AIDS-Defining Conditions, also known as 
AIDS Indicator Conditions, is provided on the second page of the Diagnostic Coding 
Module. 
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HIV Stage: Using the initial CD4 count and any OIs recorded in the previous section, 
clearly mark the box corresponding to the individual’s earliest HIV Stage.  
 
Hypertension: The ICD-9-CM or ICD-10-CM code for hypertension should be 
obtained from the Home Page screen, Problems tab. The date of the diagnosis should 
also be recorded. If the date is missing, enter N.D. for no date in the box reserved for the 
date. Record the results of the ELISA and Western Blot if these tests were conducted six 
months before or anytime after the diagnosis of hypertension and record the date 
corresponding to the test results. Record the CD4 count result and/or HIV PCR result 
within six months of the hypertension diagnosis, if applicable. Note that the date 
corresponding to the different diagnosis and test results must be on a new line and the 
results should correspond to the date line. 
 
Obesity: The ICD-9-CM or ICD-10-CM code for obesity should be obtained from the 
Home Page screen, Problems tab. The date of the diagnosis should also be recorded. If 
the date is missing, enter N.D. for no date in the box reserved for the date. Record the 
results of the ELISA and Western Blot if these tests were conducted six months before 
or anytime after the diagnosis of obesity and record the date corresponding to the test 
results. Record the CD4 count result and/or HIV PCR result within six months of the 
obesity diagnosis, if applicable. Note that the date corresponding to the different 
diagnosis and test results must be on a new line and the results should correspond to the 
date line. 
 
A diagnosis of obesity can also be determined by calculating the BMI. Using the most 
current height and weight recorded from the Home Page screen, calculate the BMI using 
the tables in the appendix of this manual, record the BMI and determine if the BMI is 
associated with any level of obesity then mark yes or no, as appropriate.  
 
Diabetes Mellitus: The ICD-9-CM or ICD-10-CM code for diabetes mellitus should be 
obtained from the Home Page screen, Problems tab. The date of the diagnosis should 
also be recorded. If the date is missing, enter N.D. for no date in the box reserved for the 
date. Record the results of the ELISA and Western Blot if these tests were conducted six 
months before or anytime after the diagnosis of diabetes mellitus and record the date 
corresponding to the test results. Record the CD4 count result and/or HIV PCR result 
within six months of the diabetes mellitus diagnosis, if applicable. Note that the date 
corresponding to the different diagnosis and test results must be on a new line and the 
results should correspond to the date line. 
 
Depression: The ICD-9-CD or ICD-10-CD code for depression should be obtained from 
the Home Page screen, Problems tab. The date of the diagnosis should also be recorded. 
If the date is missing, enter N.D. for no date in the box reserved for the date. Record the 
results of the ELISA and Western Blot if these tests were conducted six months before 
or anytime after the diagnosis of depression and record the date corresponding to the test 
results. Record the CD4 count result and/or HIV PCR result within six months of the 
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depression diagnosis, if applicable. Note that the date corresponding to the different 
diagnosis and test results must be on a new line and the results should correspond to the 
date line. 
 
Tobacco Use: The ICD-9-CM or ICD-10-CM code for tobacco use should be obtained 
from the Home Page screen, Problems tab. The date of the diagnosis should also be 
recorded. If the date is missing, enter N.D. for no date in the box reserved for the date. 
Record the results of the ELISA and Western Blot if these tests were conducted six 
months before or anytime after the diagnosis of tobacco use and record the date 
corresponding to the test results. Record the CD4 count result and/or HIV PCR result 
within six months of the tobacco use diagnosis, if applicable. Note that the date 
corresponding to the different diagnosis and test results must be on a new line and the 
results should correspond to the date line. 
 
Tobacco use on the Home Page screen, Problems tab should be recorded as Current, 
Ever or Never. Mark “yes”, “no” or “unknown” for the appropriate tobacco use, as 
determined from the EMR. 
 
NOTE: Information recorded in the Home Page screen, Medications tab SHOULD 
NOT be used to determine a diagnosis not recorded on the Home Page screen, Problems 
tab. Only information recorded in the Home Page screen, Problems tab has been verified 
via review by personnel in the Billing Office and Medical Records Department. 
Information contained on the Home Page screen, Problems tab is maintained by the 
Billing Office and Medical Records Department, making this information the most 
current and accurate diagnostic information available in electronic medical records. 
 
Breast Cancer Screening Module 
 
Breast Cancer: The ICD-9-CM or ICD-10-CM code for breast cancer should be 
obtained from the Home Page screen, Problems tab, as well as a review of the progress 
notes. Mammogram data is recorded in one of three sections: a) mammograms between 
ages 40-49; b) mammograms between ages 50-74; c) problem-focused mammograms. If 
abstractor is unable to determine if a mammogram was completed for screening versus 
problem-focused reasons, the mammogram data should be recorded as a screening test 
in the appropriate age section.  
 
Date should be recorded in MM/DD/YYYY format. Description should list the type of 
screening test. Result should restate the interpretation/summary information on the 
report. The CD4 and/or HIV PCR data should reflect any of these tests conducted 
nearest to the date of the mammogram, preferably within six (6) months of the 
mammogram and/or prior to the mammogram. Timing is determined based on the age at 
completion of the mammogram, as appropriate to the U.S.P.S.T.F. screening 
recommendations at the time of the mammogram. 
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Note: N should be circled for each section in which no mammogram was completed. U 
should be circled if the review of the progress notes indicates a mammogram was 
ordered, but no report is found in the EMR. Y should be circled for each section in 
which a mammogram was completed. N/A should be circled if the section is not relevant 
to the participant, such as the participant if less than 50 years of age or no problem-
focused mammogram was completed.  
 
Cervical Cancer Screening Module 
 
Cervical Cancer: The ICD-9-CM or ICD-10-CM code for cervical cancer should be 
obtained from the Home Page screen, Problems tab. PAP smear data should be obtained 
from a review of the progress notes. PAP smear data is recorded in one of two sections: 
a) PAP smears for screening purposes; b) PAP smears for problem-focused purposes. If 
the abstractor is unable to determine if a PAP smear was completed for screening versus 
problem-focused reasons, the PAP smear data should be recorded as a screening test in 
the appropriate age section.  
 
HPV Testing data should be obtained from a review of the laboratory reports. HPV 
Testing data should be recorded in one of two sections: a) HPV Testing for screening 
purposes; b) HPV Testing for problem-focused purposes. If the abstractor is unable to 
determine if a HPV Test was completed for screening versus problem-focused reasons, 
the HPV Test data should be recorded as a screening test in the appropriate section. 
 
Date should be recorded in MM/DD/YYYY format. Description should list the type of 
screening test, if any, conducted during the HPV Testing. Result should restate the 
interpretation/summary information on the report. The CD4 and/or HIV PCR data 
should reflect any of these tests conducted nearest to the date of the HPV Testing, 
preferably within six (6) months of the HPV Test and/or prior to the HPV Test. Timing 
is determined based on the age at completion of the HPV Test, as appropriate to the 
U.S.P.S.T.F. screening recommendations at the time. 
 
Note: N should be circled for each section in which no PAP smear or HPV Test was 
completed. U should be circled if the review of the progress notes indicates a PAP smear 
or HPV Test was ordered, but no report is found in the EMR. Y should be circled for 
each section in which a PAP smear or HPV Test was completed. N/A should be circled 
if the section is not relevant to the participant, such as the participant who had a 
hysterectomy with removal of the cervix or the participant was diagnosed with HPV 
infection at the time of a PAP smear for screening purposes. 
 
Colorectal Cancer Screening Module 
 
Colorectal Cancer: The ICD-9-CM or ICD-10-CM code for colorectal cancer should 
be obtained from the Home Page screen, Problems tab. Colorectal screening data should 
be obtained from a review of the progress notes. Colorectal screening test results are 
recorded in one of two sections: a) colorectal results at age 50 years; b) colorectal results 
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for problem-focused purposes. If the abstractor is unable to determine if a colorectal 
screening test was completed for screening versus problem-focused reasons, the 
colorectal screening data should be recorded as a screening test in the appropriate age 
section.  
 
Date should be recorded in MM/DD/YYYY format. Description should list the type of 
screening test, such as FOBT, sigmoidoscopy or colonoscopy, conducted. The CD4 
and/or HIV PCR data should reflect any of these tests conducted nearest to the date of 
the colorectal screening test, preferably within six (6) months of the colorectal screening 
test and/or prior to the colorectal screening test. 
 
Note: N should be circled for each section in which no colorectal screening test was 
completed. U should be circled if the review of the progress notes indicates a colorectal 
screening test was ordered, but no report is found in the EMR. Y should be circled for 
each section in which a colorectal screening test was completed. N/A should be circled 
if the section is not relevant to the participant. 
 
Conclusion 
Date Completed and Initials: At the bottom of each page of each module, the date each 
module page was completed should be recorded, as well as the initials of the person 
completing the module. If the module was completed over more than one day, the last 
day, or the day on which all the information in the module was recorded, should be used. 
If either the date or the initials are missing, the page should be reviewed and checked 
against the EMR for completeness, then the reviewer should date and initial the page. 
Modules for Data Entry: The PID Linking Page Module should not be kept with 
the remainder of the modules at any time. Prior to sending the completed modules to 
data entry, the abstractor and/or reviewer should examine each set for completeness, 
including date completed and the initials of the person completing the form. The 
following modules should be forwarded to data entry when complete: 
Characteristics Module (2 pages) – confirm eligibility 
Diagnostic Coding Module (3 pages) 
Breast Cancer Screening Module (2 pages) 
Cervical Cancer Screening Module (2 pages) 
Colon Cancer Screening Module (1 page)  
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Appendix F: Updated SPSS Code Book 
   SPSS   Values/ Data Type/  
Variable  Label     Codes  Measurement Level 
 
Female Gender FEMGEN  No=0  Discrete/Nominal 
      Yes=1 
 
HIV Status  HIV   No=0  Discrete/Nominal 
      Yes=1 
 
Age   AGE   In years Continuous/Interval 
 
Age – 2 Groups AGE3   40-53=1 Discrete/Ordinal 
      54-80=2 
 
Age Cohort  COHORT  40-49=1 Discrete/Ordinal 
      50-59=2 
      60-69=3 
      70-79=4 
      80-89=5 
      > 90 =6 
 
Age – 2 Cohorts AGE2   40-49=1 Discrete/Ordinal 
      50-79=2 
 
Census Age Group CENSAGE  35-44=1 Discrete/Ordinal 
      45-54=2 
      55-64=3 
      > 65 =4 
  
Distance  DIST   0.0-28.8 Continuous/Interval 
     
Distance – Corrected DISTA  0.0-28.8 Continuous/Interval 
    
 
Distance – 2 Groups DIST2   0.3-6.6=1 Discrete/Ordinal 
      > 6.7 =2 
 
 
 
 
 
 
 
288 
 
  SPSS   Values/  Data Type/  
Variable  Label     Codes    Measurement Level 
 
Race   RACE   Black=1  Discrete/Nominal 
      White=2 
      API=3 
      AIAN=4 
      Other=666 
      Unknown=888 
      Missing=999 
 
Ethnicity  ETHNIC  Non-Hispanic=0    Discrete/Nominal 
      Hispanic=1 
      Declined=777 
      Unknown=888 
      Missing=999 
 
Marital Status  MARITAL  Single/   Discrete/Nominal 
         Never Married=0      
      Married=1   
      Partnered=2 
      Separated=3 
      Divorced=4 
      Widowed=5 
      Other=666 
      Declined=777 
      Unknown=888 
      Missing=999 
 
Education  EDLEV  Omitted 
 
Employment  EMPLOY  Omitted 
        
Insurance  INSURE  Medicare=1  Discrete/Nominal 
      SS Disability=2 
      Medicaid=3 
      Private Insurance=4 
      State HMO=5 
      Charity Care=6 
      Self-Pay=7 
      Other=666 
      Declined=777 
      Unknown=888 
      Missing=999 
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  SPSS   Values/  Data Type/  
Variable  Label     Codes    Measurement Level 
 
Deceased  DECEASE  Not Decreased=0 Discrete/Nominal 
      Deceased=1 
 
Earliest Year of  HIVYR  In YYYY format Continuous/Ratio 
   HIV Diagnosis    Unknown=888 
      Missing=999 
 
Years Since  HIVTIME  In whole years  Continuous/Ratio 
    HIV Dx     Unknown=888 
      Missing=999 
 
AIDS-Defining OPINF   No=0   Discrete/Nominal 
   Conditions/     Yes=1 
   Opportunistic Infections   Unknown=888 
      Missing=999 
 
HIV Stage  HIVSTAGE  A1=1   Discrete/Ordinal 
      A2=2 
      A3=3 
      B1=4 
      B2=5 
      B3=6 
      C1=7 
      C2=8 
      C3=9 
      Missing=999 
 
AIDS vs. Not AIDS A_NonA  Non-AIDS=0  Discrete/Nominal 
      AIDS=1 
 
HIV Stage by CD4 STAGE2  < 200=1  Discrete/Ordinal
       200-499=2 
      > 500=3 
 
HIV Stage by  STAGE3  Asymptomatic=1 Discrete/Ordinal 
   Symptoms     Symp/Non-AIDS=2 
      ADC/OI=3 
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  SPSS   Values/  Data Type/  
Variable  Label     Codes    Measurement Level 
 
Hypertension  HTNDX  Never=0  Discrete/Nominal 
      Hx of/Past=1 
      Current=2 
      Unknown=888 
      Missing=999 
 
Body Mass Index BMI   In 00.0 format, Continuous/Interval 
      from height and 
      weight measures 
        
BMI Categories BMI2   14.9-18.4=1 
      18.5-24.9=2 
      25.0-29.9=3 
      > 30.0=4 
 
Obese Per BMI OBSBMI  No=0   Discrete/Nominal 
      Yes=1 
      N/A=9 
      Unknown=888 
      Missing=999 
 
Obesity Listed  OBSEMR  No=0   Discrete/Nominal 
   in EMR     Yes=1 
      N/A=9 
      Unknown=888 
      Missing=999 
 
Obese in EMR OBSBOTH  No=0   Discrete/Nominal 
   and by BMI     Yes=1 
      N/A=9 
      Unknown=888 
      Missing=999 
 
Diabetes Mellitus DMDX  No=0   Discrete/Nominal 
      Yes=1 
      Unknown=888 
      Missing=999 
 
Depression  DEPDX  No=0   Discrete/Nominal 
      Yes=1 
      Unknown=888 
      Missing=999 
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  SPSS   Values/  Data Type/  
Variable  Label     Codes    Measurement Level 
 
Tobacco Use  TOBUSE  No=0   Discrete/Nominal 
      Yes=1 
      Unknown=888 
      Missing=999 
 
Base Mammogram BASE40  No=0   Discrete/Nominal 
   at age 40     Yes=1  
      Not Applicable=9 
      Unknown=888 
      Missing=999 
 
Base Mammogram BASE50  No=0   Discrete/Nominal 
   at age 50     Yes=1  
      Unknown=888 
      Missing=999 
 
Mammogram  MTx   Not Done=0  Discrete/Ordinal 
   at interval x  (MT1-MT12)  On Time=1 
      Early=2 
      Late=3 
      Not Applicable=9 
      Unknown=888 
      Missing=999  
 
HPV Positive  HPV   No=0   Discrete/Nominal 
      Yes=1 
      Not Applicable=9 
      Unknown=888 
      Missing=999  
 
Hysterectomy  HYSTER  No=0   Discrete/Nominal 
      Yes=1 
      Not Applicable=9 
      Unknown=888 
      Missing=999  
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  SPSS   Values/  Data Type/  
Variable  Label     Codes    Measurement Level 
 
Pap Smear  PAPTx  Not Done=0  Discrete/Ordinal 
   at interval x  (PAPT1-PAPT7) On Time=1 
      Early=2 
      Late=3 
      Not Applicable=555 
      Unknown=888 
      Missing=999  
 
Colorectal Cancer  CRCTx  Not Done=0  Discrete/Ordinal 
   Screening  (CRCT1-CRCT4) On Time=1 
   at Interval x     Early=2 
      Late=3 
      Not Applicable=555 
      Unknown=888 
      Missing=999  
 
 
 
